An investigation into the effects of circadian rhythm on the efficacy of sibutramine and d-fenfluramine, two centrally-acting anorectic agents: focussing on the impact on the enhancement of satiety by Willmott, Graham Timothy
        
University of Bath
PHD
An investigation into the effects of circadian rhythm on the efficacy of sibutramine and









If you require this document in an alternative format, please contact:
openaccess@bath.ac.uk
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 11. May. 2021
An Investigation into the Effects of Circadian 
Rhythm on the Efficacy of Sibutramine and d -  
Fenfluramine, two Centrally-Acting Anorectic 
Agents: Focussing on the Impact on the 
Enhancement of Satiety

An Investigation into the Effects of Circadian Rhythm on the 
Efficacy of Sibutramine and {/-Fenfluramine two Centrally-Acting 
Anorectic Agents: Focussing on the Impact on the Enhancement of
Satiety
Graham Timothy Willmott
A thesis submitted for the degree o f Doctor o f Philosophy
University o f Bath 
Department o f Pharmacy and Pharmacology
August 2006 
COPYRIGHT
Attention is drawn to the fact that copyright o f this thesis rests with its author.
This copy o f the thesis has been supplied on condition that anyone who consults it is 
understood to recognise that its copyright rests with its author and that no quotation 
from the thesis and no information derived from it may be published without the prior
written consent o f the author.
^  /z// 2/&c
This thesis may be made available for consultation within the University Library and 




INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
Dissertation Publishing
UMI U223129
Published by ProQuest LLC 2013. Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved. This work is protected against 
unauthorized copying under Title 17, United States Code.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346
UNIVERSITY OF BATH 
LIBRARY
V^> 1 2 JUL 2007 
Pk.p.
Acknowledgements
I would like to thank my supervisors, Professor Peter Redfem and Dr Paul Mitchell 
for their support and advice throughout the process of researching, studying and 
writing up this thesis. Thanks also go to David Heal for advice and information, 
specifically information concerning sibutramine.
Thanks is also reserved for the staff o f 5 West Level 1 -  particularly Louise, Lesley, 
Jane, Jean and Alan -  who were the closest thing I had to work colleagues during 
many long days down there, and without whom it would have been impossible to 






3.1 A Brief Overview of the Control of Appetite and Food Intake 8
3.2 The Role of Serotonin and Noradrenaline 13
3.3 The Importance of Circadian Rhythm 18
3.4 Sibutramine 22
3.5 Fenfluramine 26
3.6 Figures for Chapter 3 31
4.0 Calibration of the Behavioural Satiety Sequence (BSS) for
Circadian Work 36
4.1 Introduction 36
4.1.1 What is the BSS and how does it help discriminate
the mechanisms of drug action? 36
4.1.2 How to measure the BSS 40
4.2 Materials and Methods 41
4.3 Results 46
4.4 Discussion 49
4.5 Figures for Chapter 4 55
5.0 The Effect of Sibutramine and (/-Fenfluramine on Locomotor
Activity, Measured at Different Times Spread Across the
Circadian Cycle 70
5.1 Introduction 70
5.2 Materials and Methods 73
5.3 Results 76
5.4 Discussion 78
5.5 Figures for Chapter 5 86
6.0 The Effect of Sibutramine and (/-Fenfluramine on Exploratory
Locomotor Activity 99
6.1 Introduction 99
6.2 Materials and Methods 101
6.3 Results and Discussion ’ iU-
4
6.4 Figures for Chapter 6 105
7.0 The Effects of Sibutramine and //-Fenfluramine on the BSS Measured
Across the Circadian Cycle: Impact of Circadian Rhythm 110
7.1 Introduction 110
7.2 Materials and Methods 111
7.3 Results 112
7.3.1 Looking Individually at Each Circadian Time 112
7.3.2 Collated Data -  Overall Effects of Treatment and
Circadian Time 116
7.4 Discussion 121
7.5 Figures for Chapter 7 129






This thesis is concerned with the impact of circadian rhythmicity upon the effect of 
two centrally acting anti-obesity agents, sibutramine and ^/-fenfluramine, in the 
behavioural satiety sequence (BSS) and their impact on locomotor activity. 
Experiments were carried out at 6 timepoints evenly spread over the circadian cycle 
and the results compared to provide a measure of the effect of circadian rhythm on 
drug efficacy and action. The BSS was exhibited and recorded at all times except late 
in the light phase when animals showed no interest in feeding regardless of drug 
treatment. Using a time-sampling methodology in animals subjected to 6-hour food 
deprivation both sibutramine (1.67 mg/kg) and J-fenfluramine (1.0 mg/kg) produced 
hypophagic effects through the enhancement of satiety, at all circadian times except 
late in the light phases when there was no feeding response under control conditions. 
Both drugs showed greater potency for satiety enhancement during the dark phase 
when natural feeding is more prevalent. Drug treatment accelerated the offset of 
feeding and the onset of resting (promoting total observations of resting and 
suppressing those of feeding) to greater degree in the dark phase, obscuring the 
circadian changes in behaviour seen under control conditions. Both drugs reduced 
food intake at all points in the dark phase and early in the light phase. At mid-light 
phase <7-fenfluramine decreased food intake but sibutramine did not. In locomotor 
activity studies using the same doses, food deprivation, food presentation paradigms 
and circadian timepoints as the BSS studies, sibutramine decreased activity in a 
manner consistent with the enhancement of satiety when pooling data from all 6 
timepoints. In contrast ^/-fenfluramine had different effects on motor activity' at mid­
light and mid-dark phase but no overall impact. At mid-light phase J-fenfluramine 
caused an initial depression of activity but the animals were more active over the 
second half of the experiment; this pattern was not seen in the dark phase. This 
discrepancy could explain previous reports of ^-fenfluramine disrupting the BSS in 
experiments carried out in the mid light-phase, although results described here suggest 
the BSS is preserved at mid-light phase. Neither drug significantly modified 
exploratory locomotion, an indicator of sedation, at the doses used for the circadian 
locomotor activity or BSS studies. The present results suggest that circadian rhythms 
have an influence over the response to sibutramine and ^/-fenfluramine: tests with 
tnese drugs snouia oe targeted to tne aarx pnase ior maximal effect ana relevance.
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2.0 Abbreviations
5-HT -  5-Hydroxytryptamine; Serotonin
AgRP -  Agouti-related protein
ANOVA -  Analysis o f Variance
ARC -  Arcuate nucleus (of the hypothalamus)
BSS -  Behavioural Satiety Sequence
CART -  Cocaine-and amphetamine-regulated transcript
CCK -  Cholecystokinin
CNS -  Central Nervous System
CT -  Circadian Time
DOI -  l-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane
ED50 -  Effective Dose 50; the dose which produces a 50% response
GMT -  Greenwich Mean Time
up. -  Intra-peritoneal
LHA -  Lateral Hypothalamic Area
mCPP -  1 -(m-chlorophenyl)piperazine
MDMA -  3,4-methylenedioxy-metamphetamine; ecstasy
MSH -  Melanocyte Stimulating Hormone
NA -  Noradrenaline
NPY -  Neuropeptide Y
NTS -  Nucleus o f the Solitary Tract
POMC -  Pro-opiomelanocortin
PVN -  Paraventricular Nucleus
RBI -  Research Biochemicals International
SCN -  Suprachiasmatic Nucleus
SNRI -  Serotonin-Noradrenaline Re-uptake Inhibitor
SSRI -  Selective Serotonin Re-uptake Inhibitor
VMH -  Ventromedial Hypothalamus
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3.0 Introduction
3.1 A Brief Overview of the Control of Appetite and Food Intake
Obesity has become a worldwide problem of epidemic proportions (e.g. James et al., 
2001). The study of appetite, feeding and satiety has therefore become a major subject 
of research, with the dual aims of understanding how such processes are controlled 
and investigating possible pharmacotherapies to aid the obese in losing weight. This 
thesis is based on work done to extend knowledge about the centrally-acting anti­
obesity drugs sibutramine and d-fenfluramine, specifically with regard to how1 
circadian rhythm affects the efficacy of these agents. A brief look at the control of 
feeding is an appropriate beginning.
In the Western World we live in an environment where food is never scarce and 
famine is something that happens to other people. It was not always so, and in an 
evolutionary' sense this is a recent development, one which appears to have led to a 
breakdown in the homeostatic regulation of bodyweight and an ever more obese 
population. So what are the systems that control appetite and food intake, and how are 
they disrupted in obesity ?
There are both tonic and episodic elements to the control of appetite and feeding, 
released from a variety of tissues and in response to different stimuli. Perhaps the 
most closely studied of the factors is leptin, a cytokine hormone synthesised and 
released from adipose tissue, which serves as a tonic indicator of adiposity and acts to 
depress appetite, but there are a multitude of other factors at work, including insulin, 
galanin, cholecystokinin, orexins and more.
Tonic Regulation. Tonic regulation is achieved primarily through leptin and insulin, 
released from adipocytes and the pancreas respectively. Leptin is released in relation 
to the degree of fat stores in the adipocytes, with fat-laden cells releasing more leptin 
than those with less stored. Insulin release is stimulated by blood sugar levels, so the 
two primary tonic signals are responsive to different macronutrient stores, although 
insulin is also responsive to adinositv  as blood glucose levels tend to be elevated ir  
obesity (Arch, 2005). Both these tonic signal molecules are released in the periphery
and are relayed to the central nervous system, where they signal for a reduction in 
food intake. Conversely, a period of restricted food intake leads to a decline in leptin 
and insulin levels (Wynne et al., 2005). Leptin and insulin are both capable of 
increasing energy expenditure too. But how do these signals bring about their 
responses?
Leptin receptors are widespread in the hypothalamus and the brainstem: the former 
being a well characterised centre of homeostatic regulation with a prominent role in 
the control of food intake and with strong interconnections with areas of the latter. 
Leptin is actively transported across the blood-brain barrier, a transport which is 
decreased under conditions of starvation (Wynne et al., 2005) but also in obesity 
(Arch, 2005); once across leptin activates receptors in various different nuclei. 
However, although there are leptin receptors in many areas that are protected by the 
blood-brain barrier, perhaps the primary sites of action are in the arcuate nucleus of 
the hypothalamus (ARC) and the nucleus of the solitary tract (NTS) in the brainstem, 
two structures that are situated in close proximity to sites where the blood-brain 
barrier is incomplete -  the median eminence and the area postrema respectively. The 
ARC is considered to be central to the integration of appetitive signalling (Wynne et 
al., 2005) and has extensive interconnections with both other nuclei of the 
hypothalamus such as the ventromedial hypothalamic nucleus (VMH), lateral 
hypothalamic nucleus (LHA) and the paraventricular nucleus (PVN) as well as with 
the NTS in the brainstem (Wynne et al., 2005; Berthoud, 2002). All of these areas 
express leptin receptors and may be targets for endogenous leptin; administration of 
exogenous leptin directly into the fourth ventricle or over-expression of leptin in the 
hypothalamus both reduce food intake. Additionally these nuclei all have further roles 
in the control of feeding and appetite, with neuronal circuits interlinking them 
extensively.
These neuronal circuits include neurons which express the leptin receptor -  a single 
transmembrane cytokine receptor -  and signal through neuropeptides. The ARC is a 
point of integration between these neuropeptide signals and circulating peripheral 
signals (Wynne et al., 2005; Bethoud 2002). It contains two primary cell populations 
-  one which stimulates feeding and one which inhibits food intake fWvnne e< a!. 
2005; Bethoud 2002). The feeding-inhibitory neurons express pro-opiomeianocoran
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(POMC), a pre-cursor protein for melanocortins and melanocye stimulating hormones 
(MSHs), and cocaine- and amphetamine-regulated transcript (CART). The other 
population o f cells express neuropeptide Y (NPY) and agouti-related protein (AgRP), 
two mediators that both stimulate feeding -  NPY by agonistic action at postsynaptic 
receptors, and AgRP by antagonising a-MSH, a POMC cleavage product (Wynne et 
al., 2005). Both populations express receptors for leptin, which activates the 
POMC/CART-expressing cells and inhibits the activity of NPY/AgRP cells. Thus, in 
principle, when adiposity, and thus leptin levels, is high in times of plenty the 
orexigenic neurones are inhibited whilst the populations that inhibit feeding are 
activated. In times of starvation when leptin levels are lower the NPY/AgRP neurons 
are freed of inhibition and the POMC/CART neurons lack stimulation, so the 
orexigenic response dominates.
But if leptin inhibits feeding and is raised in times of high adiposity, why is obesity 
not prevented or counteracted by the increased leptin that fat laden adipocytes 
produce? Part of the issue is believed to be the decreased brain penetration by leptin in 
obesity and the phenomenon of secondary resistance -  where persistent high levels of 
leptin result in desensitisation of leptin receptors- in a parallel to mechanisms seen 
with other signalling molecules. However it is also possible that it is not true 
resistance and simply a result of leptin not being a sufficient mechanism to cope with 
the modem lifestyle and environment (Arch, 2005).
Returning to the neuropeptide circuits, both populations of neurons project into other 
hypothalamic nuclei in tandem -  such as the PVN, where elevation of NPY 
(endogenous or exogenous) stimulates feeding and conversely a-MSH (an 
endogenous neuropeptide arising from cleavage of POMC) inhibits food intake 
(Wynne et al., 2005). The PVN is also responsive to many other episodic mediators 
affecting food intake -  including the monoamines serotonin and noradrenaline 
[section 3.2, below], and insulin.
Insulin, like leptin, is a peripherally-produced hormone with widespread receptors in 
the hypothalamus -  including the ARC and PVN. Activation of these receptors can
both prevent starvation-induced riser ir NPY and increase the expression of the
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POMC mRNA (Wynne et al., 2005). Thus insulin can act as a tonic regulator of 
feeding, and does so through similar neuropeptide pathways as leptin.
Episodic Regulators. Together with the tonic factors there are a variety of short-term, 
episodic, signals involved in the control of appetite and food intake. There are too 
many to cover them all in depth, with different factors released from different parts of 
the body in response to different stimuli -  some that stimulate feeding and some that 
inhibit food intake. Some of these signals are released into the peripheral circulation 
(e.g. ghrelin), w’hilst others are relayed to the brain by the vagus nerve (e.g. peripheral 
cholecystokinin signals), and some -  like the orexins -  are themselves neuropeptides 
released when neurons detect changing metabolite levels.
Ghrelin is an example of an orexigenic peripheral factor. Released into the circulation, 
it is primarily produced by cells in the stomach, but also to a lesser degree from 
populations lower down the gut. Plasma lewis are high in times of fasting, and low 
after ingestion of energy (food or glucose solution) but not after ingestion of water 
alone -  so ghrelin release is not simply regulated by gastric distension. Peripheral 
ghrelin is thought to produce its orexigenic effect via the activation of NPY neurons 
in the ARC (Wynne et al., 2005) but ghrelin is also expressed centrally by some 
hypothalamic neurons with projections to various nuclei, such as the PVN or LHA 
which are implicated in the control of feeding, where they act on populations 
expressing both POMC/CART and NPY/AgRP. They also terminate on orexin 
neurons in the LHA.
Cholecystokinin (CCK) is a gut satiety factor predominantly expressed in duodenum 
and jejunum and expressed in the aftermath of ingesting nutrients. It has many actions 
to do with co-ordinating digestion of food, but is also capable of directly inhibiting 
food intake. Peripheral CCK signals activate the vagal nerve, which projects to the 
NTS in the brainstem, and the signal is then forwarded from the NTS to the 
hypothalamus (Wynne et al., 2005). The NTS contains many POMC/CART neuron 
cell bodies which are activated by peripheral CCK. Although this is the primary 
pathway for CCK signalling, it is also possible that circulating CCK is transported 
across the blood-brair barrie^ and direetlv  into the central nervous system It is also
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true that CCK is widely expressed in the brain, where it functions as a neuropeptide 
and is involved in many and varied neural pathways -  including satiety circuits.
A pattern is clearly visible with the examples given here: whether tonic or episodic, 
conducive or inhibitive o f feeding, the factors involved in appetite control exert their 
effects by influencing the neural circuits in the hypothalamus, activating either 
POMC/CART neurons or NPY/AgRP neurons.
But what of the orexins -  which are themselves peptide neurotransmitters that 
stimulate feeding? In contrast to ghrelin, CCK, leptin and insulin which lie upstream 
of the hypothalamic circuits described above, orexin may be downstream of NPY, 
with the orexin cell bodies in the LHA expressing receptors for NPY (and leptin). 
Additionally, orexin neurons may be responsive to circulating glucose levels -  
certainly there are glucose-sensitive cells in the LHA -  and thus it is possible that dips 
in blood glucose may help initiate feeding behaviour (Arch, 2005). Orexin neurons 
project widely to other regions of the hypothalamus as well as to structures involved 
in arousal and motor control, but what lies downstream o f orexin systems is not yet 
fully clear (Wynne et al., 2005).
The above should give a little background on the control o f feeding and appetite 
(although far from an exhaustive description). However this thesis is concerned with 
drugs which exert their effects by acting on monoamine neurotransmitter systems and 
so a discussion o f these circuits and how they relate to feeding control follows.
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3.2 The Role of Serotonin and Noradrenaline
This section concentrates on giving an overview of the role o f the monoamines 
noradrenaline (NA; figure 3.6.1) and serotonin (5-hydroxytryptamine, 5-HT; figure 
3.6.2) in the control o f feeding behaviour as these are the neurotransmitters upon 
which sibutramine and cZ-fenfluramine predominantly act. Many in-depth reviews o f  
the processes involved with feeding and satiety have been written over the last 20  
years (e.g. Blundell and Halford, 1999; Blundell, 1986; Hoebel, 1997; Leibowitz and 
Alexander, 1998; Leibowitz and Hoebel, 1998; Leibowitz and Shor-Posner, 1986; 
Simansky, 1996) and the reader is encouraged to look to these for further and more 
complete understanding of the regulation of food intake and feeding behaviour.
Both NA and 5-HT are heavily implicated in general behavioural arousal. Equally 
both have been proven to have specific actions in regulating feeding behaviour (NA  
and 5-HT) and satiation and satiety (5-HT), the process of attaining and maintaining a 
state of “fullness” that accompanies the natural termination of feeding. The 
hypothalamus -  and in particular the paraventricular nucleus (PVN) -  is considered to 
be the region o f the brain most central to the control o f feeding behaviour and food 
intake though other regions are undoubtedly involved (e.g. Leibowitz and Hoebel,
1998).
Both ai and CI2 adrenoreceptors have a role in modulating feeding in the 
hypothalamus, and specifically within the PVN (Goldman et al. , 1985; Jhanwar- 
Uniyal et al., 1986; Leibowitz and Hoebel, 1998; Morien et al., 1999; Wellman et a l ,  
1993). It has been shown that whilst a i receptor activation leads to the cessation o f  
feeding and a reduction in food intake, agonists at 0(2 receptors actually increase food 
intake and stimulate a feeding response in satiated animals (Goldman et a l,  1985; 
Jhanwar-Uniyal et a l ,  1986; Leibowitz and Hoebel, 1998; Wellman et a l, 1993). In 
vivo NA acts preferentially through 0(2 receptors over di receptors (Wellman et al., 
1993), hence the specific increase in food consumption seen (on top of general 
increases in arousal) if  NA is administered into the PVN. The balance of di and d2 
receptors is thought to play a role in the extent o f this.
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The interaction between the two receptor types is not only directly antagonistic, but 
also linked in terms of receptor expression; the time of peak expression for one 
subtype corresponding with the nadir of expression for the other. Binding studies on 
tissue harvested at times spread across the circadian cycle found expression of <3i 
receptors to be highest in the light phase and lower during the dark phase (Morien et 
al., 1999). The opposite was true of 0  ̂receptors (Jhanwar-Uniyal et al., 1986; Morien 
et al., 1999); thus receptors that stimulated feeding exhibited greater expression in the 
PVN at times of peak food and water intake. Studies with selective agonists and 
antagonists have demonstrated that these two receptor subtypes can be in direct 
competition; Goldman et al. (1985) showed that administration of the Oj antagonist 
corynathine enhanced the feeding response induced by intra-PVN injections of NA. 
The interaction between the levels of Cii and QXi receptors is linked to circadian time 
and is just one reason why circadian rhythm [section 3.3, below] may be an important 
factor in relation to drug treatment of obesity, with NA re-uptake inhibition being a 
crucial part of the mechanism of action of sibutramine [see section 3.4 for a review of 
sibutramine].
The role played by NA seems small compared to the impact of 5-HT on food intake, 
feeding and satiation. This latter neurotransmitter is very prevalent in the 
hypothalamus, where it has roles in two systems central to this thesis. First, 
modifications of 5-HT can cause modulations in the suprachiasmatic nucleus (SCN) -  
the brain region at the centre of the circadian clock functions [section 3.3], and not 
entirely dissociated from feeding (Leibowitz and Alexander, 1998) -  and secondly 5- 
HT plays a large part in regulating food intake, with specific reference to the 
processes of satiation and satiety (Halford and Blundell, 1999; Leibowitz and 
Alexander, 1998; Simansky, 1996). Serotonin plays a role in modulating satiety, both 
in the periphery and within the central nervous system (e.g. Edwards and Stevens, 
1991; Simansky, 1996). It is considered to be a short-term satiety factor, working in 
conjunction with other modulators such as cholecystokinin (CCK; Cooper et al., 
1990a; Leibowitz and Hoebel, 1998) -  which itself is a peripheral satiety factor (e.g. 
Antin et al., 1975) -  yet whilst the 5-HT releasing agent fenfluramine produced 
anorexia dependent on CCK (Cooper et al., 1990a) the anorectic effect of the 5-HT 
re-untake inhibitor fluoxetine did nof. share this denendence (Coone” e* a 7 100 
Many drugs that enhance 5-HT neurotransmission -  such as sibutramine [section 3.4]
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and fenfluramine [section 3.5], the two drugs with which this thesis is concerned -  
exert actions on feeding behaviour and food intake by facilitating or speeding up the 
natural processes of satiation and satiety, as measured by the Behavioural Satiety 
Sequence (BSS; Antin et a l , 1975; Halford et a l , 1995; Halford et a l , 1998; chapters 
4 and 7). This is to say that the normal behavioural structure of feeding and meal 
termination is preserved but temporally advanced, mimicking the effect of “pre- 
feeding.” Serotonin exerts its actions through a large number of different receptor 
types (see Barnes and Sharp (1999) for a review of 5-HT receptors), not all of which 
are strongly linked to appetite, feeding or satiety. Of primary importance to these 
functions are the 5-HTib and 5-HT2C subtypes, which play specific roles in 
determining food intake (5-HTib) and the rate of eating (5-HT2c) respectively 
(Grignaschi and Samanin 1992; see Clifton (2000), Simansky (1996) and Leibowitz 
and Alexander (1998) for reviews). Activation of the 5-HTia receptor has been shown 
to elicit hyperphagia (Hutson et a l , 1988; Simansky, 1996). These roles have been 
determined by studies with specific agonists such as CP-94,253 (a 5-HTib receptor 
agonist; Halford and Blundell, 1996a; Lee and Simansky, 1997; Lee et a l, 2002) and 
using specific antagonists, such as ritanserin, cyanopindolol and metergoline, to 
investigate the contributions of various receptor subtypes to fenfluramine hypophagia 
(Grignaschi and Samanin, 1992). Additionally, in the case of the 5-HT2c receptor 
experiments have been done using knockout mice (Tecott et al, 1995; Vickers et a l,
1999); animals lacking this receptor developed obesity in adulthood and exhibited less 
of an anorectic response to fenfluramine, argued to be a result of a reduced satiating 
effect (Vickers et al., 1999). Selective agonists at 5-HTib receptors such as CP-94,253 
tend to enhance satiety, as defined by advancing and preserving the BSS (Halford and 
Blundell, 1996a, Lee and Simansky, 1997; Lee et a l, 2002; see section 4.1). Agonists 
acting at 5-HT2c receptors have produced mixed results with some producing 
disruption of the BSS through sedation, at least at high doses {e.g. MK-212; Halford 
et a l, 1996), whilst others appear to advance and preserve the BSS (e.g. mCPP (\-{m- 
chlorophenyl)piperazine) and Ro 60-0175 ((S)-2-(6-chloro-5-fluoro-indol-l-yl)-l- 
methylethylamine hydrochloride); Hewitt et a l, 2002). All these drugs reduced food 
intake, however.
Acfyatior of othe * 5-HT reeeoto~ siibtvpc? car influence food intake and fee choc, tor 
though without specifically affecting satiety and satiation. For example as mentioned
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above, activation of the 5-HTiA receptor can cause hyperphagia (Hutson et al, 1988; 
Simansky, 1996). This is related to this receptor’s primary function as a cell body 
autoreceptor on 5-HT neurones, including those projecting to the hypothalamus; 
activation of these inhibitory autoreceptors decreases neuronal firing rates and 
consequently reduces neuronal 5-HT release, thus inhibiting 5-HT mediation of 
satiety. In contrast the 5-HT2 receptor agonist l-(2,5-dimethoxy-4-iodophenyl)-2- 
aminopropane (DOI) reduces food intake, but does so by facilitating a general 
increase in activity (Kitchener and Dourish, 1994), reminiscent of the effect of 
dopaminergic agents like amphetamines, which disrupt natural satiety' {e.g. Halford et 
al., 1998).
As with NA, the PVN is thought to be the primary site of action for 5-HT effects on 
feeding behaviour {e.g. Simansky, 1996; Leibowitz and Alexander, 1998) but its 
effects are not limited to those produced in this nucleus. Lesions of the PVN fail to 
prevent the modification of feeding by some serotonergic agents (Fletcher et al., 1993) 
and other nuclei -  including the SCN -  are thought to play a role {e.g. Simansky, 
1996; Leibowitz and Alexander, 1998). Both 5-HTiB and 5-HT2c receptors are 
expressed in high numbers in the hypothalamus as a whole, and specifically in the 
PVN and related structures like the SCN, whilst 5-HTiA receptors are scarce in these 
regions (Leibowitz and Alexander, 1998).
So how do these monoamine neurotransmitters fit in with respect to the neuronal 
peptide circuits mentioned in section 3.1? Are the two systems separate or do they 
interact with each other? The answer is intuitive: the systems must interact somehow, 
and they do. Neurons expressing the feeding-inhibitory 5-HTib receptor are not just 
found in the PVN, but also in the ARC, the LHA and other feeding-associated nuclei. 
At least in the PVN and LHA this pattern of expression is consistent with populations 
of NPY neurons -  thus the inhibitory action of 5-HT on feeding could in part be down 
to a suppression of NPY activity. Moreover, activation of PVN 5-HT 2A/2c receptors 
can also antagonise NPY-induced increases in feeding (Ramos et al., 2005). It is also 
known that, when given peripherally, the 5-HT releasing agent ^-fenfluramine 
[section 3.5, below] can decrease NPY concentrations in several hypothalamic nuclei 
(Ramos e' a\ 2005s and noradrenaline car be found ir the same neumns ir
some areas of the bram and NPY can also stimulate NA release. The mechanisms and
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role o f NPY in modulating noradrenergic systems are not fully elucidated yet (Ramos 
et al., 2005). Less still is clear about interactions between POMC-cleavage products 
such as a-MSH and monoamines, but it has been shown that blocking the receptors 
through which a-MSH acts can lessen the anorectic response to the serotonin 
releasing agent ^-fenfluramine (Heisler et a l, 2002; Ramos et al., 2005).
The above is a focussed summary o f some actions o f 5-HT and NA in the control o f 
feeding and satiety. There are many other roles played by both these neurotransmitters 
in fields related to appetite, obesity and satiation -  including impact on dietary 
selection of macronutrients for example -  and by other compounds such as the 
peptides CCK and neuropeptide Y, or hormones such as leptin. Rather than paint the 
complete picture o f  the neuroscience o f feeding behaviour, the aim here was to 
provide an insight into how NA and 5-HT modulations can affect feeding behaviour 
and why drugs that work through these systems may show efficacy in treating obesity. 
For further understanding o f  the roles played by other modulators the reader is 
advised to consult Leibowitz and Hoebel (1998).
The above-overview also highlighted one reason why circadian rhythm is an 
important factor to consider -  namely the circadian variation in PVN a-adrenergic 
receptor expression and the balance between the two subtypes. This is not the only 
factor that varies with circadian time, whether related to the interference with the 
control of feeding specifically or drug treatment in general, and the next section will 
give an overview of why circadian rhythm is an important factor to consider in 
pharmacology.
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3.3 The Importance of Circadian Rhythm
Mammalian organisms exhibit rhythmic changes in a number of biological parameters 
with time of day. These 24-hour rhythms are driven by an endogenous pacemaker 
located in the SCN (see Weaver, 1998 for a single review article or the special issue 
of Chronobiology International (15(5), 1998) for a collection of in depth articles on 
the SCN), and also influenced by environmental cues such as those provided by light. 
The circadian rhythm is an endogenous rhythm. Isolating an organism from external 
cues does not eliminate rhythmicity (Rae, 1998), thus proving the endogenous 
component. Moreover, the endogenous rhythms -  such as that shown in the level of 
activity -  “free run” in the absence of external cues (Rae, 1998); rather than the 
periods o f activity occurring at the same time every day, they occur with a periodicity 
of just over or just under 24 hours. It is from here that the term “circadian rhythm” 
comes (Latin: circa (around) and dies (day) and hence literal meaning of circadian is 
“around a day”). In the presence of a regular light cycle, and the photic cues this 
provides, these endogenous circadian rhythms become entrained to the 24-hour 
photoperiod (e.g. Bunning, 1964; Davies et al., 1972; Rae, 1998). Since the driving of 
the rhythmicity is at least partially endogenous, this entrainment by external factors 
affects most, if not all, of the biological systems that exhibit rhythmicity.
Circadian rhythmicity is expressed in the variation in biological parameters with time 
of day. Many different systems exhibit circadian rhythmicity, though the most easily 
observed is a simple measure of when an organism is active or inactive. The 
complexity of circadian rhythm goes far beyond this, however, and it is this 
complexity which makes time of day a key factor in pharmacology, one that requires 
quantifying. As mentioned above [section 3.2], levels of receptor expression are one 
pharmacologically relevant parameter that can vary in circadian manner, in this case 
the expression of C (i and <32 adrenergic receptors in the PVN (Jhanwar-Uniyal et a l , 
1986; Morien et al., 1999). Clearly such variation is of direct relevance to 
pharmacological study, as variation in receptor populations will mean variation in the 
response to agents which act via these receptors. This is just one example of how 
circadian rhythms may affect drug treatment and thus a brief discussion of circadian 
rbythmieip and why investigating these effects if imoprtaiit fpllowr
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The central control of the circadian system is accepted as being located in the SCN, 
within the hypothalamus; this is demonstrated by the fact that in animals where the 
SCN is ablated all behavioural and physiological rhythms are lost if photic cues -  
changes in light -  are removed (Weinert, 2005; Weaver, 1998). One of the 
neurotransmitters heavily implicated in the circadian system is 5-HT, and this 
transmitter and various receptors for it are prevalent in the SCN (Rae, 1998). 
Activation of certain subtypes of 5-HT receptors (e.g. 5-HTia, 5 -HT7; Biello and 
Dafters, 2001; Lovenberg et al., 1993; Rae, 1998) can cause “phase shifts” -  temporal 
shifts of activity rhythms observed in constant light or darkness -  in animals isolated 
from zeitgeibers (the environmental cues that entrain the internal clock). Interestingly 
direct injection of 5-HT into the SCN also alters feeding behaviour (mentioned in 
their review of serotonin and feeding behaviour by Leibowitz and Alexander, 1998). 
For more complete understanding of the SCN, the reader is referred to the special 
issue of Chronobiology International (Volume 15, Issue 5, 1998) devoted to reviews 
concerned with this nucleus, and to other recent reviews (Weinert, 2005; Weaver, 
1998).
Of more direct relevance to this thesis is how circadian rhythm can influence 
pharmacology; specifically how such variation may interact with interventions in 
central nervous system control of feeding and satiety. One such mechanism -  
variation in receptor expression -  has been mentioned above; changes in the balance 
of <3i and O2 adrenergic receptors could have a significant impact on the efficacy of 
sibutramine [section 3.4], which blocks NA (and 5-HT) re-uptake. Adrenergic 
receptors are not the only receptor type that exhibit circadian rhythmicity, nor are 
changes in the level of receptor expression the only mechanism by which rhythmicity 
may be expressed. For example, Garabette et al. (2000) found circadian variation in 
the functional activity of SCN 5-HTib receptors, although no variation in levels of 
expression had been reported.
Perhaps yet more relevant is the natural circadian variation in levels of the 
neurotransmitters themselves -  whether of tissue levels, extracellular levels, or the 
rate of synthesis or release. Both NA and 5-HT levels vary over 24 hours, although 5-
HT. more marked*' thsr N- /see> the reviev b' Martin and R.ed|err toc*'7 Bpty 
transmitters are recorded as having pronounced circadian variation in tissue levels, but
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the more important differences appear to be in the nature of the variation in release. 
The circadian variation in release of NA is very closely tied to overall arousal and 
behavioural activity, at least in the hippocampus (Kalen et al., 1989); consequently in 
nocturnal animals like rats the basal level of NA was high during the dark phase and 
lower during the light. Telencephalon NA levels -  intra and extracellular -  match this 
pattern (Philo et al., 1977). In addition to this, NA levels in the PVN showed short- 
lasting peaks at the beginning and end of the dark phase; these peaks disappeared in 
food deprived animals, replaced with a slow accumulation of NA until the animals 
were fed, at which point the levels of NA dropped immediately (Stanley et al., 1989). 
This suggests that PVN levels of NA are driven by external factors and the 
rhythmicity of feeding behaviour as opposed to being endogenously generated on a 
circadian basis.
By contrast, tissue levels of 5-HT are highest during the light phase in the rat; 
however this does not translate to a pattern of release or usage. Further investigation 
revealed that 5-HT synthesis was greatest in the light, but breakdown greatest during 
the dark phase. This finding by Hery et al. (1972) was the first to suggest that more 5- 
HT was used and released during the active phase, and was backed up by in vivo 
voltammetry studies by Faradji et al. (1983). Also in contrast to NA there are 
indications that rhythms in 5-HT levels are endogenously generated (Cagampang and 
Inouye, 1994), at least in the SCN. As is seen with locomotor activity rhythms {e.g. 
Davies et a l, 1972), rhythms in 5-HT levels -  at least in the SCN -  “free run” when 
animals are moved into constant darkness (Cagampang and Inouye, 1994). Further 
study showed that there are circadian variations in almost every function of 5-HT 
turnover -  from synthesis, to neuronal firing rate, to receptor function and ultimately 
metabolism (see Martin and Redfem 1997 for a complete review). Given the primary 
neurotransmitter(s) on which both fenfluramine and sibutramine act exhibit such a 
wide array of circadian changes it is not a large conceptual leap to expect circadian 
variation in the response to these drugs. Additionally whilst most is known about how 
5-HT levels vary with circadian time, and NA levels are also known to vary, it is 
reasonable to expect that a similar degree of variation may be seen with other 
neurotransmitters, including others with an influence -  however tangential -  on 
feeding behaviour such as donamine or some of the nentide neurotransmitters
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Variation in transmitter levels is not the only way in which the efficacy of these drugs 
may be affected by the time of day at which they are administered. Circadian variation 
in pharmacokinetic properties has been reported with many drugs, from common 
aspirin, to penicillins, to cardiovascular therapies, to centrally acting compounds like 
diazepam (Labreque and Belanger, 1991; Reinberg and Smolensky, 1982). This is 
perhaps especially relevant to the current work, as sibutramine is a parent compound 
with not just one, but two active metabolites. It is these metabolites which are 
responsible for the majority of the in vivo actions o f sibutramine to inhibit reuptake o f  
NA and 5-HT [section 3.4]. Fenfluramine also has a metabolite that contributes to its 
therapeutic use; whilst fenfluramine itself functions as a re-uptake blocker at low  
concentrations and 5-HT releasing agent at higher concentrations [section 3.5], its 
metabolite norfenfluramine is a direct agonist at 5-HT2C receptors {Gibson et al., 1993; 
Simansky, 1996). Circadian rhythms in the breakdown of the parent compounds could 
thus potentially contribute significantly to circadian variation in the efficacy o f  
treatment. Labrecque and Belanger (1991) reviewed why circadian rhythm in 
pharmacokinetics is an important factor to consider in pharmacology.
Finally, another obvious reason why time o f  day might be a significant factor in the 
efficacy of anti-obesity therapy, and specifically therapies that act by enhancing 
natural satiety, is that standard activity rhythms -  including those associated with 
feeding -  are under fairly stringent circadian control. Rats consume the vast majority 
of their daily intake in the dark phase when they are also most behaviourally active. It 
would thus appear intuitive to target treatment towards times of peak intake.
With the above thoughts in mind it is now appropriate to consider the drugs to be 
investigated in this thesis.
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3.4 Sibutramine
Sibutramine hydrochloride {1 -(4-chl<^ophenyl)-N,N-dimethyl-a-(2-methylpropyl)- 
cyclobutanemethanamine) is a 5-HT and NA reuptake inhibitor. Developed by Boots 
Pharmaceuticals (Nottingham, UK), originally with a view to producing a rapidly 
acting anti-depressant, sibutramine has been investigated and used as a novel 
anorectic (anti-obesity) agent (Heal et al., 1998a). The following is a brief overview 
of this drug, its pharmacology, experimental history and (pre-)clinical effects.
Sibutramine (figure 3.6.3) exerts its effects primarily through two active metabolites 
-  primary and secondary amines (desmethyl- and di-desmethyl- sibutramine) -  which 
are also both active as inhibitors o f  NA and 5-HT reuptake and more potent than die 
parent compound (table 3.6.1; Heal et a l , 1998a; Luscombe et al., 1989). Upon 
administration sibutramine is rapidly demethylated in the liver and it is subject to 
extensive first pass metabolism if  given orally whilst the metabolites have long half- 
lives; in man the pharmacokinetics are not variable with age (e.g. Hind et al., 1999). 
In the rat similar extensive first-pass metabolism occurs if the drug is administered 
either orally or i.p., so much so that by 30 minutes after administration sibutramine 
plasma concentrations are very low, whilst the concentrations o f both metabolites are 
at close to peak levels (personal communication, D. Heal). Buckett et al. (1988) 
describe experiments where sibutramine was examined by in vivo, ex vivo and in vitro 
experimental models designed to give indication o f therapeutic potential for the 
treatment o f depression. These authors found that sibutramine was potently active in 
behavioural paradigms predictive o f  anti-depressant activity, as well as being capable 
of rapid down-regulation o f P-adrenoreceptors -  a functional change believed very 
important in depressive therapy at the time (Vetulani and Sulser, 1975). The 
compound was further developed and made it to phase II clinical trials where, against 
expectation, it failed to exhibit anti-depressant efficacy. However, a side effect of 
treatment with sibutramine in these trials was that patients lost weight (e.g. Heal et al., 
1998#); this finding has since been replicated in many other clinical trials (Weintraub 
et a l, 1991) and the drug has since been widely studied with respect to anti-obesity 
therapy (as reviewed by Heal et a l, 1998a).
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The results of numerous experiments illustrate that sibutramine and its metabolites 
work solely via re-uptake inhibition. Rather than stimulating release of NA or 5-HT 
from neurons -  via electrical stimulation, by transporter reversal or other mechanism 
-  sibutramine leads to a slow build up of extracellular neurotransmitter (Gundlah et 
a l, 1997; Heal et al., 1998a,b) as the transmitter released by nerve firing simply 
cannot be removed from the extracellular fluid. This is in contrast to fenfluramine 
which causes the release of stored 5-HT (Gundlah et al., 1997; Heal et al., 1998a,b\ 
section 3.5). Comparatively the magnitude of change in extracellular levels is much 
greater with releasing agents than it is with re-uptake inhibitors and the maximal 
extracellular concentration is also reached sooner (Gundlah et al., 1997; Heal et al, 
1998a,b). The ability of a re-uptake inhibitor to elevate extracellular 5-HT is therefore 
potentially more likely to exhibit circadian variation in efficacy than might be the case 
for a releasing agent. Re-uptake inhibition requires endogenously-generated neuronal 
firing to increase extracellular 5-HT, whilst suppressing such firing by ensuring the 
continued presence of 5-HT in the synapse, where it can activate terminal 
autoreceptors (Gundlah et al., 1997; Heal et al, 1998a,b), thus exerting a negative 
feedback on neuronal 5-HT release.
Sibutramine induces weight loss by working on both sides of the energy balance. Not 
only does it reduce food intake by enhancing satiety (Halford et a l, 1995; Halford et 
al, 1998; Heal et a l, 1998a) but it also induces an increase in energy usage by 
promoting thermogenesis in brown adipose tissue, raising basal metabolic rate 
(Connoley et a l, 1999; Heal et al., 1998a, Stock, 1997). Both facets of this action 
involve synergistic interactions of NA and 5-HT and are sensitive to a variety of 
antagonists of adrenergic and serotonergic systems (see below). The work presented 
in this thesis will concentrate on the satiety enhancing actions of sibutramine. The 
reader is advised to look to other reviews and publications for further information on 
the thermogenic properties of sibutramine {e.g. Connoley et al, 1999; Heal et a l, 
1998a\ Stock, 1997).
Before going on to consider the satiety enhancement it is pertinent to describe more 
fully the pharmacology of sibutramine and its metabolites. Table 3.6.1 (reproduced
from data reported ir Heal et al. 1°9 8 ^  indicates the potencies of sibutramin° an: 
both of its metabolites -  as well as those of related compounds and the anorectic
monoamine releasing agents ^-amphetamine and ^/-fenfluramine [section 3.5 below] -  
to inhibit re-uptake of monoamines in vitro in tissue collected from rat brain. 
Although this shows the relative selectivity for 5-HT and NA over dopamine, the data 
presented suggest that dopamine re-uptake might be a contributing factor to the 
pharmacology of sibutramine. However, Heal et al. (1992) used a drug discrimination 
paradigm to show that sibutramine generalised to saline rather than amphetamine; 
these authors additionally showed that sibutramine did not mimic dopaminergic 
agents in inducing circling behaviour in rats with unilateral lesions of the nigrostriatal 
pathway. There have been findings that sibutramine did indeed increase extracellular 
dopamine in the striatum and hypothalamus of rats (Balcioglu and Wurtman, 2000; 
Rowley et al., 2000), but these effects were observed with relatively high doses of 
sibutramine. Administration of sibutramine at doses close to the ED50 for inhibition of 
2 hour food intake (2.0 mg/kg; Halford et al., 1995; Rowley et a l, 2000) caused no 
significant increase of extracellular dopamine (Balcioglu and Wurtman, 2000; Rowley 
et al., 2000). Even at doses at which sibutramine did induce a significant increase in 
extracellular dopamine there was no evidence of an effect on locomotor activity 
(Rowley et al., 2000). Further evidence of a relative lack of dopaminergic 
contribution to the actions of sibutramine is that the compound appears to lack the 
abuse potential of amphetamine (Gosden et al., 1996; Heal et al., 1998a; Schuh et al., 
2000).
Sibutramine is accepted as producing its inhibition of food intake by advancing the 
behavioural satiety sequence (Halford et al., 1995; Halford et al., 1998; Heal et al., 
1998a) -  indicative of the drug enhancing the natural process of satiation. Jackson et 
al. (1997a) investigated the contribution of various receptor subtypes to 8 hour 
sibutramine hypophagia and found roles for aj but not a 2, and for pi but not p2, 
adrenoreceptors, as well as for 5 -HT2A/2c receptors. As described above [section 3.1], 
activation of di receptors in the PVN suppresses feeding (Leibowitz and Hoebel, 1998; 
Wellman et al., 1993). Given this, it is unsurprising that blocking this receptor 
negated the hypophagic effect of a drug that induces a rise in extracellular NA levels 
(Jackson et al. 1997a), especially given that endogenous NA preferentially activates 
a 2 receptors over dj receptors (Wellman et al., 1993) and a 2 receptor activation in the 
PVN can stimulate feeding even in satiated rats (Goldman et al.. 19853 It is also 
unsurprising tnai a paraai attenuation 01 sioutramine nypopnagia can oe acmevea D)
blockade of 5-HT2 receptors -  and the 5-HT2c subtype in particular; the activation o f  
these receptors has been shown to reduce the rate o f feeding in rats (Clifton, 2000; 
Grignaschi and Samanin, 1992; Simansky, 1996; section 3.2). This work with 
selective antagonists complements more work by Jackson et al. (19976) using the 5- 
HT uptake inhibitor fluoxetine in combination with the NA uptake inhibitor 
nisoxetine. These experiments showed that while re-uptake inhibition o f either NA or 
5-HT alone was not sufficient to reproduce the effects o f sibutramine, in combination 
these drugs were able to inhibit food intake in a manner consistent with the effect o f  
sibutramine, and with similar potency.
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3.5 Fenfluramine
In addition to sibutramine [described in section 3.4 above] the other drug central to 
the experiments described in this thesis is the d-isomer of fenfluramine (iV-ethyl-l-[3- 
(trifluoromethyl)-phenyl]propan-2 -amine).
Fenfluramine bears some chemical relation to amphetamine (figure 3.6.4), whilst 
exhibiting a very different pharmacological profile -  despite both having a proven 
record as anorectic agents (Ziance et a l,  1972; Dobrzanski and Doggett, 1976; 
Thurlby et a l, 1983; Rowland and Carlton, 1986; Heal et a l, 1998a). Where 
amphetamine is primarily active upon the catecholamines, NA and dopamine, 
fenfluramine is primarily a serotonergic agent though with some lesser impact on 
catecholaminergic systems (Ziance ei a l, 1972; Rowland and Carlton, 1986; Heal et 
al, 1998a). In terms of its affinity for, and efficacy at inhibiting, the uptake carrier d- 
fenfluramine is approximately equipotent at the NA and 5-HT carriers (e.g. table 
3.6.1; Heal et a l, 1998a), however there is a significant separation in the 
concentrations at which ^-fenfluramine is active at releasing serotonin and 
noradrenaline, Whilst there is only a 3-fold difference in the concentration required to 
block re-uptake or stimulate release of 5-HT, there is a 40-fold separation between the 
concentration of fenfluramine required to block NA re-uptake and that required to 
cause significant NA release, thus in terms of its potential to cause monoamine release 
fenfluramine is selective for serotonin (Heal et a l, 1998a).
Amphetamine increases spontaneous locomotor activity, whilst fenfluramine 
decreases the same parameter (e.g. Ziance et a l,  1972; section 5.1). Similarly, where 
amphetamine is associated with high potential for abuse, fenfluramine is not 
(Rowland and Carlton, 1986) and where amphetamine disrupts the behavioural satiety 
sequence fenfluramine enhances it (e.g. Halford et a l, 1998) -  although there have 
been contradictory reports upon fenfluramine’s action in the past [see section 4.1]. 
Interestingly, too, racemic fenfluramine actually has a negative impact on dopamine 
systems, thought to be a result of receptor antagonism mediated by the /-isomer 
(Rowland and Carlton, 1986). This is just one contributory reason why the ^-isomer 
ha - ’■enlaced the raeemate a r the r>fima '̂ form in which fenfluramine if used
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Yet despite these differences there are also important similarities between 
amphetamine and fenfluramine. Both are monoamine releasing agents. Like 
amphetamine, fenfluramine binds to re-uptake sites (see table 3.6.1) -  indeed 
fenfluramine acts as a 5-HT re-uptake inhibitor at low concentrations (Rowland and 
Carlton, 1986; Garattini et al., 1986). Both compounds enter neurons, where they 
stimulate release from intracellular stores - an effect seen in vim  and replicated in 
brain slices in vitro (Garattini et al., 1986; Sulzer et al., 2005; Wortley et a l, 1999; 
Heal et a l, 1998a,b; Gundlah et al., 1997). Therefore fenfluramine causes an increase 
in extracellular 5-HT lewis independently of neuronal firing, as amphetamine does 
with both dopamine and NA; fenfluramine also releases NA but with much lower 
potency (see table 3.6.1 and above; Rowland and Carlton, 1986). In fact, binding to 
the re-uptake transporter is required for fenfluramine entry into neurons as pre­
treatment with a selective inhibitor of these sites (like fluoxetine or indeed 
sibutramine) attenuates fenfluramine-induced 5-HT release (Gundlah et al., 1997). 
The ^-isomer has greater affinity for the carrier than the /-isomer (Rowland and 
Carlton, 1986).
Fenfluramine - and so too, separately, the ^-isomer - had previously been licensed for 
the clinical treatment of obesity in the USA but both were voluntarily withdrawn in 
1997 following concerns over cardiovascular side-effects. In rodents the drug works 
primarily by reducing food intake, mediated by a 5-HT-dependent enhancement of 
post-ingestive satiety -  an effect determined by several experiments observing the 
behavioural satiety sequence [section 4.1]. The <7-isomer is more potent in terms of 
reduction of food intake (Rowland and Carlton, 1986), which is the primary' clinical 
effect of taking fenfluramine, and the J-isomer of norfenfluramine -  a fenfluramine 
metabolite -  is similarly more potent than its /-counterpart. In fact, J-norfenfluramine 
is a direct agonist at 5-HT2c receptors (Gibson et a l, 1993) which, together with its 
long half-life {e.g. Rowland and Carlton, 1986; Garattini et al., 1986), contributes 
significantly to the anorectic potential of <7-fenfluramine as this receptor type is 
implicated in feeding behaviour, specifically with reference to the rate of eating 
(Grignaschi and Samanin, 1992). That ^-fenfluramine itself may have some direct 
agonist potential on some yet unconfirmed receptor is also a possibility given that the 
h '̂pophagiE orpduoed by L^-fenfuramine is not blocked, by nre-treatmery vritv 5rxjrr-
27
reuptake inhibitors but is by the non-selective 5-HT antagonist metergoline (Raiteri et 
al., 1995; Curzon et al., 1997).
Another factor that may contribute to the efficacy of fenfluramine in treating obesity 
is that it has transient effects on muscular energy expenditure. Even and Nicolaidis 
(1986) discovered that ii-fenfluramine increased the energy cost of muscular effort. 
Not entirely unrelated to this are reports of fenfluramine as a sedative, as measured by 
recordings of locomotor activity (Ziance et al., 1972; Aulakh et al., 1988; Callaway et 
al, 1993), though significant sedation is not thought to play a role in the reduction of 
food intake by fenfluramine, and the drug does not sedate heavily enough at 
appropriate anorectic doses to disrupt the behavioural satiety sequence [chapter 4]. 
Moreover, the sedative or motor-depressant actions of fenfluramine haw been shown 
to be mediated by a different pathway to the effects on food intake (Callaway et al.,
1993). On top of all this, fenfluramine has been shown to increase diet-induced 
thermogenesis, although this effect has only been reported with doses well above 
those required for hypophagia (Rowland and Carlton, 1986) and it is not thought that 
this is physiologically relevant to the anorectic effects of fenfluramine. Another 
interesting effect of fenfluramine is that if it is given to animals after they have eaten 
to satiation they experience a taste aversion reaction and eat less the next day 
(Rowland and Carlton, 1986).
The four pharmacological criteria that Gundlah et al. (1997) defined for 
differentiating 5-HT re-uptake inhibitors and releasing agents in vivo proved 
sibutramine and its primary amine metabolite were acting as reuptake inhibitors. The 
same criteria also provide evidence that fenfluramine acts primarily as a releasing 
agent in vivo.
These criteria (Gundlah et al., 1997) are:
• The magnitude of the change in extracellular neurotransmitter levels; the
increase is much higher with releasing agents.
• The dependence on neuronal activity; re-uptake inhibitors rely on neuronal
actri'fr' tc elevate. extnaceljula*Transm;tte* .
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• Whether pre-treatment attenuates the effect of known releasing agents 
dependent on the 5-HT carrier; re-uptake inhibitors prevent entry of these 
releasing agents into the neuron, thus reducing the magnitude of their effect, 
whilst releasing agents do not.
• Whether the systemic administration of a drug during an intra-hypothalamic 
infusion of that same drug attenuates the large initial increase seen on local 
infusion; peripheral administration of a re-uptake inhibitor during its local 
infusion will reduce the magnitude of the change in extracellular transmitter 
lewis
The recorded rise in extracellular 5-HT is too fast and of too great a magnitude for it 
to be due to re-uptake inhibition (Gundlah et a l, 1997; Heal et a l, 1998b). A degree 
of re-uptake inhibition may well be involved in limiting the rate at which the released 
5-HT is cleared, however. The levels of release obtained with fenfluramine are so 
high compared to basal levels of 5-HT {e.g. Gundlah et al., 1997; Heal et al., 1998b) 
that one might expect less circadian variation in the response to be caused by changes 
in 5-HT availability than might be attributable to postsynaptic receptor changes. That 
the in vivo hypophagic response to fenfluramine is not dependent on 5-HT availability 
(though 5-HT release could still play a role in normal mediation of the response; 
Curzon et al., 1997) would tend to suggest that any circadian variation in the response 
to fenfluramine would be more likely to be dependent on 5-HT receptor variations 
than on tissue lewis of 5-HT (highest in the light phase), the rate of 5-HT synthesis or 
on the basal activity of serotonergic circuits. On the other hand, since fenfluramine is 
reported as having additional actions other than to enhance satiety -  namely the 
sedatiw and metabolic effects described above -  there is every chance that these 
parameters may exhibit some level of circadian variation especially since the effects 
on motor activity can be functionally dissected from the hypophagic effect (Callaway 
et al., 1993). This means that there are at least two distinct mechanisms in which 
circadian variation may influence drug action, on top of any circadian changes in 
pharmacokinetics. There are clinical reports of lower doses of fenfluramine (in the 
common “fen-phen” combination with phentermine) proving effectiw at inducing 
weight loss when given in the afternoon (Katz et al., 1999) and as discussed above 
rsectior ,?.3l circadian vanatiqr jr efficacy may b? tied more tc/bythnj? ir nature’
feeding behaviour and activity than directly to effects on neurotransmitters. 
Fenfluramine has also shown to inhibit food intake differentially at various points in 
the circadian cycle (Davies and Wellman, 1991),
3.6 Figures for Chapter 3






Figure 3.6.2 The chemical structure of 5-hydroxytryptamine (5-HT)


















Table 3.6.1 In vitro inhibition constants for the re-uptake of monoamines by 
sibutramine and its metabolites compared to other monoamine re-uptake inhibitors 
and other anti-obesity drugs.
C o m p o u n d N o r a d r e n a l i n e S e r o t o n i n D o p a m i n e
Sibutramine 283 3131 2309
Metabolite 1 2.7 18 24
Metabolite 2 4.9 26 31
Nisoxetine 2.1 296 279
Fluoxetine 320 11 2025
c/-Amphetamine 45 1441 132
cf- Fenfluramine 260 279 6227
Values are the nanomolar (nM) concentrations for the inhibition constant (Ki). 
Metabolite 1 is the secondary amine (desmethylsibutramine) and metabolite 2 is the 
primary amine (didesmethylsibutramine; figure 3.6.3), This table is reproduced from 
data found in Heal et al. (1998a).
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4.0 Calibration of the Behavioural Satiety Sequence (BSS) for Circadian Work
4.1 Introduction
4.1.1 What is the BSS and how does it help discriminate the mechanisms of drug 
action?
The behavioural satiety sequence is a well characterised method for investigating the 
anorectic activity of drugs. Initially described by Antin et al. (1975), the BSS is a 
preserved behavioural pattern exhibited as feeding animals satiate. It is important to 
note, however, that the interpretation of the BSS is based on trends and behavioural 
patterns over time rather than a rigid, temporally-determined progression which never 
varies. The sequence, a progression from initial feeding via brief periods of activity 
and grooming to a state of post-prandial resting, is specific to satiety and satiation 
rather than feeding per se. It is not seen with sham feeding, wherein ingested food is 
drained from the stomach via an implanted cannula, although sham feeding rats will 
exhibit the full satiety sequence if given cholecystokinin (CCK). This finding, by 
Antin et al. (1975), when coupled to their observations of a behavioural progression 
in normal animals, was responsible for highlighting the role of CCK in natural satiety. 
Their findings were also a fundamental on which a lot of subsequent research into 
satiety has been built.
Since the BSS was first described it has been used extensively for examining the 
impact of drugs on feeding behaviour. As the BSS is a naturally occurring 
phenomenon the manner in which pharmacotherapies alter the expression of the 
behaviours involved can inform on their physiological effects and the mechanisms 
underlying them. In the laboratory, where the conditions associated with testing, 
observation and food intake can be kept constant, it is reasonable to suggest that any 
changes seen in the profile of the BSS are the result of factors consciously changed by 
the researchers -  such as drug treatment. Behavioural changes help elucidate 
pharmacology in many fields of drug research -especially with regards to the central 
nervous system, e.g. research into addiction, depression, neurodegeneration etc. (e.g. 
Shoaib and Stolerman 1999; Mitchell 2005; Mitchell and Redfem 2005; Yamada and
action can produce different changes to the profile of the BSS, and the nature of these 
changes gives an insight into the physiological properties of the drug. Appetite 
suppression can be achieved through a number of different mechanisms such as 
making food unpalatable, sedation, hyperactivity or the enhancement of natural satiety. 
These distinct physiological mechanisms manifest differently in the BSS, each 
producing characteristic changes. Those effects that alter the behavioural profile such 
that the characteristic sequence is not seen are said to disrupt the BSS.
Amphetamine has long been used as pharmacotherapy against over-eating, as have 
analogues such as phentermine (Kordik and Reitz, 1999); the major contributing 
mechanism of action for amphetamine is to cause release of stored noradrenaline and 
dopamine from neurons (Heal et a l , 1998u; Sulzer et a l , 2005; Wort ley et al, 1999). 
One of the primary consequences of this is a general increase in activity levels, and it 
is this hyperactivity that is chiefly responsible for the reduction in food intake in rats 
dosed with amphetamine (Halford et a l, 1995, 1998; Halford, 2001). Such 
hyperactivity would also have beneficial effects for weight loss through other means, 
as more energy is expended during the hyperactivity as well as less food consumed. 
When looked at in the BSS, this reduction results from a displacement of feeding 
behaviour to other forms of active behaviour; similarly such hyperactivity is not 
compatible with long periods of resting behaviour, and the onset of resting is delayed 
(Halford et al, 1998). Moderate increases in general activity levels may not 
necessarily disrupt the BSS. Significant hyperactivity on the other hand, whether 
displacing feeding behaviour as with amphetamine or delaying resting behaviour as 
with the intra-accumbens administration of moderate doses of the direct dopaminergic 
agonists SKF-38393 (Di receptors) and LY-171555 (D2 receptors) (Philips et al., 
1995) or systemic administration of the non-subtype-selective 5-HT2 receptor agonist 
l-(2,5-dimethoxy-4-iodopheny!)-2-aminopropane (DOI; Kitchener and Dourish,
1994), is easily determined by observation and causes a disruption of the BSS.
Significant sedation, such as that seen with high doses of the 5-HT2 receptor agonist 
MK-212, manifests in the BSS by a displacement of feeding and active behaviours by 
resting behaviour (Halford et al., 1996a). As with moderate increases in activity, 
moderate sedation m av result in a seemingly preserved satietv seouence but a reduced
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expression of active behaviours, such as that seen with fluoxetine by Halford and 
Blundell (1996A).
Addition of quinine (or other unpalatable compounds) makes food distasteful to rats 
(Antin et al., 1975), altering the BSS profile; satiation is delayed, if indeed it is 
reached at all. This is because the animals make a large number of short, un-sustained 
trips to the food source, leaving it aside due to its unwelcome taste and exhibiting 
other active behaviours instead, thus not consuming enough food to satiate in the 
same way that animals presented with untreated food would.
Satiety enhancing drugs are compounds that facilitate the natural process of satiation 
and satiety. Drugs that act in this manner produce a temporal shift in the BSS, with 
both the offset of feeding and the onset of resting occurring earlier in the observation 
period (Halford et al., 1998). This satiety enhancement matches the change in the 
profile of the BSS produced by pre-feeding (Halford et al., 1998). Pre-feeding implies 
the return of food a while before the observations begin, thus animals are part-fed as 
the observation commences and naturally satiate sooner. This kind of change is 
referred to as an advancement of the BSS. Several drugs fall into this category, 
including the selective serotonin re-uptake inhibitors (SSRIs) fluoxetine (Clifton et al., 
1989; Halford and Blundell, 1996b; Halford et al., 1998; McGuirk et al., 1992a; 
Willner et al., 1990), paroxetine and femoxetine (McGuirk et al., 1992b), the 
serotonin and noradrenaline re-uptake inhibitor (SNRI) sibutramine (Halford et al., 
1995, 1998) and with the serotonin releasing agent (</-)fenfluramine (Halford et al., 
1995, 1998). This last drug was, for a while, a subject of debate as to whether it 
advanced or disrupted the BSS (McGuirk et al., 1992a; Montgomery and Willner, 
1988; Willner et al., 1990), but the balance of evidence and the current thinking is for 
a satiety-enhancing (and BSS-advancing) action for (o'-jfenfluramine.
This list of compounds implicates 5-HT as quite heavily involved in natural processes 
of satiety [section 3.1], and many other drugs which act primarily through 5-HT 
systems also preserve and advance the BSS, including other re-uptake inhibitors and 
direct agonists at receptor subtypes (see Halford et al., 1998, for a review of drug 
action and the BSS) No+ al1 drug? acting or serotonergic svstem? advance and 
preserve the BSS however; as noted anove MK-212 and DO! are two examples of
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serotonergic drugs which disrupt the BSS. Nor are serotonin enhancing drugs the only 
type o f compound capable o f advancing and preserving the BSS, with antagonists of 
the peptide neurotransmitter orexin-A {Rodgers et a l , 2001) now known to do 
likewise; orexin-A, in contrast, delays the BSS (Rogers et al., 2000); the peripheral 
satiety signal molecule CCK (Antin et al., 1975) and others compounds, including 
peripherally administered 5-HT (Edwards and Stevens, 1991; Simansky, 1996), haw  
also been shown to advance and preserve the BSS.
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4.1.2 How to measure the BSS
How to observe, record, and interpret the BSS has been a matter of debate. There are 
two primary schools of thought, one espoused by Halford, Blundell and colleagues 
(Halford et a l , 1995, 1996, 1998; Halford and Blundell 1996ajb\ Rodgers et a l , 2000, 
2 0 0 1 ) of continuous analysis from videotaped observ ation sessions and the alternative 
of some form of time-sampled observations as utilised initially by Antin et a l (1975) 
and adapted since then by many groups (e.g. Clifton et al., 1989; Montgomery and 
Willner, 1988; McGuirk et a l , 1992a,b', Lee and Simansky, 1997). In their review of 
the BSS and its contribution to the behavioural pharmacology of anorectic drugs, 
Halford et al. (1998) perhaps unsurprisingly backed their continuous analysis 
methodology as superior, and all things being ideal it does offer advantages as laid out 
in that review; continuous analysis provides a complete behavioural picture with full 
details of the duration and frequency of each behaviour recorded, which no time- 
sampling method can match. However, while the more in-depth nature of the 
continuous analysis makes it a much more accurate, it also makes carrying out BSS 
experiments a lot more demanding, and increases the reliance on specialised apparatus. 
Compared to a time-sampling method it reduces the number of animals used but 
therefore leaves the results open to larger distortions caused by non- or poorly- 
responding animals -  including those which, for any reason, do not feed whilst under 
observation. Coupled to the more time-intensive nature of the analysis and the greater 
reliance on a specialised set-up this makes continuous analysis a technique best suited 
to dedicated laboratories doing a large body of such work.
None of which is to say that time sampling does not have its own faults. The 
behavioural picture achieved with time-sampling is far from complete and most such 
methods track far fewer behavioural categories than would be possible with 
continuous analysis. There is also the question of observer bias, where transitions of 
behaviour are often scored in favour of frequent but short-lasting behaviours (e.g. 
locomotion) over longer lasting, less frequent behaviours such as resting; this is 
known as “event over state observer bias” (Halford et al., 1998). On the other hand, 
time-sampling does facilitate the testing of many animals at once and findings from 
studie' using time-sampling have moyided valuable information on a nurobr* ^  
compounds (e.g. fluoxetine; Clifton et al., 1989) that has later been corroborated by
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continuous analysis (Halford and Blundell, 19966; Halford et a l , 1998). It is therefore 
important to determine what one is looking for before embarking on a prolonged 
sequence o f  BSS experiments, and evaluate which method is more appropriate to the 
task at hand. For studies where an in-depth record o f total behaviour or behavioural 
microstructure is required then it is clear that continuous analysis is the way to go. 
Whether such an intensive technique is necessary to identify trends and changes in 
behavioural macrostructure is another matter, especially if there are issues in 
assembling a unit capable o f supporting such detail.
Thus the first steps taken in this study were to evaluate whether a time-sampling 
technique with behavioural coding done during the observation period, or a more 
detailed approach using analysis from videotaped sessions, would be appropriate for 
investigating the BSS in relation to sibutramine, ^-fenfluramine and circadian rhythm 
[chapter 7 (below) describes this circadian work], and once decided, to find 
appropriate doses o f  the drugs to use in future work and to establish a common 
protocol for the experiments to come.
41
4.2 Materials and Methods
AH experiments described in this thesis were carried out in accordance with The 
Animals Scientific Procedures Act 1986.
The following were maintained across the BSS experiments to be described in this 
thesis (here and chapter 7) except where specifically countered.
Animals. Male Wistar rats from the University of Bath breeding colony (150-280 
grams at the start of experiments) were used in all procedures described here. Animals 
were housed in pairs with ad libitum access to food (CRM(E) pellets; Special Diets 
Services, Witham, UK) and water. The room was maintained at 21°C {+/■ VC) and on 
a regular 12:12 hour light/dark cycle, with a 15 Watt red light bulb mounted above 
each cage providing illumination during the dark phase.
Drugs. Sibutramine hydrochloride monohydrate and d-fenfluramine hydrochloride 
(RBI, donated by RenaSci (Nottingham, UK)) were both dissolved in 0.9% saline 
(Fresenius Kabi, Warrington, UK). Drug solutions were made up freshly each day and 
all injections were made with 2  ml/kg of the drug solution or vehicle into the 
peritoneum, such that doses outlined in the individual experiments below were 
administered.
General Procedure. 12 animals were weaned and separated into paired housing as 
described above where they were left to habituate to the new surroundings for 2  
weeks. On the third week the process of habituating animals to the experimental 
chambers and procedures began. Animals were isolated into roofless cages 
(dimensions 40 x 56.5 cm, with solid sides and a clear Perspex front 89.5 cm high, 
with the bottom tray sliding forward to allow' access; figures 4.5.1 to 4.5.3) 24 hours 
before observations began, still with free access to food and water. Six hours prior to 
observation, animals were deprived of food by sliding a metal plate down to block 
access to the food hopper; animals retained free access to water at all times. Animals 
would also be weighed at this time and returned to the observational cage. Thirty 
minute: Drio~ to obse-vatjor animal; would be dosed, .wit! druc j)~ . saline sc- 
appropriate, and once more returned to the observational cage. When the time of
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observation arrived food, in the form of ground up standard chow presented in feeding 
jars (10.5 cm diameter, 9 cm diameter at rim; figure 4.5.4) with a 4 cm diameter hole 
cut into the lid through which the food was accessible, was re-introduced to the cage 
and recording began. For the next 60 minutes each animal was observed sequentially 
for 5 seconds in every 30, and the predominant behaviour exhibited in that time was 
scored by hand into one of four mutually exclusive categories, similar to those used 
by Clifton et al. (1989). These were: feeding (eating, drinking, showing active interest 
in food or water source), grooming (licking, scratching, washing), resting (non­
moving or still, awake or asleep) or active (activities such as sniffing, rearing and 
locomotion not covered by the above). This active category was reserved for active 
behaviours not covered explicitly by feeding or grooming. Six animals were observed 
at any one time, and a total of 120 observations were made for each animal. After 60 
minutes animals were returned to their home pair with free access to food and water. 
The food jars were weighed before and after presentation to the animals and the 
difference in the readings was recorded and assumed to represent food intake.
Each animal was tested once per week, with 6  animals observed per testing session. 
Animals were used as their own controls, and were tested in random treatment order. 
Experiments lasted until each animal had been given each treatment once.
Prior to any scored runs, animals were given 3 weeks of habituation to the procedure. 
Feeding from the food jars was a learnt behaviour, as the form the food was presented 
in differed from that the animals received in the home cage. Therefore the first 2 
exposures to the observation cages were accompanied by a 24 hour food deprivation 
in order to further stimulate interest in the presented food jars and aid the learning 
process. On these occasions the animals were not observed. In the final week of 
habituation the deprivation was reduced to six hours, and all animals were dosed with 
saline ( 2  ml/kg i.p.); animals were actively observed (though not scored) following 
presentation of the food jars on this occasion.
Statistical analysis. For analysis, the scored behaviours were transferred into a 
spreadsheet and tallied into 5-minute epochs. One way ANOVAs with post-hoc
I>unner’s tests were used or cumulsf ve.;dg:^’frptr .5 mmuteeopch? through ■; tbs fuf 
60 minute period; these examined each behaviour independently, with feeding and
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resting behaviour of primary interest. Each behaviour was also examined 
independently by repeated measures ANOVA across the discrete epochs. If this 
indicated an effect then separate one-way ANOVAs were performed for each time bin, 
with post-hoc Dunnetf s tests to elucidate any drug effect. Food intake was examined 
by a one-way ANOVA with post-hoc Dunnett’s test where appropriate. Animals were 
excluded from statistical analysis if their saline profile w*as atypical of the group 
insofar as they showed no inclination to feed from the food jars at any stage. Statistics 
are reported with the following format: [F(A) = B; p  < C] where A is the degrees of 
freedom and B is the F value from the relevant ANOVA; C is the probability arising 
from post-hoc comparisons.
Randomisation. Each experiment was organised so that every animal received every 
treatment in randomised order, allowing animals to act as their own controls and 
reducing animal usage. Six animals were tested on any given test day, with 2 test days 
every week (Tuesday and Thursday) for the duration of the experiments. Animals 
tested on a Tuesday were always tested on a Tuesday, and the same applied to animals 
tested on Thursdays. Each of the 6  test cages was thus used for different animals on 
Tuesdays and Thursdays, but housed the same animal every Tuesday and Thursday. 
Thus not only did every animal receive every dose, but every test cage also saw each 
dose twice over the course of any given experiment, again in randomised order. Every 
treatment was given to at least one animal on each test day.
Experiment 1. Procedures differed from those outlined above in that it was the method 
of observation that was itself being assessed. On the day of testing animals were 
either scored as per the general method, or their session was recorded from a camera 
mounted high over the cage pens for later analysis. In place of drug treatment, the 
satiety-enhancing mechanism used was a 15 minute period of pre-feeding -  in other 
words, introducing food 15 minutes before observation began. Six animals were 
tested in any given session, three coded live and three taped for video-analysis. Tapes 
were analysed, coding the animals into the same four distinct behavioural categories 
by timing and tallying the duration (to the nearest second) o f each behavioural type 
within 5-minute time bins. For each method of observation the behaviour profiles of 
the pre-fed, anc5 nop-pre-fed. conditions were ther examined ftr evidence ar 
advanced BSS, with animals used as their own controls. Statistical analysis w'as not
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used. Randomisation differed from the general protocol in that only 3 of the test cages 
were set up with cameras to record sessions, thus each cage saw 4 different animals 
rather than 2 , and each animal was exposed twice to each of two cages (pre-fed and 
non-pre-fed conditions in both a cage with a camera mount, and one without one). 
Observations were carried out 4 hours into the dark phase. One animal was excluded 
from analysis for having removed the barrier to the food hopper during one session.
Experiment 2. Procedures differed from the general method in that the treatments 
given were 3 different doses of ̂ -fenfluramine plus a vehicle condition. Each animal 
was again used as its own control, and received 0.3 mg/kg, 1.0 mg/kg and 3.0 mg/kg 
d-fenfluramine plus a saline control dose in a randomised treatment order. Animals 
were under a light cycle such that observations began 4 hours into the dark phase, and 
dosing was carried out immediately before the food jars were presented. Animals 
were scored from live observations as described above.
Experiment 3. Procedures differed from the general method in that the treatments 
given were 3 different doses of sibutramine -  0.5 mg/kg, 1.67 mg/kg and 5.0 mg/kg -  
a 1.0 mg/kg J-fenfluramine positive control plus a vehicle condition. Each animal was 
again used as its own control, and received all four drug treatments and a saline 
treatment in a randomised treatment order. Dosing was such that animals received 2 
injections; saline or an appropriate dose of sibutramine was given 30 minutes prior to 
the presentation of the feeding jars, and saline or ^-fenfluramine was injected 
immediately before observation began. Animals only received one drug dose on any 
given day. Animals were under a light cycle such that observations began 4 hours into 
the dark phase and were scored from live observations as described above.
Experiment 4. Procedures differed from the general method in that the treatments used 
were 1.0 mg/kg of J-fenfluramme or a saline control dose. Administration of the 
doses was carried out 30 minutes prior to the presentation of the food jars. Animals 
were under a light cycle such that observations began 4 hours into the dark phase and 
were scored from live observations as described above.
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4.3 Results
Experiment 1. Figure 4.5.5 shows the behavioural profiles for animals observed by 
either live time sampling or coded from videotapes of sessions in the pre-fed or non- 
pre-fed conditions; results from all animals were averaged (video data) or summed to 
give a representation of how time in each 5-minute epoch was spent. A visual scan of 
the data indicates that the live-coding technique revealed a leftward shift in the 
behavioural satiety sequence in pre-fed animals. This was as expected from a satiety 
enhancing treatment, with an earlier onset of resting behaviour and corresponding 
reduction in feeding behaviour. A similar pattern can also be seen in the video-coded 
data. Live-coding was significantly less time consuming, and better suited the set-up 
already in place. Thus given it proved sufficient to highlight satiety enhancements and 
advancements of the BSS such as that with 15 minute pre-feeding it was decided that 
a live-coding methodology was sufficiently powerful for future investigations. Figure 
4.5.6(tf and b) illustrates the level of variation recorded with each of the two methods.
Experiment 2. Figure 4.5.7 shows behavioural profiles for animals dosed with vehicle, 
0.3, 1.0 or 3.0 mg/kg fenfluramine. The lowest dose of ^-fenfluramine caused no 
variation from control conditions until 50 minutes into the observation period when 
cumulative feeding counts were significantly lower than observations under control 
conditions [F(3,32) = 13.698; p < 0.05]. Treatment with both 1.0 and 3.0 mg/kg d- 
fenfluramine advanced the offset of feeding, with feeding observations significantly 
lower than under control conditions after 25 and 10 minutes of observation 
respectively [F(3,32) = 3.034; p  < 0.05 after 10 minutes for 3.0 mg/kg; F(3,32) = 
9.689; p  < 0.01 after 25 minutes for 1.0 mg/kg}; in all cases these differences were 
preserved over the 60 minute observation [F(3,32) = 15.811 ;p  < 0.01 for 1.0 and 3.0 
mg/kg d-fenfluramine; p  < 0.05 for 0.3 mg/kg ^-fenfluramine]. Activity observations 
were decreased by highest dose of ^-fenfluramine compared to controls after 55 
minutes [F(3,32) = 4.522; p < 0.05], and over the whole hour, but after other doses 
the levels of activity were always equivalent to those seen after saline dosing. No dose 
affected grooming at all. After animals had received 3.0 mg/kg ^-fenfluramine the 
onset of resting was also significantly advanced with total resting observations 
signifipanth • higher thar control;.sftsr minute- rz7T.;2 r C nr - ar:
remaining so thereafter [F{3,32) = 18.913; p  < 0.01 after 60 minutes]. Under
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conditions of treatment with 1.0 mg/kg 7-fenfluramine, animals were observed resting 
more often late in the observation and this increase led to significantly more resting 
over the 60 minute observation period than seen under control conditions fF{3,32) = 
18.913; p  < 0.05]. The low dose of 7-fenfluramine had no effect on the number of 
observations of resting behaviour. Drug treatment affected food intake in dose 
dependent manner [F{3,32) = 22.065; p  < 0.001 for each drug dose], with all three 
doses significantly reducing one-hour food intake (figure 4.5.10).
Experiment 3. Figure 4.5.8 show's behavioural profiles for animals dosed with vehicle 
or 0.5, 1.67 or 5.0 mg/kg sibutramine hydrochloride. The profile for 1.0 mg/kg 7- 
fenfluramine is not shown. The 1.67 mg/kg and 5.0 mg/kg doses of sibutramine 
inhibited feeding early on, and significantly inhibited feeding throughout [after 5 
minutes, F(4,45) = 6.720; p  <0.01 for both doses; after 60 minutes F(4,45) = 13.230; 
p < 0.01 for both doses] with a corresponding increase in resting (first seen after 5 
minutes at 5.0 mg/kg [F{4,45) = 8.61; p  < 0.01] and after 15 minutes with 1.67 mg/kg 
[F(4,45) = 13.085; p  < 0.05]) which was likewise significant over the whole of the 
observation period [F(4,45) = 8.867; p  < 0.01 for both doses]. The lowest dose, 0.5 
mg/kg sibutramine, exhibited no quantifiable effect on feeding or resting behaviour at 
any time. 1.0 mg/kg 7-fenfluramine inhibited feeding compared to controls after 25 
minutes [F(4,45) = 11.507; p  < 0.05], an effect maintained over 60 minutes [F(4,45) 
= 13.230; p  < 0.01]; although animals were only first noticed to be resting more after 
55 minutes when treated with this drug [F(4,45) = 8.941 \ P<0.  05] it did significantly 
increase total resting observations over the hour long observation period [F(4,45) = 
8.867; p  < 0.05]. Activity observations were unaffected by any treatment, while 
animals were observed grooming less often over the course of the 1 hour observation 
when dosed with 1.67 or 5.0 mg/kg sibutramine [F(4,45) = 14.110; p  < 0.05], and 
more often after they were dosed with 7-fenfluramine [F{4,45) = 14.110; p  < 0.01], 
than when injected with saline. Food intake (figure 4.5.10) was unaffected by 0.5 
mg/kg sibutramine but decreased in dose-dependent manner at higher doses [F(4,45) 
= 13.943; p  < 0.01 for both 1.67 and 5.0 mg/kg sibutramine compared to saline], and 
with 1.0 mg/kg 7-fenfluramine [F(4,45) = 13.943; p  < 0.01].
Exnenmen* 4. 4.5.° illustrate^ the adyaneemetf o^the BSC seer wfter dosir;
with 1.0 mg/kg 7-fenfluramme 30 minutes before food presentation. Feeding was
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significantly inhibited after 10 minutes compared to saline [F(l,20) = 7.561;/? < 0.05] 
and remained significantly lower throughout the observation period [F(l,20) = 17.428; 
p  < 0.001 after 60 minutes], whilst resting was significantly higher after d- 
fenfluramine administration right from the moment of food return [F(l,20) = 9.543; p  
< 0.01 after 5 minutes; F (l,20) = 5.485; p  < 0.001 over the full 60 minutes]. 
Grooming was increased by ^-fenfluramine over the early part of the observation 
period [F(l,20) = 5.172; p  < 0.05 over the first 25 minutes] but not over the 
observation as a whole [F(l,20) = 2.193; NS] whilst activity was majorly decreased 
throughout [F(l,20) = 25.534; p  < 0.001]. Food intake (figure 4.5.10) was 
significantly decreased by drug treatment [F(l,20) = 7.778;p  < 0.05].
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4.4 Discussion
It is clear from figure 4.5.5 that the temporal shift in the BSS produced by a 15 
minute bout of pre-feeding is picked up by the time-sampling method. At first glance 
the same would not be said of the video-analysed data as there appears to be little 
change in the onset of resting. However the incidence of feeding is reduced from the 
start in the pre-fed condition and resting observations are made a little earlier, so it 
appears that both methods did pick up the pre-feeding induced advance in the BSS. 
The traces in figure 4.5.6 indicate that the degree of variation in data collected with 
either method is, by and large, comparable. If anything, the video-analysed data gave 
a slightly tighter data set. However had the time sampling method been carried 
forward, given it’s more intensive and time-consuming nature the number of animals 
used would have been reduced and thus potentially opening the data up to more 
variation. Given this, and the fact that the laboratory had not previously done BSS 
observations and was lacking a number of features specified by Halford et al. (1998) 
as essential for BSS recording, a time-sampling methodology was unquestioningly 
more suited to the situation here. As such, since the time-sampling method detected a 
pre-feeding induced advancement it was decided to carry such a methodology' forward 
through future experiments. All that said, standard time-sampling methods such as 
that used by Clifton et al. (1989) involve momentary sampling, scanning many cages 
and recording the behaviour electronically. The set-up here was sufficiently different 
to warrant further discussion, as it influenced the final decision to use time sampling 
and the method of sampling used. The cages used (figures 4.5.1-4.5.3) had been 
originally designed for use in social hierarchy experiments but were well suited to 
allowing full observation of the animals as required in a BSS paradigm from the point 
of view of live, time-sampled behavioural coding. Each cage also had a camera mount, 
but one that only allowed a single angle of observation, as opposed to the multi­
angled view that Halford et al. consider essential for continual analysis. However, the 
cages were also built into surrounds that lined them up in two rows of three cages 
which, while having limited portability, would not line up in situ and thus scanning 
and momentary sampling as used by Clifton et al. (1989) was not possible. This 
limitation, the lack of an electronic recording in place, and the potential difficulties of 
acouiring and setting such a system up. informed the decision to use a samnling 
perioa oi nve seconds, recording tne predominant oenaviour shown in tnai time oy
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marking one of four behavioural categories on a timesheet. The final difference from 
established paradigms is that rats were pair housed when not undergoing observation 
or habituation. This was a concession ma<ie to the Home Office who were not happy 
with single housing of animals for the length of the trials, especially given the 
observation cages were not the home cages. This limitation actually increased the 
length of the experiments as it became necessary to allow' 24 hours isolation before 
the experiments to try to reduce the impact of any isolation stress on the BSS 
observations (stress being a known confounding factor in CNS pharmacology; 
Stanford, 19%). Furthermore such isolation stress could have been a significant factor 
in the non-responding of some animals, where they would just sit in the comer of the 
observation cage and show no interest in the presented food, even after significant 
food deprivation ( 6  hours; 24 hours during initial habituation) and under control 
conditions.
This is clearly far from an ideal method. Altmann (1974) suggested that for true 
accuracy in determining the frequency of behaviours the sampling interval should be 
shorter than the shortest duration of any behaviour and with rats this is frequently 
under one second for general behaviours such as sniffmg or rearing. The inference is 
thus that a time sampling method can never give a true estimate. Furthermore, it could 
be argued that a longer observation per sample increases observer bias as the coding 
requires a conscious choice of dominant behaviour from a number of observed 
behaviours as opposed to an almost instantaneous judgement made on a momentary 
observation. The counter-argument is that a longer observation period per sample 
should help counter “event over state” bias with longer lasting, state-like, behaviours 
now given more weight. The risk that the balance may swing the other way, overly in 
favour of state-like behaviours, is a valid concern; however both feeding and resting 
are arguably state-like behaviours, at least when examined as described here, and 
activity is a catch-all category for all behaviours that are not covered by the other 
categories. Since active behaviours will often give way to other active behaviours a 
sequence of active behaviours could also be said to be “state-like” activity and thus it 
is the grooming observations that are most likely to be affected by this change. A 
comparison of the time-sampled data and rudimentarily video-analysed data in figure
4.5.5 suggests that observations of grooming are indeed affected and under-recorded 
witn tne time-sampnng metnoa. However tne oase temporal snift in tne BSS is cieari)
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visible and, with the shift from feeding behaviour to resting behaviour being of prime 
importance, the technique was sufficient to measure the key feature. Additionally the 
methodology carried forward and used from this point on does carry' one distinct 
advantage over previously characterised methods. By using animals as their own 
controls within each discrete experiment, animal usage is reduced and the degree of 
error by interpreting results across different animals is also minimised. Additional 
rationalisation for the approach and methodology used here is discussed briefly later 
on [chapter 8 .0 ].
Moving on to look at the drug trials, the first stage, whilst awaiting the arrival of the 
sibutramine donation, was to chose an appropriate dose of fenfluramine to serve as 
a comparison to sibutramine in later circadian trials. Both racemic fenfluramine and 
the d-isomer used here have been extensively studied using the BSS (e.g. Halford et 
al., 1995, 1998; McGuirk et al., 1992a; Montgomery and Willner, 1988; Willner et al., 
1990). The majority' of work supports the observation that this drug advances the 
satiety sequence, though some suggest it disrupts resting by encouraging activity 
(Montgomery and Willner, 1988; Willner et al., 1990). The present results support the 
former conclusion; at the two higher doses tested, 1 .0  and 3.0 mg/kg, ^-fenfluramine 
caused a temporal shift in the BSS profile, advancing the offset of feeding in the first 
half of the observation period and promoting the onset of resting such that animals 
were observed resting more over the length of the observation period. The lowest dose 
of ^/-fenfluramine (0.3 mg/kg) produced no change in resting, while the effect on 
feeding was small and observed late in the observation period. At the highest dose 
tested the offset of feeding behaviour was advanced so that animals were observed 
feeding significantly less after 10 minutes into the observation when given the 3.0 
mg/kg dose than when given saline. A similar decrease in feeding was seen after 25 
minutes in observations carried out after dosing with 1.0 mg/kg ^/-fenfluramine. A 
corresponding advance in the onset of resting behaviour was observed after the 3.0 
mg/kg dose, with resting observations scored more often than under saline conditions 
after 1 0  minutes, and total observations in the hour-long observation remained lower 
than when these same animals were dosed with saline. There was a trend of increased 
resting after dosing with 1 .0  mg/kg J-fenfluramine too, and instances of resting were 
raised in the latter period of the observations compared to controls leading to t  
significantly mgner numoei oi resting ooservations over tne oo minute test penoc.
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Perhaps more relevant than the base statistics is the general profile in these cases; 
associated behavioural symptoms not revealed by the profiles shown in figure 4.5.7 
may also be a factor. Firstly it is difficult to investigate temporal shifts in the offset of 
feeding if there is not a significant initial feeding response. After being given 3.0 
mg/kg <i-fenfluramine the animals’ initial feeding response was almost completely 
ablated, with virtually no feeding seen beyond 5 minutes. While it could be argued 
that this is indicative of a strong satiating effect and an extreme advance in the satiety 
sequence, the magnitude of the drug effect could prove unhelpful in identifying 
underlying changes due to circadian rhythm in later experiments. This dose also 
caused animals to exhibit a low, outstretched body posture when moving and 
inhibited activity as a whole over the hour-long observation. This inhibition is 
consistent with reports of racemic fenfluramine being sedative at doses lower than 3.0 
mg/kg (e.g. Aulakh et al., 1988). The J-isomer has itself been shown to decrease 
locomotor activity and increase the energy cost of muscular effort (Even and 
Nicolaidis, 1986) at 7.0 mg/kg; though this is much higher than the dosages used in 
the present work, a smaller effect may contribute to some degree to the behavioural 
profile seen here with 3.0 mg/kg J-fenfluramine. This apparent sedation, regardless of 
the mechanism behind it, could have interfered with recording of circadian variation 
in satiety enhancement had the 3.0 mg/kg dose been selected for that work. Therefore, 
given that a noticeable shift in the BSS profile is seen with 1.0 mg/kg ^-fenfluramine, 
a dose considered equipotent with the ED50 of sibutramine for 2 -hour inhibition of 
food intake and at which ^-fenfluramine has been seen to advance the BSS before 
(Halford et al., 1995, 1998), this intermediate dose was chosen as the most 
appropriate to use as a comparison with sibutramine in later circadian trials.
Figure 4.5.8 shows the profiles from three log-separated doses of sibutramine and 
saline control. Again, as with the ^-fenfluramine results above, the aim of the 
experiment was to select an appropriate dose of sibutramine to use in the forthcoming 
circadian trials. Here the lowest dose tested produced no significant change from the 
saline condition. On the contrary the medium (1.67 mg/kg) and high (5.0 mg/kg) 
doses of sibutramine both exhibited a profound effect on the BSS profiles. Under both 
treatments the instance of feeding was significantly reduced throughout the 
observation period when compared to the observations after saline injections Both 
tnese orug treatments atso mcreascu me ooservatiom> Oi resting benavioui ovei me
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hour long test session. The 1.67 mg/kg dose accelerated the onset of resting, with 
animals observed resting significantly more often after 15 minutes compared to when 
they were injected with saline. By contrast, the 5.0 mg/kg dose increased resting 
throughout the observation period, with a high level of resting observations even in 
the first 5 minutes after food was returned. Both these doses of sibutramine also 
reduced the observation of grooming behaviour over the course of the hour-long 
observation period, without affecting the instance of activity counts. In contrast, the
1 .0  mg/kg d-fenfluramine dose selected after the experiments described above 
actually caused an increase in grooming observations over the hour. This drug also 
increased total resting observations, statistically significant only after 55 minutes 
despite a trend of increased resting throughout when compared to controls, as well as 
advancing the offset of feeding behaviour, with significantly fewer observations of 
feeding after 25 minutes than under control conditions.
Looking at the behavioural profiles, the high dose of sibutramine did not so much 
advance the satiety sequence as ablate feeding altogether. The initially high frequency 
of resting observations is typical of a sedative effect, although activity scores remain 
unaffected. It is possible that at 5.0 mg/kg sibutramine is satiating the animals enough 
to prevent any feeding, even after 6  hours of food deprivation, 4 hours of which was 
at a time in the light: dark cycle when rats tend to consume the majority of their daily 
intake. Regardless of whether this lack of intake is due to sedation or satiety it wTas 
clear that with no intake present at this circadian time, it was not feasible to study this 
high dose of sibutramine for differing effects on the BSS at times when animals 
would naturally feed less. Likewise, the low' dose of sibutramine caused no detectable 
change in the BSS profile and was not a viable candidate for future work. The 1.67 
mg/kg dose on the other hand provided a clearly visible shift in the BSS whilst 
maintaining a definite feeding response, albeit a very much reduced one. This dose 
was also effective at reducing food intake, and is close to a previously reported ED50 
dose of 2.0 mg/kg for 2-hour inhibition of food intake (Halford et al., 1995). As such 
this dose of 1.67 mg/kg sibutramine wTas selected as the dose to be used in the 
circadian experiments described below. Moreover in this experiment the 1.67 mg/kg 
dose of sibutramine and the 1 .0  mg/kg dose of ^/-fenfluramine were equipotent in 
reducmi food intake las showm ir fteure 4.5 and thus t  good matching nr~ to use 
in studies spread across the circadian cycle..
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With the doses to be used selected, and the methodology settled upon, the final 
variable to decide upon before progressing onto the circadian studies was the dose-test 
interval. To this point, sibutramine had been administered 30 minutes prior to the 
return o f food and the beginning o f observations, time enough for the drug to be 
metabolised to its active forms, whilst previous dosing with J-fenfluramine had been 
done immediately prior to the start o f observations . Although the doubledosing used 
in Experiment 3 above was one way of dealing with this dichotomy it still left the 
possibility o f an injection-induced effect in the early stages of the experiment, which 
may have a masking effect on early effects o f  the drugs. To see if this could be 
avoided, animals were tested with 1.0 mg/kg ^-fenfluramine given 30 minutes before 
the re-introduction of food to investigate whether this procedural change would still 
allow* detection o f the advance in the BSS caused by this drug dose and 
simultaneously remove any immediate reaction to injection from the observations 
made. The resulting BSS profile can be seen in Figure 4.5.9. This change appears to 
increase the resting observations, but there is still a robust feeding response and an 
earlier cessation of feeding than seen with saline-treated animals, and was therefore 
accepted into the procedure used from here on.
In summary, the experiments described above allowed for selection of a protocol and 
drug doses to be used in the circadian studies that form chapter 7 of this thesis. The 
doses selected were 1.0 mg/kg ii-fenfluramine and 1.67 mg/kg sibutramine, to be 
administered 30 minutes prior to the return o f food. Observations were then made by 
a time sampling method and coded live for 60 minutes following the return o f food. 
The doses determined here were also used for circadian locomotor work {chapter 5, 
below].
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4.5 Figures for Chapter 4
Figure 4.5.1 An example of the cages used for behavioural satiety sequence (BSS) 
observations, shown in situ
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Figure 4.5.2 Closer detail on a BSS observation cage tray, showing the food hopper 
and water provision
Figure 4.5.3 Photograph showing the sliding plate mechanism by which access to 
food was restricted in the run up to, and during, BSS observations. Access to water 
was not similarly restricted
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Figure 4.5.4 Photographs illustrating the feeding jars in which ground food was 
presented for BSS, and circadian locomotor activity, experiments
Figure 4.5.5 Behavioural profiles from BSS observations by two methods; animals 
were either pre-fed (B, D) or presented with food immediately prior to observations.
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Behavioural profiles generated in the BSS by analysis o f  videotapes (A, B) or live 
coded data (C, D). Food was returned either at the beginning o f the first epoch (A, C) 
or 15 minutes before the start o f the observation period (B, D). n = 11 in every case, 
and the same animals were used under each o f  the 4 conditions . Each epoch was 5 
minutes long. The values for Seconds Showing Behaviour are averages across the 12 
animals whilst those for the Number o f Observations are aggregates of scores for all 
12 animals during any given epoch. Both methods indicate a leftward shift in the 











Figure 4.5.6a Cumulative measures of behaviour coded from videotape over 60 
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Cumulative time-plots for all 4 coded behaviours indicating the variation in the data 
under both pre-fed and non-pre-fed conditions when scored from videotaped sessions 
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Figure 4.5.7
Behavioural profiles generated after administration o f  three different doses o f d- 
fenfluramine or saline 4 hours into the dark phase. Observations are aggregates o f all 
scores for each animal in any given 5-minute epoch. A clear advance in the BSS is 
seen with both 1.0 and 3.0 mg/kg «i-fenfluramine but the lowest dose o f 0.3 mg/kg had 
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Behavioural profiles generated after administration o f  three different doses o f  
sibutramine or saline 30 minutes prior to food return (4 hours into the dark phase). 
Observations are aggregates of all scores for each animal in any given 5-minute epoch. 
A clear advance in the BSS is seen with both 1.67 and 5.0 mg/kg sibutramine but the 
lowest dose of 0.5 mg/kg had no effect. n=10 in every case, and the same animals 
were used with all 4 treatments. A profile generated with 1.0 mg/kg c/-fenfluramine is 
not shown.
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Figure 4.5.9 Behavioural profiles from BSS observations carried out with 1.0 mg/kg 
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Behavioural profiles generated after administration of ^-fenfluramine or saline 30 
minutes prior to food return (4 hours into the dark phase). Observations are aggregates 
of all scores for each animal in any given 5-minute epoch. A clear advance in the BSS 
is seen compared to saline, n = 11.
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Figure 4.5.10 Food intake as measured in experiment 2 (a), experiment 3 (b) or 
experiment 4 (c)








Saline 0.3 1 3
Dose of Fenfluramine (m g/kg i.p.)
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Saline  0.5 m g/kg 1.67 mg/kg 5.0  m g/kg 1.0 m g/kg d-
sibutram ine sibutram ine sibu tram ine fenfluramine
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& p  < 0.05 compared with saline treatment.
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5.0 The Effect of Sibutramine and tf-Fenfluramine on Locomotor Activity, 
Measured at Different Times Spread Across the Circadian Cycle
5.1 Introduction
The circadian influence on activity and other biological rhythms is well documented, 
as reviewed above [section 3.3]. Alongside the investigation into the effects of 
circadian rhythms on behavioural satiety sequence observations with the centrally 
acting anorectics sibutramine and ^/-fenfluramine [chapter 7, below], parallel 
investigations were carried out to examine any circadian influence on locomotor 
responses to these drugs, and to examine how this might impact on the interpretation 
of the BSS observations.
Both sibutramine and fenfluramine have been examined previously for effects on 
locomotor drive, with sibutramine exhibiting no effect (Rowley et al., 2000) and with 
(*/-)fenfluramine showing signs of sedative activity (Aulakh et a l , 1988; Callaway et 
al., 1993 Ziance et al., 1972) that is independent of its primary pharmacological 
mechanism of precipitating serotonin release (Callaway et al., 1993). This effect may 
be in part, or in full, the result of an increase in the energy cost of locomotion induced 
by d-fenfluramine (Even and Nicolaidis, 1986). However neither sibutramine nor 
indeed (J-)fenfluramine has been previously investigated for locomotor effects with 
full regard to the possible impact of circadian rhythm. While circadian impact on 
therapy with (t/-)fenfluramine has been reported in the clinic (Katz et al., 1999) and 
((A)fenfluramme has been used as a tool in other circadian serotonergic studies (e.g. 
Biello and Dafters, 2001), the effect on locomotor activity has not been looked at 
across the circadian cycle. Understandably given the lack of locomotor effects 
previously observed with sibutramine (Rowley et al., 2000) this drug has not been 
further investigated for circadian influences. The nature of circadian variation is such 
that not only do basal levels of activity change but so do neurotransmitter levels, and 
many other functions -  including how an organism responds to, or metabolises, 
pharmacotherapy (e.g. Martin and Redfem, 1997; Labreque and Belanger, 1991; 
section 3.3). Drugs like sibutramine and J-fenfluramine exert effects via 5-HT -  a 
neurotransmitie; wriicn exmoiiS a iugmj variable circadian rhythm (Martin an̂ .
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Redfem, 1997) -  and are therefore effectively, in vivo, working against a very 
different neurochemical backdrop depending on when they are administered. As such 
it is plausible that while they might have little or no acute effect on locomotor 
behaviour when given at one time of day, they may exert more noticeable or 
significant influence at other times. The general field of circadian influence is 
reviewed above [section 3.3], both with respect to 5-HT rhythmicity and to locomotor 
activity.
It is also important to consider for a moment the general control of motor activity, and 
specifically the role of 5-HT in motor control. For a long while 5-HT was generally 
considered to have a negative action on motor activity, inhibiting its expression. The 
rationale for this was that 5-HT antagonised dopaminergic increases in activity, such 
as those produced with amphetamine, and studies showed a trend for increased levels 
of activity in 5-HT-deficient animals (see Gerson and Baldessarini (1980) for a 
period-appropriate review). These views were supported by the fact that in rats the 
period of greatest activity also corresponds to the period of lowest brain 5-HT. levels 
(see review by Martin and Redfem (1997) and section 3.3). More recently however, 
while the fact that 5-HT can have an inhibitory effect has not been questioned (for 
example see Di Matteo et al., 2001, a review of tonic inhibitory control by 5-HT2c 
receptors over dopaminergic systems), it has become clear that the full role of 5-HT in 
locomotor control is a lot more complicated. Additionally it is now known that 5-HT 
release, usage and metabolism are greatest during the active phase [see section 3.3], 
Some direct serotonergic agonists, particularly those primarily active at 5-HTiB 
receptors, and some 5-HT releasing agents (e.g. 3,4-methylenedioxy-metamphetamine; 
MDMA) can have a potentiating effect on activity (Geyer, 1996), whether by 
modulating mesolimbic dopaminergic control in the venteral tegmental area or 
nucleus accumbens (reviewed by Mylecharane, 1996), or through other pathways 
such as the 5 -HT4 receptor activity in the hippocampus described by Takahashi et al. 
(2002) where the mechanisms underlying the effects on activity are yet unknown. 
Interestingly, (J-)fenfluramine is an exception, a 5-HT releasing agent which 
suppresses rather than increases locomotor activity (Aulakh et al., 1988; Callaway et 
al., 1993; Geyer, 1996; Ziance et al., 1972). These effects are independent of 5-HT 
release fCallawa* ? al ]° ° ?  and may be due tc the drug increasing the energy cos-
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of locomotor activity (Even and Nicolaidis, 1986). For a more complete review of 
serotonergic influences on motor control see Geyer (1996).
The previous body of work on sibutramine and the BSS suggests that its anorectic 
effects are due to an enhancement of satiety (Halford et al., 1995, 1998) rather than 
behavioural activation (as seen with amphetamine for example; Halford et al., 1995, 
1998), sedation (as with MK-212; Halford et a l , 1996a, 1998) or making food 
unpalatable (like quinine does, Antin et al., 1975). My own initial results from BSS 
experiments looking at sibutramine would support this assertion [chapters 4 and 7]. 
However, with the neurochemical background so variable over the circadian cycle and 
the potential impact of circadian variation in hepatic metabolism of sibutramine to its 
active metabolites [section 3.4, above], it was considered interesting, and pertinent, to 
investigate whether circadian variation had an impact on the effects of both 
sibutramine and ^/-fenfluramine on locomotor function in parallel with investigating 
any circadian influence under a BSS paradigm [chapter 7], The existing research on 
acute racemic fenfluramine in the BSS is .somewhat conflicting; although the 
prevailing view is that acute fenfluramine advances the BSS (e.g. Halford et al., 1995, 
1998) there are some reports of a disruption of the sequence due to a displacement of 
resting behaviour to active behaviours (including locomotor activity and grooming) 
after the offset of feeding (Montgomery and Willner, 1988; Willner et al., 1990; 
McGuirk et al., 1992a). Couple this to the reports of fenfluramine as a locomotor 
depressant or sedative agent (Aulakh et al., 1988; Callaway et al., 1993, Ziance et al., 
1972) and a mixed picture emerges of the effects of fenfluramine on locomotor 
activity, and that before examining any potential circadian influence.
Given that the BSS paradigm used [chapters 4 and 7] did not itself explicitly record 
locomotor activity, the experiments described below were carried out to quantify 
locomotor effects of drug treatment with sibutramine and d-fenfluramine across the 
circadian cycle in animals subjected to similar food deprivation schedules used in the 
BSS studies.
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5.2 Materials and Methods
Animals Adult male Wistar rats (Bath University strain; 150-280g at the start of 
experiments) were used in all experiments, unless otherwise noted. Animals were 
kept at 21°C (+/- 1°C) under a 12:12 light/dark cycle. Rats were housed in pairs with 
free access to food (CRM(E) pellets; Special Diets Services, Witham, UK) and water 
for 10 days, then singly housed with ad libitum access to food and water for a further 
week before locomotor testing began. Dark-phase illumination was provided by a 
single 15 Watt red light bulb on a mobile fitting so as to allow examination of all 
cages.
Drugs. Sibutramine hydrochloride monohydrate and ^-fenfluramine hydrochloride 
(RBI, donated by RenaSci) were both dissolved in 0.9% saline (Fresenius Kabi, 
Warrington, UK). Fresh drug solutions were made up each day and all injections were 
with 2 ml/kg of the drug solution or vehicle into the peritoneum, such that doses 
outlined in the individual experiments below were administered.
General Procedure. Animals were housed individually in transparent cages, which sat 
inside a 7x4 infra-red beam locomotor monitoring grid (figures 5.5.1 to 5.5.4), Two 
and a half weeks were allowed for animals to habituate to the light cycle.
Animals were food deprived 6 hours before the testing period, matching the 
deprivation schedule used for the BSS [chapters 4 and 7], Animals were dosed 30 
minutes before food was re-introduced in the form of ground up pellets in a glass 
feeding jar (figure 4.5.4), These jars had metal lids with 4 cm diameter round holes 
cut in them to allow access to the food inside and animals were habituated to feeding 
on the ground pellets at least once before test runs began. Once dosed, animals were 
free from human interaction until the following morning.
Locomotor activity records were amassed for 8 hours following the withdrawal of 
food (i.e. 6 hours during food deprivation and 2 hours after food re-introduction) with 
the period of particular interest being the hour after food was returned. Animals were
usee a: th e r  o;wr control/ an;' were, djsee vith eacV trsatmen* once jr. i ranch// ■/: 
order. Every animal was tested three times over the course of 3 days. The difference
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in weight of the food jars between their return and their withdrawal the next morning 
was recorded in each case.
Statistical Analysis. At each circadian time, one way ANOVA tests were used on 
cumulative data for 5 minute epochs through the 60 minute period post food re- 
introduction with post-hoc Dunnett’s tests used where appropriate. Collated data from 
all circadian times were examined by two-way ANOVA for the effect of drug 
treatment {post-hoc Dunnett’s test) and circadian time {post-hoc Bonferroni test) on 
total locomotor activity in the hour following the return of food. The effect of 
circadian time was then further investigated on a treatment-specific basis, with one­
way ANOVAs used on cumulative data with post-hoc Bonferroni tests used to 
elucidate any effect of circadian time. Statistics are reported with the following format: 
[F(A) = B; p  < C] where A is the degrees of freedom and B is the F value from the 
relevant ANOVA; C is the probability arising from the ANOVA or post-hoc 
comparison as applicable.
Randomisation. Treatments were randomised such that every animal received every 
treatment, in random orders. With 12 animals in 12 cages and three treatments, 4 
animals received each treatment each day.
Six separate experiments of this nature were carried out such that discrete groups of 
animals were tested at Circadian Times (CT) 1, 5, 9, 13, 17 and 21 where CTO was 
lights-on, and CT12 was lights-off. Light cycles were set accordingly for each time 
point so that food deprivation would be at 10.00 hours GMT, and re-introduction at
16.00 hours GMT -  so for example, when testing at CT5, lights were set to be on 
from 11.00-23.00 GMT, with food re-introduced at 16.00 GMT.
Experiments at CT1, CT5 and CT17 differed from the above procedure. In these cases 
one set of animals was used for saline and sibutramine conditions as above but 
received 1.0 mg/kg d-fenfluramine immediately prior to food re-introduction. This 
differed from the prior dosing regime of 30 minutes before food return used in every 
other case. Subsequently separate sets of animals were used to investigate the effects 
of 1.0 mg/kg ^/-fenfluramine when given 30 minutes prior to food re-introduction at 
eacn oi tnese circadian times. Tnese lattei data are presented nere arid related to me
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relevant saline and sibutramine results. Thus at Circadian Times 1, 5 and 17 animals 
were not used as their own controls in the case of ̂ -fenfluramine treatment.
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5.3 Results
For simplicity, the separate experiments have been re-ordered such that they are 
reported in order of advancing CT, from CT1 (early light phase) to CT21 (late dark 
phase). The results outlined below are summarised in figure 5.5.5 and shown 
individually in figures 5.5.5a-f.
CT1. Following food re-introduction, neither drug exhibited any initial effect -  neither 
stimulation nor depression -  on locomotor activity as measured by cumulative beam 
breaks. Animals treated with ^-fenfluramine never differed from controls. After 30 
minutes of access to the feeding jars there were signs that under sibutramine 
conditions animals were exhibiting less total activity than controls [F(2,33) = 3.467;p 
< 0.05]. However by 55 minutes after the re-introduction of food these earlier 
differences were non-significant.
CT5. A significant decrease in locomotor activity was noted from the moment that the 
food jars were presented in animals treated with <7-fenfluramine, and this depression 
of motor activity was noticeable until 35 minutes after food had been returned [after 5 
minutes F(2,33) = 8.637; p  < 0.001; after 35 minutes F(2,33) = 4.383; p  < 0.05]; by 
40 minutes into the recording it was non-significant. Animals treated with sibutramine 
also showed less locomotor activity than controls over the first 35 minutes post food 
re-introduction [F(2,33) = 4.383; p  < 0.05], an effect that first became significant 
after 15 minutes access to the feeding jar [F(2,33) = 8.784; p  = 0.01]. However, after 
40 minutes the effects of both drugs had subsided, and they remained no different 
from controls thereafter.
CT9. Drug treated animals showed no variation from controls at any point during the 
60 minutes following food presentation at this circadian time.
CT13. Following food re-introduction animals treated with <i-fenfluramine showed a 
brief locomotor activation compared to controls [F(2,33) = 4.545; p  < 0.05 after the 
first 10 minutes] which had subsided by 15 minutes. Sibutramine treated animals
neve* differs: frorr cont~o!'. ;v tht cours?" of the. hou* foil ovine’ acee? r  thf 
feeding jars.
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CT17. Sibutramine treated animals never exhibited any differences from control 
conditions. Animals treated with ^-fenfluramine showed a brief initial locomotor 
depression [F(2,33) = 4.270; p  < 0.05 after 5 min] that was non-significant again by 
10 minutes after food re-introduction. Total activity in d-fenfluramine animals was 
again significantly reduced after 30 minutes [F(2,33) = 3.842; p  < 0.05] and 
cumulative beam breaks this time remained significantly reduced through to one hour 
after the return of food [F(2,33) = 3.299; p < 0.05].
CT21. Cumulative activity levels never differed from control animals with either drug 
treatment in the hour following food presentation.
v̂ lmuicu uuiu. i iguic j.^.o auminai isCs me tuiai atuvii) ictuiucu anu aeuvity uvu
the first 20 minutes following the re-introduction of food at different points of the 
circadian cycle. A two-way ANOVA showed there to be an effect of both circadian
v r r r c  1 q o \  _  c  c c n .  ~  ^  n n n i i  a — ~  r rrv"i i q o \  — c  1 A f \ .  _  ^  n  n  ntime |y — u .uu /,^  i/.UUi j .anu ui ug \iy^,i7o) ~ kj. i~t\j, jj i/.Oj j un miai
activity in the hour after food was returned, but no interaction over the whole hour 
[F(10,198) = 1.201;/? < 0.292; not significant]; a significant interaction [F(10,198) = 
2.358; p  < 0.05] was observed over the first 20 minutes following the return of food. 
Across all circadian times sibutramine significantly reduced total activity compared to 
controls [F(2,198) = 6.140;/? < 0.01] while ^-fenfluramine did not. Across all drug 
treatment, locomotor activity was significantly increased at CT21 compared to CT1, 
CT5 and CT9 [F(5,198) = 6.667; p = 0.001, p  = 0.001 andp  < 0.001 respectively], 
and at CT17 compared to CT9 [F(5,198) = 6.667;p  < 0.05].
Looking solely at the saline condition, activity was increased at CT21 versus CT9 
over the 1 hour following food return [F(5,66) = 4.031; p  < 0.01], whereas in the first 
15 minutes post food re-introduction activity was significantly increased at CT5 
compared to CT1, CT9 and CT13 [F(5,66) = 3.520; p  < 0.05 in each case]. When the 
animals were treated with <7-fenfluramine, locomotor activity was higher at CT13 
compared to CT1, CT5, CT9 and CT17, but only over the first 5 [7^(5,66)= 5.628;/? < 
0.05 compared to CT1 and CT5;/? < 0.01 compared to CT9 and CT17] or 10 minutes 
following fooc1 returr [7*75.66' ~ 2.960: r  0.05 eomoared tc CT1'7 and
Animals showed levels of activity that were significantly higher at CT5 tftPTC +1 O’TI......................a n
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early in the post-food period [F(5,66) = 2.912;p <  0.05 at 10 minutes] after receiving 
sibutramine and overall activity was higher at CT17 and CT21 than CT1 -  significant
a u £ i i u i u u l C S  | i  vy,OOj “  i ^  u u l  n u t 2>u a n ^ i Ou m m ui^S In uud
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5.4 Discussion
Looking at the results, there docs appear to be a differential effect of both sibutramine 
and tZ-fenfluramme compared to controls at different circadian times. When treated 
with sibutramine animals exhibited slight signs of depressed locomotor activity, but
— i . . p t i  — , a  r " t c  a  i ; *1     *
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significant over the whole period, but visible over the first half (CT5) or latter half 
(CT1) of the hour following the presentation of the feeding jars. When looking at
1 1 a4*/% /J <4 /\  f»» /% /»1 1 ^ A41*A<% /J 4 «> ♦<% +4 />4i% / \  41 4-L <̂V 4 /4 4*«N /\ /> /X rt 4  ̂ 1 O C>4-4 -r t4 4̂  T 4 4 tL 4 L
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though present at each CT, bar CT9, were not significant in isolation, indicate a 
consistent and significant reduction in locomotor activity in animals dosed with 1.67 
mg/kg sibutramine in the 60 minutes following the return of food. By contrast, d- 
fenfluramine treatment produced differences to saline injections at CT5, CT13 and 
CT17, but over 60 minutes of post-food recording ^-fenfluramine did not significantly 
reduce activity irrespective of circadian time. As with sibutramine, the effects of d- 
fenfluramine at CT5 were not significant over the full hour, but the decreased activity 
was noted immediately and for 35 minutes. This compares to the effect at CT17, 
where the opposite was true;, whereas during the mid-light phase the effect was an 
initial decrease not significant beyond 40 minutes, in the mid-dark phase the effect 
was significant from 30-60 minutes after food was returned. Though an initial 
depression was noted with d-fenfluramine at CT17 it was not a significant decrease in 
activity compared to controls (figure 5.5.6, first panel). Similarly, at CT13 d- 
fenfluramine produced an initial effect that didn’t last more than 10 minutes; at the 
early dark phase timepoint however, this effect was an increase in locomotor activity. 
The animals tested at CT21 exhibited the greatest activity in the hour long post-food 
session, regardless of treatment, whilst the nadir for activity was CT9 or CT1 for 
sibutramine-treated animals. Within treatment boundaries, a look at the cumulative 
data indicates brief differences in activity as a result of circadian time early in the 
post-food recording but no extensive difference in activity levels over the full hour of 
recording — only w'hen animals had been injected with saline did circadian rhythms 
prove a significant modifier of total activity. Even then the only significant 
differences were between the nadir of behavioural activation at CT9 and the zenith at
1 a  u i  ~ u  ___i   ____+ ;   a : c c ~  — i ---------— * u -/-xiinuuiii siati.Miwa CAainiiiauui luvtaitc u.iiiti&uww:' utivvuci uk r. ■ .
activity shown across the circadian cycle with animals given 1.67 mg/kg sibutramine,
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activity levels were not significantly different at any one circadian time from any 
other.
To tackle the differences due to circadian rhythmicity first, it is wholly unsurprising 
that the total activity counts tended to be highest at points during the dark phase, and 
that the late light phase was the time of least activity. This fits in with rats being 
nocturnal creatures. The relative lack of activity at CT9 also correlates well with 
observations from the BSS at this time [chapter 7, below]. On the other hand, the total 
differences in activity levels observed across the circadian cycle in these experiments 
are actually quite small. Under control conditions only the peak and lowest activity 
level were significantly separable over 60 minutes of post-food recording, but looking 
at all drug conditions, the peak activity at CT21 was significantly higher when 
compared to all points during the light phase, and activity during the mid dark-phase 
was also significantly higher than at the nadir of locomotion at CT9. It is perhaps 
surprising that there were not more marked differences in activity levels, but this 
could be down to the design of the experiment.
A couple of possible procedural explanations spring to mind; firstly, the feeding jars 
themselves are sizeable, and occluded a number of the infra-red beams of the 
locomotor monitor when placed into the cage, preventing these beams being broken 
(again) during the course of the recording and thus discounting any movement 
covered solely within the confines of the occluded beams (see figure 5.5.7). This 
could be of importance during the dark phase, when one would expect not only 
general activity to be higher but also to see a specific increase in the feeding drive and 
animals are likely to spend more time at or around the food source.
Alternatively, the food deprivation of 6 hours meant that even at the mid-light phase 
point, CT5, the animals had been food deprived for an hour of their more active 
period; the resulting hunger motivation could have been a levelling factor, increasing 
baseline activity at CT1 and CT5 to statistical equivalence with dark phase levels.
A decrease in locomotor activity with d-fenfluramine is consistent with previous
renortF that th f drug ha? sedative action if the ra* .'Auiak'r & a\- 198f: C cT h.t c 
u/., 1993, Ziance ct al., 1972), though here the locomotor behaviour inhibited was
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home-cage behaviour as opposed to that shown on exposure to a novel environment, 
and the dosage used in the present work is smaller. It is notable, however, that the
  „ a : ~ ~  a : c c  ^ a  i;~ u +  a , a  a
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inhibition of activity wore off after 35-40 minutes, whereas in animals dosed mid­
dark phase the onset of the effect was seen later and the effect remained statistically
t «-«-««%« -C+ r% 4- ' I /> 4  1 t rvh  4- <4 t* ̂  /%«««/« 4  l%* » /> «»1 r /\ /J  +<-» * 1 /n ■CP ««% /x t  r« -
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shown in controls; after the 35 minute mark, control animals were averaging 10-15 
beam breaks per 5 minute time bin, compared to around 40 beam breaks per time bin 
under u-fenfluramine treatment conditions. The most likely explanation for the tail off 
in controls is their progression to a post-prandial resting state as would be expected if 
they fed to satiety. One might expect a similar progression in the ^/-fenfluramine 
treated animals given the apparent advance in the satiety' sequence with this drag {e.g. 
Halford et a l , 1995, 1998; chapters 4 and 7) but observations carried out in the mid­
light phase by Willner and colleagues (Montgomery and Willner, 1988; Willner et al., 
1990; McGuirk et a l , 1992u) report acute fenfluramine as disrupting the resting state, 
and the current observations are consistent with this eventuality. By contrast, when 
tested at mid-dark phase, when activity is naturally higher, animals under control 
conditions did not exhibit a tail-off in activity, nor did u-fenfluramine treated animals 
show an activity spurt 30-60 minutes after food was returned; the significant 
difference in activity between the treatments remained throughout an hour of 
recording, indicating a possible sedative effect. Rats generally show a higher baseline 
activity during the dark phase, and though not always significant the data presented 
here do suggest this. Increased general activity could be a reflection of the lack of a 
sustained resting period in saline treated animals because of a quick progression to the 
next meal at this time. Observations from the BSS experiments at CT17 would seem 
to support this, with feeding counts suggesting a second meal after 40-50 minutes
  i   j : * ; rr u ~  ~i  > u  .1    ~ d c c  r ^ rr i n
u u u t i  c .O iiu u i v ^ u iiu iu u iis . m e  u u a c iv a u u H s  w iu i  u - i c u m u a u n i i c  in  u ic  u o o  a i  i  i  /
parallel the findings here with a significant reduction in activity scores over the hour 
recording compared to controls. The pattern of observations also shows a second meal 
after 45-50 minutes, and the general profile [figure 7.5.13 chapter 7] resembles a 
compressed version of the saline profile, possibly indicating a mild sedative effect.
an sigus tna. a. luiiC; .-.-ien.■ urat..itiji.. it .exe. .mg c seaai've rfic.".• ~r\ l 
cautionary note in interpreting these findings is that in the present experiments the
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locomotor depressant effect was only observed at two timepoints where the d- 
fenfluramine treated animals were not their own controls. This is further flagged as 
potentially confounding given dosing with 1.0 mg/kg u-fenfluramine did not produce 
a CT-independent decrease in total activity as was seen with sibutramine; this dose of 
d-fenfluramine was also not seen to be sedative in exploratory locomotor activity
/-» •« < A r% /> 1% A « 4-V» /-> «% ■» r4- /\ k  f~ /C h  1 « t  ?1c X p c i im e in d  u c i u i u c u  in  u i^  n c X l C ila p itn  [u ,  u c i u w j .
The brief initial activation that was seen at CT13 is at odds with all previous reports 
of ̂ -fenfluramine impact on locomotor activity (Aulakh et al., 1988; Callaway et al., 
1993, Ziancc et al., 1972). This effect could perhaps be explained by a displacement 
of early feeding behaviour at a time when feeding drive is high at the beginning of the 
rat’s active phase. Perhaps the state of partial satiety induced by the drug causes the 
rat to exhibit other activity rather than feeding from the newly presented food jar. This 
activation was only seen at CT13, and was only present after 5 and 10 minutes into 
the post-food recording; at this point activity levels in J-fenfluramine treated animals
a t  u i  1-j w e r e  a iM J a i g i n i i e a i i u ^  m g u e i  m a n  i n  a m n i a i d  u u s e u  W iu i  u iiS  u i  u g  a i  u m e i
circadian times. This finding is not backed up by a corresponding increase in activity 
scores compared to saline treatment over this first period from BSS experiments 
carried out at CT13 [chapter 7], While activity scores from the BSS are not directly 
representative of locomotor activity, the discrepancy does suggest the current findings 
are anomalous. No sign of this locomotor activation was seen at any other circadian 
time in the current paradigm, nor was it observed m exploratory locomotor activity 
studies. Moreover, the long since reported sedative effects of (d-)fenfluramine 
(Aulakh et al., 1988; Callaway et al., 1993, Ziance et al., 1972) tally with other
l i u u i i i g s  p i c a t n i t u  u t i t -  a i i u  u i  w i i a j j i t i a  -r a i i u  u  w u c j c  a  n i g u t i  u u a c  u i  u - i c u i i u i a u u u c ;
(3.0 mg/kg i.p.) was used in certain cases. However, these previous reports were both 
at higher doses than the l.O mg/kg used in the above experiments and found to be 
independent of 5-IIT release (Callaway et al., 1993), leaving open the possibility that 
the specific neurochemical backdrop at CT13 is such that release of 5-HT from 
neuronal stores could be the signal for behavioural activation. If so, this would bear 
further investigation, as behavioural activation could lead to an increase in metabolic 
rate, a desirable effect in anti-obesity therapy however small it may be.
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The effects seen with sibutramine are interesting, too. At five of six circadian times at 
which trials were carried out animals showed less activity after having been dosed 
with sibutramine than with saline. Although at each individual circadian time the 
difference in total activity over an hour of recording was not significant, when looked 
at independently of circadian time these results show a significant decrease in total 
activity' compared to controls. This finding is consistent with the assertion that 
sibutramine enhances satiety and advances the BSS, as animals that have advanced to 
a state of post-prandial resting would not exhibit high levels of activity. It could also 
be indicative of a low-level sedative effect.
Looking at the individual circadian times, at early and mid light phase (CT1, CT5) 
there were signs of significant reductions in activity when animals were treated with 
sibutramine. At CT5 the activity chart for sibutramine treatment (figure 5.5.5b) 
plateaus off before the saline curve, and at a lower level of activity. This finding is 
consistent with an accelerated behavioural satiety sequence, and the idea that 
locomotor activity plateaus as animals satiate, approaching and reaching a state of 
post-prandial resting. At CT1, however, the trace shows fewer signs of the tail-off in 
activity, and is perhaps more indicative of a non-specific sedative effect. Comparing 
this to satiety sequence observations reveals that resting is increased in sibutramine 
treated animals as early as 10 minutes into the post-food observation at both CT1 and 
CT5 and although total activity scores in that paradigm were not significantly reduced, 
feeding did exhibit a concurrent decrease. Further comparison with BSS behaviour 
profiles from CT1 and CT5 also suggest that the effect at CT5 is due to satiety- 
induced resting, whilst at CT1 there was an initial active response giving way to 
resting as opposed to a robust feeding observation and progression through a satiety 
sequence. Previous findings that sibutramine -  even at higher doses -  does not affect 
locomotor activity, positively or negatively, despite raising extracellular dopamine
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decrease in locomotor activity seen with sibutramine in this paradigm at CT1 and CT5 
being a sedative effect at the 1.67 mg/kg dose used. Experiments looking at 
exploratory locomotor activity were also earned out as a follow up to the data 
presented here to investigate whether acute sibutramine could be exerting a sedative 
action [chanter 6] but while in one experiment a higher dose of 5.0 mg/kg exhibited 
seaatlve activity, tins unoing couiu not oe reproouceci in subsequent experiments. iNoi
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did 1.67mg/kg of sibutramine show significant signs of sedation or other decrease in 
locomotor function.
Finally, the BSS experiments described in chapter 7 (below) revealed that while 
animals dosed with sibutramine were observed resting approximately 30% more often
m a n  w i ic i i  g i v e n  s a n n e  u u i i n g  i c ^ t in g  a i  u i  i  a n u  i n e  u i i le iC liC C  111 tu u ii  i c s u n g
observations was much greater during the dark phase when sibutramine also led to 
increased total resting observations relative to controls, yet locomotor activity at these 
circadian times was not significantly decreased by sibutramine when the circadian 
times were examined independently.
All this seems to paint a mixed picture as to the effects elicited by both drugs in this 
locomotor paradigm, but it appears that sibutramine, at a dose of 1.67 mg/kg, does 
tend to reduce locomotor activity. The reduction is slight, however, requiring a large 
sample size (resulting from pooling data across the circadian cycle) to show as 
statistically significant. This reduction in locomotor activity does not appear to be a 
direct sedative effect and it is more noticeable at times of low activity, not specifically 
observed at times of peak activity. Furthermore this dose of sibutramine proved to 
have no impact on exploratory locomotor activity as described in chapter 6, below. 
The reduced locomotor response is therefore more likely to be due to the satiety 
enhancing effect of sibutramine and the resultant increase in resting and inactivity as 
the animals reached satiety sooner following the presentation of food when treated 
with sibutramine than they did when dosed with saline. This theory fits generally with 
both the above results and the findings from BSS studies described in chapters 4 and 7 
(dealing with BSS experiments), and the existing work suggesting sibutramine acts to 
enhance satiety (Halford et al., 1995, 1998, Heal et al., 1998a). By contrast, d- 
fenfluramine showed no overall effect on locomotor activity', but did seem to have a 
locomotor-activating effect over the first 10 minutes of the post-food period at CT13. 
Depressant effects on locomotor activity were present at times during the tests at CT5 
and CT17, and while u-fenfluramine is a known sedative at higher doses (Aulakh et 
al., 1988; Callaway et al., 1993, Ziance et al., 1972) the 1.0 mg/kg dose used in these 
trials did not reduce exploratory locomotor activity [chapter 6, below]. These results 
shouk D; treat e*. with caunor t»ecsusc tnes. twc circs aiar timet i.us* narrcr t 
two where d-fenfluramine was tested in a separate group of animals, rather than using
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them as their own control; however, the depression o f activity does mirror decreases 
seen in activity scores from the BSS [chapter 7, below].
In short, while there are some potentially interesting significances thrown up by 
investigating the minutiae at each circadian time independently, the findings above 
suggest that u-fenfluramine does not, as a rule, significantly reduce locomotor activity 
at the dose used, while sibutramine does so in a way consistent with enhancement o f  
satiety and early induction of post-prandial resting rather than by causing sedation. 
Moreover the effect of each drug does not appear to be different when administered at 
different circadian times, at least not over a 60 minute period -  the full length o f  both 
these recordings and the BSS observations described in chapter 7.
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5.5 Figures for Chapter 5
Figure 5.5.1 Photograph of one of the cages used for locomotor activity studies (both 
the exploratory and circadian experiments) shown in situ.
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Figure 5.5.2 Photograph showing the locomotor monitor i n  s i t u  without the cage.
8 7
Figure 5.5.3 Photograph illustrating the layout of the 7 infra-red cross-beams arrayed 
in the locomotor monitor. Obstruction of a beam would generate a count.
88
Figure 5.5.4 Photograph illustrating the layout o f the 4 infra-red beams aligned with
the length of the cage.
Figure 5.5.5
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Figure 5.5.6 Variation in activity levels with sibutramine, d-fenfluramine or saline 
across the circadian cycle after 20 minutes or 60 minutes of recording.
First 20 minutes □ Saline
ad-Fenfluramine 
■  Sibutramine
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Figure 5.5.7
Schematic illustrating how the feeding jars might produce artificially low locomotor 
activity counts. The highlighted beams are occluded by the jar and thus any 
movement of the animal within areas of the cage normally covered by these beams 
would not generate any activity counts. In this example, beams B, C, F and G are 
occluded and could not be broken by the rat; movement around the feeding jar may 
therefore not be recorded. Movement further from the jar would record as normal as 
other beams (A, D, E and H) are not occluded.
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6.0 The Effect of Sibutramine and ^-Fenfluramine on Exploratory Locomotor 
Activity
6.1 Introduction
There were indications from early behavioural satiety sequence observations that the 
high doses of both sibutramine and, more particularly, ^-fenfluramine may have 
decreased locomotor activity in animals, not necessarily reflected in activity counts 
(the activity category being a catch-all for active behaviours not covered by other 
categories, including -  but not limited to -  locomotion). Additionally, resting tended 
to be increased (though not always statistically significantly) from the start in drug- 
treated animals. This increase in initial resting left lingering doubts about a possible 
sedative effect of drug treatment contributing to the decreased food intake and the 
alterations in the satiety sequence. Previous groups have characterised <7-fenfluramine 
as sedative, with potential to decrease locomotor activity (Aulakh et al., 1988; 
Callaway et al., 1993, Ziance et al., 1972), though this is not a universal finding either 
acutely or chronically (e.g. Vickers et a l, 2000). There are also reports that this may 
be caused by the drug inducing an increase in the energy cost of muscular effort (Even 
and Nicolaidis, 1986). Administration of ^-fenfluramine has also been reported to 
disrupt the behavioural satiety sequence by decreasing resting behaviour 
(Montgomery and Willner, 1988; Willner et al., 1990; McGuirk et al., 1992<a). This 
latter view is contradicted by my own experiences with ^-fenfluramine and the satiety 
sequence, where I found both the onset of resting generally accelerated and the overall 
observations of resting increased in c/-fenfluramine treated animals and when animals 
had been treated with sibutramine [chapters 4 and 7],
While the effect of both sibutramine and ^-fenfluramine on locomotor activity were 
investigated in the home cage in experiments spread across the circadian cycle 
[chapter 5] that tied in with BSS observations described in chapter 7 (below), in order 
to determine the full extent of any sedative effect of either drug treatment both 
sibutramine and J-fenfluramine were examined for any effect on exploratory 
locomotor activity. Rats placed in a novel environment experience a drive to explore 
anc subsequent!' big: initia iev?.«: c:~ iocomotc; activir Thi: increase;
activity is sensitive to pharmacotherapy and drugs with sedative potential will
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decrease the extent to which animals explore the novel environment thus quantifiably 
reducing locomotor activity. Over the course of a 15 minute exposure to a novel 
environment, untreated animals or those given a saline control will exhibit high initial 
activity levels as they explore, reducing to a baseline activity level over time; 
characteristically, approximately 50% of their total activity is recorded in the first 5 
minutes of exposure, assuming a 15 minute session. Drugs affecting exploratory 
locomotor activity tend to reduce the levels of activity in those first 5 minutes and 
quicken the drop to baseline activity levels. This test therefore is a specific 
examination of sedative potential and action.
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6.2 Materials and Methods
Animals. Male Wistar rats (Charles River, Margate, UK; 150-250g) were used in all 
experiments, unless otherwise noted. Animals were kept at 21°C (+/- 1°) under a 
12:12 light/dark cycle. Rats were housed in groups of eight with free access to food 
(CRM(E) pellets; Special Diets Services, Witham, UK) and water for 2 weeks before 
testing to acclimatise to the facility.
Drugs. Sibutramine hydrochloride monohydrate and ^/-fenfluramine hydrochloride 
(RBI, donated by RenaSci, Nottingham, UK) were both dissolved in 0.9% saline 
(Fresenius Kabi, Warrington, UK). Drug solutions were made up freshly each day and 
all injections were with 2 ml/kg of the drug solution or vehicle into the peritoneum, 
such that doses outlined in the individual experiments below were administered.
General Procedure. Animals were bought in from Charles River at 75-100g and 
housed in groups of 8 for 2 weeks to acclimatise to the new surroundings. On the day 
of testing, animals were weighed, dosed with drug or vehicle as appropriate and 
returned to their home cage. Thirty minutes later they were placed into isolation in 
transparent cages, to which they had not been previously exposed, which sat inside a 
7x4 infra-red beam locomotor monitoring grid (see figures 5.5.1 to 5.5.4), Locomotor 
activity records were amassed for the next 15 minutes.
Statistical Analysis. Data for beam breaks in the first 5 minutes was summed and 
analysed by one-way ANOVA with post-hoc Dunnett’s test. Statistics are reported 
with the following format: [F(A) = B; p  < C] where A is the degrees of freedom and 
B is the F value from the relevant ANOVA; C is the probability arising from post-hoc 
comparisons.
Experiment 1. Procedure as outlined above. Animals were dosed with one of 3 doses 
of sibutramine hydrochloride (0.5 mg/kg, 1.67 mg/kg, and 5.0 mg/kg) or vehicle.
Experiment 2. Procedure as outlined above. Animals were dosed with one of 3 doses
ofc-fenfiuramin't k f rag/kg. ... mg/kg. anc 3*( mg/kg o: vehieil
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Experiments 3, 4 and 5. Procedure as outlined above. The doses given were a full 
range o f sibutramine doses -  0.5, 1.0, 1.67, 2.0, 3.0, 5.0, 9.0 and 10.0 mg/kg -  plus 
saline. Subsequent experiments were also earned out using the same basic method and 
dose range but varying either the dose-test interval to values between 0 minutes and 
60 minutes (30 minutes in the basic procedure) or using 10% /?-cyclodextrin solution
— u___x n a i t . a u  vxx o a x x i i t  aa a v t i x x v x t .
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6.3 Results and Discussion
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initial activity as they explore the new surroundings, giving way to reduced activity 
the longer their activity is monitored {e.g. figure 6.4.1). Figure 6.4.2 indicates the 
percentage reduction in beam breaks m the first five minutes of exposure to a novel 
environment in animals treated with ^/-fenfluramine or sibutramine with respect to 
controls. Only the highest dose tested for each drug -  5.0 mg/kg i.p. sibutramine and
'i a    .• „  j  c  n  __  __— j ,  1 --------------- 1----- . u ~ u — — _ r r?/"i o o \_>.v> xxxg/ivg i.jj. u-xtxxxxuxaxxuxit- — sxgxxxxxvaxiu;y ltuu tw  tApiuiavui) utxxa\xvxui
= 10.667;p  < 0.001 for sibutramine and F{3,28) = 4.243;p  < 0.01 for J-fenfluramine] 
in this time frame (n = 8 for control- and drug-treated groups in both experiments).
As far as sibutramine is concerned, this first result was at odds with previous reports 
that sibutramine had no effect on locomotor activity despite increasing dopamine
1------1„ fT) 1 O AAA\ T *  ------ --- 1 rx _ ------- „ltvus in vivu îvOwx̂ y ct ui., iuuuj. it was axsv vuixucu}1 vu xinuxxxga uy uiuvvu c-i ut.
(2002) that while drugs with similar mechanisms to sibutramine -  selective serotonin 
re-uptake inhibitors (SSRIs) and serotonin-noradrenaline re-uptake inhibitors (SNRIs) 
— increased locomotor activity in mice exposed to novel environments, they had no 
effect on locomotor activity in the rat.
Attempts were therefore made to replicate this decrease and further investigate the 
impact of sibutramine on exploratory locomotor activity. However this finding proved 
to be un-reproducible despite trying experiments with varied dose-test intervals, or
/V O A « r A l  A / I  A  A  A  t  r a ! «  1 a 1  a  A  4  A « *  4- A  .4 « «  A  a 4 « * A  4 A - k +  A A / 1 i v « * a 1  « ^ A M A a 4 -A  A * *  4using viuuwtum as a Veflivit 111 auuiuun vu tiding suaignv piuucuuiai l̂ pCavs aim
testing a full range of sibutramine doses (e.g. figure 6.4.3). This non-reproducible 
nature suggests that the decrease seen after dosing with 5.0 mg/kg sibutramine in the
 _____. _____________   ._____i . . „ a   -  ~xxixvxax wvjj&xxxxxtxxi was axi axivnxxaxy, a xuxxvuvnx ux txxt. gxuup ux axxxxxxaxs lamvi txxaxi a
consistent drug effect.
The decreased activity observed after treatment with the highest dose of u- 
fenfluramine is consistent with previous reports that racemic fenfluramine decreases 
locomotor activity (Aulakh et al., 1988; Callaway et al., 1993; Ziance et al., 1972), as
Goef tnc v- isomer (5vet anc fftcoiaidis !98v anc notr sterepisomc- ' 
fenfluramine metabolite norfenfluramine (Callaway et al., 1993).
For both drugs, the higher two doses tested (1.0 and 3.0 mg/kg for J-fenfluramine; 
1.67 and 5.0 mg/kg for sibutramine) showed significant impact on food intake
r  A U A 4 « i / \ « i / i  A  A M  J  4>lt 1 />«<« />/>■•• n  A  4-4 /-V-4-W t  A M  n 4 - i  ■» <-*n 4 - k  / 1 / 1 1  / J  / \  A /> n  / \  -Ci v x x a p m x : >  “r c u m  # j  a x x u  x v n  v i m  i v n x g ^ x - m x x n  a a t m t y  im v j v m x w ^  s i u u i w  v i m  n i m u m  u u z m a  u i
both drugs were used. While there was a trend towards decreased locomotion in 1.0 
mg/kg ^-fenfluramine treated animals it was not statistically significant, and the
« * /\  /•« 1 -V -« F* 4*Ia n  4 1% 1 4 «« ^ 4 -  1  C  H  *»■% />  / I  I- />  ̂  /4  «>11 r*  / I  A ^< T T Al ^ d u i v D  w i v u  d i u u u a i i i i i m  s u g g e s t  v n a v  i . v ? /  x x x g / j v g  v u  v i i a v  u i u g  u w a  n u i  m i u w  i m u a v i v ^
potential either.
 ' i  r v  n —  j  c — n ______ :  a : a  a    a ~ ~ ~ — — ----------------a ----- ----------i \j v v m v i u u t ,  w i i i i t  _ > .v  m g i r v g  l * - i \ ^ i i i i u i a m m t  u i u  j j i v > u u v t -  a  u & v i & a a c ,  t i n s  w a s
not used for further works given the results outlined in chapter 4 (above). Neither 
sibutramine nor ^-fenfluramine induced any substantial, consistent or statistically 
significant sign o f sedation or locomotor retardation under this exploratory paradigm 
at doses used in the circadian studies o f the BSS. This would indicate that a sedative 
action was unlikely to be solely or primarily responsible for the increased resting
O  t% A T O  V% 4  «»• V /V A  /N T A  ■* A  T  4- A  A  «A /■» t»<%1 1 *  r *X^ /S  A  4  A  4- Av x u im x v ^ u .  w n n  u v m x  u x u g a  i n  vxxo  a a u ^ v )  zm v iv m x x x m . x.v v a x x  ^ v j u a x x ^  v m  r > a m  u x a v  vxx^
anorectic effects o f both drugs do not result from displacement o f feeding behaviour 
to increased motor activity. These findings would therefore further support the initial 
assertion that sibutramine and w-fenfluramme are drugs which advance the 
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over the duration o f the recording. Animals were dosed with one o f three doses o f d- 
fenfluramine or saline 30 minutes prior to this recording. The aggregate number beam
u . — 4.u~ c: — + c —  ~ u u .  ...~1 — <. * .u ~*■ .— — a~a c:__ 1 1 nu i t a i o  111 u i S  m o v  j  c p w n s  i a  l v i u g i i i }  t v j u i v a i t m  vvj u i a v  i v a a u u x a i  w t i  v i i t  l i n a i  1 v
minutes under control conditions, and drug treatment affects the expression of 
locomotor activity in the initial phase more than the later phase. Data are means ±
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J-fenfluramine (each at 3 different doses) when compared to saline. Data are means ± 








































Figure 6.4.3 An example of a dose-response curve for the inhibition of locomotor 
activity by sibutramine suggesting the significant results in figure 6.4.2 (above) were 
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7.0 The Effects of Sibutramine and rf-Fenfluramine on the BSS Measured Across 
the Circadian Cycle: Impact of Circadian Rhythm
7.1 Introduction
r io  u iv i iv m iiv v i  a v m v v  ^ v iia p v v ia  _> a im  -rj v m v  v»i vn v  a n n a  \j i  vim  p iv a v n v  w viirv w a a  vv>
investigate the impact of circadian rhythm on the response to sibutramine and d- 
fenfluramine. As outlined in section 3.3, circadian variations affect many aspects of
„ 1   i ~ — i , ,  i__i_____: ------- — a —    ~  ______________ _— 1
p iia m ia v v i iv ig ^ ,  a im n a ir y  l v v u m g  u v n a v m u i  i s  u im v i  r su v iig , v n v a u i a n  v v m u v n . 1111s
parallel makes a behavioural feeding paradigm, such as the BSS, a prime candidate 
for investigating interplay between circadian rhythms and drugs which affect food
T U ,_______ ___________ f D C C  —  4 -~  TT„1 .f A  „ *  „ /  1 OOO C - ~ T ---------  ~ ~ . A
n u a iv v . n i t  p iv m v n a  u i  u o o  s v u u iv s  i v  v ia v t y a w  n a i i u i u  c i  u t . ,  1 7 7 0 ,  lvn  a  i v v i v w , a n u
numerous studies cited in section 4.1, above) have been carried out at a wide variety 
of circadian times and using an array of differing food sources and food deprivation
— nnLj „ . u  ~ . . u  a -------- -----------11 ^ i„ i *------------ a : c c ~~— *
a v n v u u iv o .  l i u s  v a n a u v m  v a n  m a iv v  i t  u i m v u i i  tv> vaiaw  j ja ia n v iD  u v v w v v n  u i n c i t m
investigations. Observations made during the rats’ natural activity phase, during 
which they consume the vast majority of their daily food intake, are more valuable as
 i„ *—  a  4.„  ~ „ u : u u  ~ u ; ~ u  v — —jj u „ i ; „ „ a  4 U ..„
av im a  v n n v  a n n i i a n  vvn u  vvi v a i u v i i  a  m g n  u a s v i i n v  vn lv v v m ig  u v n a v iu u i  a im  t n u s  u iu s i
rodent studies are now carried out during the dark phase. Circadian variation in 
activity, appetite, and pharmacological parameters can make extrapolating between
~ 1 -------- —  A : £ • { • „ „ 4 . ™ —  A  — .  ----------1 4 U . . ~  4 -~  A . 1 U   A —  A  „
u u a t i  v a t iv m s  m a v iv  a i  u i i i v i v m  u n iv a  vn u a )  u m i v u i v ,  a im  u iu a  ivi iu n ^  u i iu v im a im  a
drug’s action it becomes important to investigate its activity across the circadian cycle. 
It is with that aim that these two drugs were examined in the BSS at 6 different 
circadian times spread evenly over the 24 hour day.
As described above [section, 4.1], both of-fenfluramine and sibutramine have been 
examined in the BSS before now (e.g. Halford et a l, 1995, 1998) though in neither
 u ~  4-v __________________________________________i___________________- u .  .+1 . j „
v a a v  n a v v  v n v a v  u i u g s  u v v n  m v v s u g a v v u  i \ji  v n v v u s  v ii v n v a u i a i i  l i i y u m i  u n u v i  a
consistent BSS paradigm. Racemic fenfluramine has been examined for circadian 
influence with respect to its effect on food intake (Davies and Wellman, 1991) and it 
was found to have less anorectic potency, as measured by percentage reduction in 
food intake, during the light phase; however, the J-isomer was not separately tested,
no: havs either tnt racematt o: the o - isome: beer, examinee for eircadia: anaxa:
— : ( r .  i u .  -4 U .„  4-u^ d c c
a j j v v m v a i i^  w iv im i  vnv u o o .
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7.2 Materials and Methods
7 ^  A*a*v% ^ U a  a a m a 4 * a 1  a ii4 1 i« %  a  ^ a « ia 4 m U a /4  a U a y f aj-zA pC '/ unx^tuo i - u .  x  l u v w u i v a  u m v i w  u u x i x  u i v  g u i v i a i  u u v n n v  u v o v n u v u  a u u v v
[section 4.2] in so far as the 12:12 light/dark cycle was altered so that whilst 
observation was always carried at the same time (GMT) across all experiments, the
AAi««rn A *>-4- «« aIk 4>t% A w* TAOA 4a a 4 -fyA ««A ̂  a4y« rA A«« ÂrMAWN MA A«%4>A »A**a u u j ^ v v i v ^  t i i i x u  a t  w i i x v / i i  u x u  a i i i i i x a i d  w u t  t u d t u u  u x x x u x u u  u u v w ^ u x x  U A p u i i i i i u i x v d .  w u
the course of the 6 experiments animals were tested at Circadian Times (CT) 1, 5, 9, 
13, 17 and 21, where CTO was lights-on and CT12 was lights-off. A different set of 
animals was used at each circadian time point, and m each experiment animals were 
dosed with saline, 1.0 mg/kg ^-fenfluramine and 1.67 mg/kg sibutramine in a 
randomised treatment order. For simplicity of reporting they have been re-numbered
4*« Â« J Â« A-C A4«»AA /ll AM MA Ax x i u x u u  u x  i i i v i u a d i i x g  v i x u a u i a i i  t i i i x ^ .
In addition to statistical analysis carried out as described above on results from the 
individual experiments, data from experiments 1-6 were collated and subjected to
^  1 — A — A M A 1« n fA «• 4l% A ÂCa a4 A -C A4 «*A a «*] 4 A M A 1̂% A AM̂4«*A /] ÂA A a4> ««TA A A1TA4M4MA/1 H ̂1a
i u x u i u  a x i a i ^ d i d  x u x  u i u  v x i u v t  u x  u i i v a u i a x i  u n i t .  x x x c  € n u i t  u a i a ^ i  w a d  ^ a o x x x x & ^ u  w x u x
two-way ANOVAs, using post-hoc Dunnett’s tests for the overall effect of drug and 
post-hoc Bonferroni tests to examine the effect of circadian time, applied
: ~ a ----------a — 4- ^  — r ~, . _  u~i  -1  4.—  ; —  T? — ax x i u t p t i i v x t x i u } ’ t u  t a v x x  v j i  u x v  i O u i  u v a i a v i v j u i a i  v a t t - g v n x t s .  r v x v u  l i i v a i v t  w a a  dxxxxxxaxx^
examined. Additionally one-way ANOVAs were also used to examine the effect of 
circadian time on each behaviour, and on food intake, within each treatment condition,
m A a4 7<* A A ID A«* ■f>A t»MA«« -a 4aa4a ««rt% A«*A A «% »»<»A *A| *»l a4a C4a4« a4< AA A«*A «*A«% A >»4 A #4 Aw x u x  x ju x x x u x x u x x x  v u d t d  w x i ^ i u  a p p i u p x x a i u .  o u u i d u u d  a x u  x u p u x t u u  w x u x  ui^>
following format: [F(A) = B; p  < C] where A is the degrees o f freedom and B is the F 
value from the relevant ANOVA; C is the probability arising from post-hoc 
comparison.
With only three treatment conditions, the randomisation in each experiment was such 
that each treatment was administered to two animals (and thus two test cages) on
4- / .^  J a . .cvwj vtav ua) .
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7.3 Results
7.3.1 Looking Individually at Each Circadian Time
Experiment 1. Figure 7.5.1 shows behavioural profiles obtained from BSS 
observations carried out at CT1 in the early light phase. Figure 7.5.2 illustrates the 
level of behaviour recorded during each discrete epoch over the course of the 60 
minute observation, whilst figure 7.5,3 shows cumulative counts for each behaviour 
under each drug condition. At this circadian time, 1.67 mg/kg sibutramine accelerated 
the offset of feeding such that cumulative feeding counts were lower than controls 
after 10 minutes [F(2,27) = 7.301; p  < 0.01] and remained so for the hour [F(2,27) = 
19.721; p  < 0.001]. This dose concurrently accelerated the onset of resting, with 
animals observed resting more often after 10 minutes [F(2,27) = 5.422; p < 0.05], and 
they rested significantly more than when dosed with saline for 50 minutes of the 
observation period [F(2,27) = 3.841;p  < 0.05]; resting was non-significantly different 
from saline over the hour-long observation. Activity was briefly suppressed between 
20 and 25 minutes into the observation period [after 20 minutes F(2,27) = 8.092; p  < 
0,05; after 25 minutes F(2,27) = 8.318; p  < 0.05], while grooming was unaffected. 
By comparison, 1.0 mg/kg of d-fenfluramine had an immediate inhibitory effect on 
feeding [after 5 minutes F{2,27) = 3.916; p  < 0.05] which was preserved throughout 
the observation period [after 60 minutes F(2,27) = 19.721; p < 0.001], with resting 
immediately increased versus the saline condition [after 5 minutes F(2,27) = 3.823; p
< 0.05]. This increased resting became non-significant after 50 minutes. Activity was 
also suppressed throughout the observation period [after 5 minutes F(2,27) = 4.975; p
< 0.01; after 60 minutes F(2,27) = 3.775; p < 0.05], while grooming was increased 
after 10 minutes [F(2,27) = 14.403; p  < 0.001], and throughout [after 60 minutes 
F(2,27) = 12.618; p  < 0.001]. Both drugs significantly inhibited the animals’ intake of 
food during the hour-long observation period [F(2,27) = 18.106; p < 0.01] (figure 
7.5.20),
Experiment 2. The BSS profiles shown in figure 7.5.4 detail the response to saline, 
1.67 mg/kg sibutramine and 1.0 mg/kg ^-fenfluramine in animals tested at CT5, mid
Ugh: phase, Figure '.*.5 illustrated the ieve of benrsou: recorde; dur::.l eao; 
discrete epoch over the course of the 60 minute observation, whilst figure 7.5.6 shows
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cumulative counts for each behaviour under each drug condition. At this circadian 
time dosing with sibutramine caused an advance in the offset of feeding, with feeding
v^ u u iils d ig in iiv^ a iiu jy  l u w t i  m a n  w n t n  i i i c  s a i n t  a m i n a i s  i t t c i v c u  s a i i n t  u t i w r a i  u
minutes [F(2,30) = 5.445; p < 0.05] and 50 minutes [F(2,30) = 4.599; p < 0.05] 
following the return of food. Resting was concurrently increased, an effect that was 
noted earlier — after 10 minutes [7^(2,30)= 3.591;p  < 0.05] — and lasted until the same 
point, 50 minutes [F(2,30) = 4.937;p  < 0.05] into the observation period. Sibutramine 
also caused a brief decrease in activity [F(2,30) = 5.768; p < 0.05] only present after 
20 minutes, not at 15 or 25 minutes or any other point. This drug did not affect 
grooming behaviour significantly. On the other hand, uf-fenfluramine significantly 
increased grooming over the full observation period [after 60 minutes F(2,30) =
1 o i r\">- — ^  f t  f t f t  r i  u  — ________—  a  c  . —  r r?rr\  i n \  — 1 a  / to o .
i o . i u z , , j 7  ^ u . u w i  j ,  a n  t u c c i  max u t i / a m t  a j j p a i t m  a n t i  -r_; l i m iu l c a  [ i  — 1 ‘t . t z .z , ,
p  < 0.01]. Treatment with ^-fenfluramine suppressed activity between 20 and 50 
minutes after the return of food [after 20 minutes F(2,30) = 5.768; p  < 0.01; after 50
 r rY'i i n \  — o q i  i .  „  n  f t c i    a  ~  , ,  j  c — n , . - —
i m i i u i t s  [ i — j . 7 u , ^  \ j . j  c u i i i j ja n p u  tu  v c in w i t .  lo u s in g ,  w u n  u - i c i i i i u i a i n m ^
also accelerated the offset of feeding [F{2,30) = 5.445; p  < 0.05] and the onset of 
resting [F(2,30) = 9.334; p  < 0.01], with both effects becoming apparent 15 minutes 
into the observation. The effect on feeding was significant over the entire observation 
period [F(2,30) = 3.614; p  < 0.05], however the difference in resting ceased to be 
significant beyond 50 minutes. At this circadian time sibutramine did not significantly
~ ~ a  c —  a  — . a r  f t . -  1 i -  . . . .  u .,*  . J  ------— :—  a : a  r m  i a \  _
i t u u t t  i u u u  l i iu u v t  u v t i  u i t  i n u u i  u u a w  v a u u n ,  u u i  u - i t i m u i a i i i i i i t  u i u  | i 1 )  ~
6.004;p  < 0.01].
4- 2  r I 'l̂  /\ O C C 1 />n nU rr»i ^ C a+ 1 /%
i m t m  ± n t  u j j  ^ l u i n t s  s n u w n  111 n g u i c  / ••j* / w u t  g t n t i a i t \ u  a t  \ ^ ± y ,  l a t t  111
the light phase. Figure 7.5.8 illustrates the level of behaviour recorded during each 
discrete epoch over the course of the 60 minute observation, whilst figure 7.5.9 shows 
cumulative counts for each discrete behaviour under each drug condition. At this time 
there was little feeding drive in the animals regardless of which treatment they 
received -  1.67 mg/kg sibutramine, 1.0 mg/kg uf-fenfluramine or saline. Neither drug 
treatment affected observations of feeding, activity or resting, nor did they produce 
effects on food intake. However, when dosed with ^-fenfluramine animals were 
observed to groom significantly more often than after receiving saline, an effect that
Occam; signiiican afte minute:. i_  — - .8- . . r i ^  anc was prcscr< -c
over the course of the hour-long observation [F(2,35) = 18.749; p  < 0.001].
113
Experiment 4. Figure 7.5.10 presents BSS profiles garnered from observations carried 
out at CT13, early in the dark phase. Figure 7.5.11 illustrates the level of behaviour 
recorded during each discrete epoch over the course of the 60 minute observation, 
whilst figure 7.5.12 shows cumulative counts for each behaviour under each drug 
condition. At this time, dosing with 1.67 mg/kg sibutramine caused a noticeable
c  1-'__ .u.------ ~.i .  4.u~ ~u—„ .~4.; — __ — c rvo _in  i t t u i n g  t m u u g n u u i  u i t  u u s c i  v a i i i n i  j i t i m u  [ a n t i  j  l i i i i iU i t a  r) —
12.014; p  < 0.001; after 60 minutes [F(2,24) = 15.354; p  < 0.001], and concurrently 
increased the incidence of resting observations compared to the vehicle condition after
i n    ,— . j r n Y o  o /i\  — c  c o i . „   ̂ n  n  n  rrr/n n /i\  -m  i i i i i i u i t s  u i  u u a t i  v a u u n  ) — u . j o i ,  jj -- w . i / i j  a u u  u i i O u g i m u i  —
8.500; p < 0.01], In comparison, 1.0 mg/kg ^-fenfluramine prompted a similar 
decrease in feeding [F(2,24) = 12.014; p < 0.001] and increase in resting [F(2,24) = 
13.218; p  < 0.05] from the first epoch and throughout the whole period of observation 
[F(2,24) = 15.354; p < 0.001 and F(2,24) = 8.500; p  < 0.01 for feeding and resting 
respectively after 60 minutes]. Neither drug showed any appreciable effect on 
observations of activity or grooming, but both drugs caused a significant inhibition of 
food intake compared to saline in the hour long experiment [F(2,24) = 13.084; p < 
0.001 for ^/-fenfluramine; p <0.05 for sibutramine].
Experiment 5. At the mid-dark phase timepoint, CT 17, animals generated the BSS 
profiles shown in figure 7.5.13, Figure 7.5.14 illustrates the level of behaviour 
recorded during each discrete epoch over the course of the 60 minute observation, 
whilst figure 7.5.15 shows cumulative counts for each behaviour under each drug 
condition. At this time, sibutramine (1.67 mg/kg) accelerated the offset of feeding 
with significantly fewer feeding observations than vehicle after 10 minutes [F(2,33) = 
4.645; p  < 0.05], and effect maintained throughout the observation [F(2,33) = 9.814; 
p < 0.01]. Resting was increased and observed earlier with this treatment; it took 25
   +.—  f —  +u„ :  ______u -------------------—  ~ rrvo _  n  c n c \ .  ~  ^  r \  r \ cinuiiuits mi uit intitaat wi uttuint Mgnmtain [i — i.KJiy,y n.unj uui mt
differential was then preserved [F{2,33) = 13.727;p  < 0.01]. Animals also exhibited a 
brief increase in activity when dosed with sibutramine, an effect only apparent after
1 n __ *—   r rrvo t o \  — 1 a  c\cc. _  n n c i „ „  j  ___ 1 c —m annuity ui uuati vauiiii [i — iu.71111, jj j, auu gunt again u  imiiuits
into the test period. Sibutramine decreased grooming observations with respect to
connv.: afte; 5( minute. [F(2.S3 = ' i.GS^%ncpy€: tit! or^e" . :• j&r >c
as a whole \F\1,33) = 12.290; p  < 0.05]. Treatment with w-fenfluramme raised total
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grooming observations [F(2,33) = 12.290; p < 0.05 after 60 minutes], an effect first 
noticeable after 20 minutes [F(2,33) = 6.292; p  < 0.05] and significant over the hour 
of observation, but not at all points between. This treatment also caused a suppression 
of activity; from 15 minutes after the food jars were presented, animals were observed 
as active less often when they had been treated with 1.0 mg/kg <7-fenfluramine than 
when they had been dosed with saline [7 (̂2,33) = 7.170; p  < 0.05 after 15 minutes; 
F(2,33) = 22.634; p  < 0.001 after 60 minutes]. Injections of d-fenfluramine also 
suppressed total observations of feeding [F(2,33) = 9.814; p < 0.001], noticeably
i — — 1 f\ rnY'i _  a c a c .  „  n n c i  i „i___
iu w c i  a iu t i  i v  n u n u i c s  [7 — n . v ~ t A , y  ^  v . v ^ / j ,  a u u  i i i u i t a » c u  iu w i  u u s t i v a u u n s  u i
resting [F(2,33) = 13.727; p < 0.001], an effect which was immediately apparent 
[F(2,33) = 4.745; p  < 0.05]. Both drugs elicited a significant reduction in food intake
—  A  i i   r n v o  _  1 1  / in c .  „  ^
u u x x xyaxtu  i v  s a i m t  u v u  uiC  xxOux-xuxxg u u a c i  vaxxvnx p tx x u u  n  —  n . n j ,  y
0.001 for ^-fenfluramine;p  <0.05 for sibutramine].
Experiment 6. Figure 7.5.16 was generated from BSS observations carried out at 
CT21, late in the dark phase. Figure 7.5.17 illustrates the level of behaviour recorded 
during each discrete epoch over the course of the 60 minute observation, whilst figure
*7 d  1 O »n 1 VM ill r» TTrt + n f/-\ f* h oU/M 14 V 1«« aU 4«>1 1 /v /«/>«« /4 < 4-1 A 4- 4-U n
/ . j . i o  S f lu w i  t u m u i a u v t  i u i  c a w ii u c n a v iu u i  u n u ^ i  ^ aw ii u i u g  V /O iiunnm . t in s
time, J-fenfluramine (1.0 mg/kg) produced a decrease in feeding observations [F(2,27) 
= 8.592; p < 0.001] with a concurrent increase in resting [F(2,27) = 17.930; p < 0.001] 
over the 60 minute observation; both changes became significant with respect to the 
saline condition 10 minutes after food re-introduction [F(2,27) = 5.525; p < 0.01 and 
F(2,21) = 7.979; p  < 0.001 for feeding and resting respectively]. Additionally, d-
x t x ix iu ia i i i in t  s u j j j j i c s a c u  a t u v u )  aiauaixvaxx_y axgiiixxuaxxu_y u u x x iig  u x t  l a u t i  xxaxx ux u xc
experimental period [F(2,27) = 4.257; p  < 0.05 after 30 minutes and F(2,27) = 4.974; 
p  < 0.01 after 60 minutes with respect to saline], as well as increasing observations of
 u ~ u — ; __ - __   o n ___:___r ttyo _  o m - 7 .  _  /  n n z i  __ *
giuuixxixxg, u t-xxavxuu i u v c x  u xc  xxxai z . v  xxxxxxuica [i V- ^ , ^ ' )  ~  J - ^ x / ,  u u i  xxui
beyond that. In comparison, sibutramine had no effect on observations of grooming or 
activity, but caused a similar overall reduction in feeding [F(2,27) = 8.592; p  < 0.07]
j  ̂ _________________ r rrro _  i-7 m  a .  „  ^  n nn t i ------------a:£c~.----------- — c  c.— ™  — u ; ~
axxu ix iv^ xtast xxx xcsixxxg [v )  —  x / . 7 j u ,  y  21 v . w i  j ,  uxc uixxtxtxxv^cs xxuxxx vcxxxvxc;
showing significance 15 minutes into the observation [F(2,27) = 7.396; p <  0.05 and 
F(2,27) = 13.192; p  < 0.01 for feeding and resting respectively]. Both drugs caused a
sigrwiicaiT decrease ir. miaiv. over tm nour c. oPservatior wner. comnarcc iC 
saline [F(2,27) = 17.566; p  < 0.001 for ^/-fenfluramine andp < 0.01 for sibutramine].
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7.3.2 Collated Data -  Overall Effects of Treatment and Circadian Time
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treatment, feeding counts are reduced at CT9 compared to all other circadian times a 
difference that is statistically significant after the first epoch (CT5, 13, 17, 21, 
[7^5,174) = 15.196; p  < 0.05 after 5 minutes; F(5,174) = 25.528; p  < 0.001 after 60 
minutes]) or only when looking at the full hour (CT1, [F(5,174) = 25.528; p  < 0.05 
after 60 min]); in all cases the differences are maintained over the hour following the 
return of food. Mid- and late-dark phase observations of feeding were increased 
relative to all light phase counts; at CT17 this effect was significant from the first 
epoch in every case [F(5,174) = 15.196; p  < 0.05 after 5 minutes; F(5,174) = 25.528; 
p  < 0.001]', the same was true at CT21, except relative to CT5 when the difference 
only became significant after 30 minutes [F(5,174) = 22.401 ;p<0.  05]. Animals were 
also observed feeding more often at CT17 than at CT13 [F(5,174) = 25.528; p  < 0.05\ 
over the full 60 minutes only]. Activity scores over the hour were significantly lower 
at CT9 than during the mid- or late-dark phase, or the early light phase [F(5,174) = 
6.066; p < 0.00J in each case], while activity counts over the first 35 minutes of 
observation were significantly lower at this time than at any other point [7^(5,174) = 
7.523; p  < 0. 05]. Grooming counts were unaffected by time of observation over the 
hour, but animals were observed grooming more in the first 10-15 minutes at CT1
r r v c  i -7/t \  — n  nnn. -  n n ;  i n  — *.— l J r 'rrc\ r r r c  -\n a\ — n  c n c .  -  n nn j
L-i I / ' t  j  —  j . i  i  i ,  v . v ~ > ,  aiiv^i iO  i n m u i t s j  a u u  ^ 1 7  [j V -S 1 7 v  '  U . V U t ,
after 15 minutes] than in the same period when tested during the dark phase.
Concurrent with the decrease in feeding counts at CT9, resting counts were more 
frequent at this time than any other, significantly increased compared to CT1 after 25 
minutes [F(5,174) = 18.124;p < 0.05] and from the first epoch when compared to all 
other times [F(5,174) = 10.317; p  < 0.05]; in all cases the difference remained 
significant over the hour (77(5,174) = 18.425; p  £ 0.001], Mid- and late-dark phase 
observations of resting were significantly decreased compared with counts at all light 
phase times. At CT 17 resting counts were significantly less than at CT1 and CT9 
after 5 minutes [7^(5,174) = 10.317; p  < 0.01] and less than at CT5 after 40 minutes 
[F(5,174) = 19.206; p  < 0.05]-, in all cases this decrease remained significant over the 
full test period [F(5,174) = 18.425; p  < 0.01]. A similar pattern was seen at CT21, the 
oni\ amerencs Demg i sngnir earnei emergence o. signiiicance ir ins ewe:cus-..» • 
resting compared to CT5 [F(5,174) = 19.380;p  < 0.05, after 35 minutes].
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Examining the overall effect of drug treatment regardless of circadian time reveals 
that both drugs decreased feeding observations from the first epoch [F(2,174) =
1 1  r i m . „  /  n  / i  n  e c — *.________________ _a  — —  a .  i t  c r \  — ^ r m  ■\h a \ -  a  1 c c c .  „i i . y / j , y  i/.ivjj, an cucvi iiiaiiitaintu uvci uic 1U11 uu uuuuits ---n , j j j , y
< 0.00J]. Activity was observed significantly less after dosing with 1.0 mg/kg d- 
fenfluramine compared to controls [F(2,174) = 4.288; p  < 0.05 after 5 minutes, 
7^2,174) = 17.986; p  < 0.001 after 60 minutes], while grooming was observed more 
often [F(2,174) = 7.363; p  < 0.05 after 5 minutes, F(2,174) = 52.005; p < 0.001 after 
60 minutes], Sibutramine induced a decrease in grooming compared to saline 
[F(2,174) = 52.005; p  < 0.05 after 60 minutes], but this was only significant from 50 
minutes into observation [F(2,174) = 46.086; p  < 0.05]. Resting counts were 
increased with both drugs from the first epoch and throughout the observation period
r  n v o  h m  =  i a  Q i Q .  _  ✓  n n i  c  — 77/ 0  i  h a \  _  n  c a  a . „  ^  a  a a  j  c r \
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minutes].
Significant interactions between drug treatment and circadian time were noted in their 
effects on all 4 behaviours. Although non-significant over the full 60 minutes 
[F(10,174) = 1.774; non-significant], circadian time significantly changed drug effects
■FaaAin'r ar- OA CA T 77/1 A 1 HA \ — 1 n o o .  _  A AC „ o nV711 lttuillg, UVU lOfc 11131 iU-JU [i-^ iu ,l /*tj — 1.700, y  \J  .\J  J  a iltl A.KJ llllllUtt3,
F(10,174) = 1.924; p < 0.05 after 50 minutes] minutes but not the first 15 minutes of 
the observations [F(10,174) = 1.789; non-significant after 15 minutes]. Resting 
behaviour was differentially affected by drug treatment across the circadian cycle 
after 15 minutes [F(10,174) = 1.920; p < 0.05] and over the 60 minute test period 
[F(10,174) = 3.045; p  < 0.01]. A significant interaction between circadian time and 
drug treatment on the incidence of grooming behaviour was noted over the 60 minute 
observation period [F(10,174) = 1.916; p  < 0.05], whilst their effects on activity 
showed an interaction only if examined over the first 35 minutes of the test period
r 77/1 A 1 -7/1 \  _  1 A IO . _  ^  A AC! T A  4 . U ~  A - , , *  A f \  . . . U  „  1 ~
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experiment.
-L-uuiving ai uic uniciC'iiuai ciicvia ui cn^auiau nine vin cauu uidiinui uiug wimuniun,
feeding was observed less often under control conditions at CT9 than at any other
time excep: IT ., differing froif. dan' pnas-. umepoinf afte- minute. J . '  =
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preserved throughout [F(5,58) = 14.570; p < 0.01]. Feeding was observed 
substantially more in the mid- to late dark phase with observations at CT21 [F(5,58) =
1 a cn n . -  n n c c n  —  p t - i  1 ™ r ' T i  -ic — *. a
x - r . .x / u , / /  \ j . y j j  a x x t i u u  xixxxxuicd, u i i i  m a t  uxxxuxuu xxuxxx axxtx i~> m m u it -a  a u u
from CT5 after 50 minutes] and CT17 [F(5,58) = 14.570; p  < 0.05 after 60 minutes; 
CT17 first differed from CT1 after 50 minutes and differed from CT5 only over the 
60 minute observation] more frequent than at any point in the light phase. Statistically 
significant changes in activity counts due to circadian time are seen after 15 minutes 
of observation; by this time saline-treated animals were observed as active less often 
at CT9 than at CT5 [7^(5,58) = 3.018; p  < 0.95]. By 20 minutes into the observations, 
saline treated animals were less active at CT9 than at any other time except CT13 
[F(5,58) = 5.050; p  < 0.05]\ the decreases in activity remained significant over the 
hour of observation [7^(5,58) = 7.023; p  5 0.001] except differences with CT5 which 
became non-significant after 60 minutes. Grooming was barely affected by circadian 
time, although at CT9 animals were observed grooming more over the first 10
p t o i  r r Y c  c o n  _  a n c o  ■ „  - n n c i -------------------- ----- ~ e irm ififw t-
m iiiu ib ^  m a n  a i  u i i i  jx ~  - ) . z .k j o ,  j j  ia u ^ j  uxxs uxuxx u u a s u u  tu  u t  a  Mgxxxxiv^axxi
difference. Resting counts were increased from the start at CT9 compared to CT5, 
CTO, CT17 and CT21 [F(5,58) = 5.647; p < 0.05 in each case] and after 10 minutes 
compared to CT1 [7^(5,58) = 8.494; p  < G.95], differences that remained significant 
over 60 minutes [7^5,58) = 19.291; p  < 0.001]. At CT5 animals were observed resting 
more often than at CT 17 [F(5,58) = 19.291; p < 0.01 over 60 minutes] or CT21
r r v c  c o \  — i n  n m  . „  n n n i  — cn   — i J.-rr,,.-------— * u . . c c
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and 50 minutes respectively. After 35 minutes at CT1 the saline-treated animals were 
counted resting noticeably more than at CT21 [F(5,58) = 22.605; p  < 0.05], and this 
difference was maintained thereafter [7^(5,58)= 19.291; p  < 0.05 over 60 minutes].
Looking just at animals when under the effects of <7-fenfluramme, at CT1 they were 
observed feeding less than at CT17 [F(5,58) = 7.084; p  < 0.01 over 60 minutes] and
/"’TO faaAi-r-.r' *■*-- P T n  P'nrA 1 r r y c  c o n  — n no a . „  ^a i u i 7  u x t i t  w c x t  i c w u  x ttu x x x g  uuuxxio uxaxx a i u i x /  ux u i i x  [ i \ D , D o )  ~  / . u o t , ^  ^
0.01 over 60 minutes]. All these effects were significant from the first epoch onwards 
[F(5,58) = 7.552; p  < 0.01 after 5 minutes]. Activity counts in <7-fenfluramine treated 
animals showed no variation with circadian time, but grooming counts under these 
conditions exhibited variation over the first 10-15 minutes of the test period. At CT1
anc CTC animal- oosec with f-fenfiurarrjh'f were bbssfvec grooming more c:w: :fta:
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minutes] and CT17 [F(5,58) = 6.205; p < 0.05, 15 minutes]. Resting observations 
were ultimately unaffected by the circadian time of observation when looking solely 
at the u-fenfluramme condition.
Examining the sibutramine condition across the circadian cycle, feeding observations 
were suppressed throughout at CT1 [F(5,58) = 5.536; p  < 0.05 over 60 minutes, first 
observed after 5 minutes] and CT9 [7 (̂5,58) = 5.536; p  < G.001 over 60 minutes; first 
observed after 5 minutes] when compared to CT17. Feeding observations were also 
lower at CT9 compared to CT21 [F(5,58) = 5.536; p < 0.05 over 60 minutes; first 
observed after 10 minutes]. Suppression of feeding counts at CT1 relative to CT21 
was also noticeable but only after 25 [F(5,58) = 6.359; p < 0.05] or 45 [F(5,58) = 
6.302; p < 0.05] minutes of the observation period, and the effect was not maintained. 
Initial feeding was highest at CT17 (figure 7.5.13). Sibutramine attenuated circadian 
changes in activity counts, with the only differences observed between CT9 and CT17, 
and then only over the first 35 minutes of observation [F(5,58) = 2.522; p  < 0.05]. 
There was no circadian variation in grooming counts under the sibutramine condition. 
Resting counts were significantly increased from the start at CT9 when compared to 
CT17 [F(5,58) = 3.728;p  < 0.01 after 5 minutes] or CT21 [F(5,58) = 5.541;p  < 0.05
~  1 a  : ____—  a  . u — 0  --------- ™ . . . u ~ i „  u ~ . . - .  r r v c  c o \  —
axxcx i v  xxxxxxxxxcaj a u u  u i t s v  u m t i c u v c s  w t i t  xxxaxxxxaxxxvu xvx xxxt w xxvxt xxvur —
4.649; p < 0.01]. At CT1 resting observations were increased compared to CT17 
[F(5,58) = 5.966; p  < 0.05, after 30 minutes] and CT21 [F{5,58) = 6.098; p  < 0.05, 
after 25 minutes] over the first half of the observation period, but not over the 
observation as a whole.
An illustration of the level of expression for each of the four behaviours over 1 hour 
of BSS observations at each circadian time and with each drug is shown in figure 
7.5.19, whilst Table 7.5.1 summarises when drug-induced changes in observed
utxxavxvuxa ucvaxxxt Mgxxxxivaxxxî  uxxxtxtxix ixvxxx aaxxnc ax xxxt vaxxvua vxxv-auxaxx xxnits,
and when looking across all circadian times.
i uuu iruun,c. x->wivxxxg, ax xxxc cxxcvx ux uxug xxCaxxxxcxxxs xcgaxuxcad ux vxxvauxaxx xxxxxc,
both 1.0 mg/kg ^/-fenfluramine and 1.67 mg/kg sibutramine [F(2,174) = 54.386; p  <
ic~ poth’ mhihitec iboz intake c.ve~ trie perioc of obs'efvatior wher. comparec . 
saline. Examining the effect of circadian time, regardless of treatment, food intake
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was highest in the dark phase -  intake at CT17 and CT21 was greater than intake at all 
light phase points [F(5,174) = 26.832; p  < 0.001]; intake at CT13 was higher than
r*T1 — J p t o  rrrrc n / i \  _  o t t . -  ^ n /ici  i i  i~4.~ k~L4inuuve a l \ s i  i cuxu ^ 1 7  /*■t )  — z,u .oji, j j  — aiiu lUwcSi in uic laic ugnt
phase -  food intake at CT9 was significantly reduced compared to all other time 
points [F(5,174) = 26.832; p  < 0.001]). There was a significant interaction between
a 4-.'---- a ~..~ ---------  ----- 4~~— 4 r n v i  r\ m A \  — n o n  1 . „  x  n n nv^ iivau ian  u iiic  a im  u i u g  i i t a u i i t m  jx-^ iv / , i  / *t j  — u . v i j .
Looking at circadian variation in food intake on a treatment-by-treatment basis reveals 
that intake was significantly lower at CT9 than all other times in control conditions 
[F(5,58) = 16.932; p  < 0.01], but only late dark phase intake was significantly 
increased compared to other times; it was significantly higher than any point in the 
light phase [F(5,58) = 16.932; p  < 0.01 for CT1 compared with CT1, CT5 or CT9]. A 
differential effect is seen with (F fenfluramine, where the only significant difference in 
food intake is between peak consumption at CT17 and the nadir o f intake at CT9 
[F(5,58) = 16.932; p  < 0.001]. Sibutramine treated animals simply consumed 
significantly less at CT9 than at any point in the dark phase [F(5,58) = 16.392; p  <
0.01]. Figure 7.5.20 illustrates the food intake at each circadian time on a treatment 
by treatment basis, and as a percentage o f control consumption, as well as figures for
^1% A « « tI% ̂  1 M a 4- «A A A Al A ̂  A4 <«*AA /J 4 4*4 AI n c  w i k n c  u a i a a c i ,  i c g a i  u i c a d  u i  C n c a u i a n  u x n c .
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7.4 Discussion
Both uf-fcnfluraminc and sibutramine have previously been described as causing an 
advance of the BSS (e.g. Halford et al., 1995, 1998) and these reports are by and large 
in agreement with findings in this study, and the preliminary investigations described 
in chapter 4. The work presented here was undertaken to investigate whether the 
circadian time at which BSS observations are carried out has an impact on the 
efficacy of the drugs used, or indeed on the practicalities of the paradigm. The 
interactions reported above (section 7.3) suggest that the time at which the drugs are 
administered does indeed have a significant effect on the response to the drug -  both 
in terms of the behavioural response (the BSS) and in terms of their effect on food
u iu ik c .
Looking at the profiles in figures 7.5.1-7.5.18, and at the effect of the drugs on 
observations of feeding and resting in particular, the BSS is advanced by both drugs at 
almost all circadian times. The obvious exception is CT9, late in the light phase. At 
this time animals were largely inactive regardless of the treatment they were given, 
with an average of 5 of every 10 observations recorded as resting in the earliest epoch 
and throughout the test period, even in control conditions approximately 75% of 
observations were of resting behaviour (figures 7.5.7-7.5.9), With no feeding 
response even under control conditions there was no expression of satiety, and no 
BSS for the drug treatments to advance. This finding is not unexpected; rats are 
nocturnal creatures and consume the vast majority of their food during the hours of 
darkness. The six hour food deprivation before the CT9 observations began 
encompassed only light-phase hours, and is therefore unlikely to have caused the 
emergence of a significant hunger drive. This ineffective food deprivation was not 
enough to stimulate a feeding drive strong enough to rouse the animals from their 
natural inactivity', and so there was no initial feeding response when presented with 
the food and no development or expression of the satiety sequence.
At other times both sibutramine and cAfenfluramine brought forward both the offset of 
feeding and the onset of resting to some degree or other, advancing the BSS and
reducing fboc consumption over- the noun iom. tes: 'period ir c marine ;arge: 
consistent with the enhancement of satiety. These effects consistently reached the
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level of statistical significance. This is supported by the dataset as a whole. Leaving 
aside the circadian time of observation as a factor, both drugs accelerated the offset of 
feeding and the onset of resting, with the number of observations of these behaviours 
significantly different compared to when the same animals were given saline from the 
first epoch, and remaining so throughout. The inference from this is that providing 
there is a significant baseline feeding response then sibutramine and u-fenfluramine, 
at 1.67 and 1.0 mg/kg i.p. respectively, will not only reduce food intake but will do so 
by advancing the BSS and enhancing satiety regardless of the time and phase at which
they are examined.
So does the time at which BSS observations are made matter? On the surface and 
from the statistics at each discrete circadian time alone it would appear not, beyond 
avoiding times where there is little or no feeding response. However there are both 
differences between the circadian times as to when the changes induced by drug 
treatment became significant (see table 7.5.1) and differing responses to the effects of 
circadian time between drug treatments. Figure 7.5.19 illustrates the differences in 
total observations over the hour for each of the four behaviours at different circadian 
times. Looking at the totals for each drug across the circadian cycle like this
m g i m g i n a  m e  e u e a u i a n  u m e i e n e e s  111 u c i i a v i u u i a i  e A j j i e s a iu ix  u n u e i  e O n u u i  t u u u i u u n s ,
but also clearly shows that the degree of circadian variation is reduced when the 
animals received sibutramine or ^/-fenfluramine. In the case of ̂ /-fenfluramine there is 
also a robust inhibition of activity at certain times as well as a sustained drug-induced 
increase in grooming, both of which are relevant to the BSS. The other factor to 
consider is whether the animals were exhibiting the BSS at all at any given circadian 
time.
Looking at some of the discrete experiments individually then, at CT1 (see figure 
7.5.1-7.5.3) there is little evidence of satiation in controls, wdth the animals showing a 
sustained level of feeding throughout the test period. Similarly, the behavioural 
patterns with either drug show a lower level of feeding than controls, but one that is 
maintained consistently throughout the observation period (e.g. figure 7.5.2), At this 
time the inhibition of food intake by either drug was as strong as at any other (see 
figure *.£.20,. anc the animal: veer-: certain:; sauna is:: anc resting mon arts; ' 
dosed with either drug than they were after being given saline, but were they satiating
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sooner or is the difference due to other factors? At this time -  1 hour into the light 
phase -  the animals were observed resting significantly more over the course of the 
hour after saline dosing than were their counterparts observed at CT21 (e.g. figures 
7.5.16-7.5.18), with the opposite effect being noted on feeding counts. This in itself is 
no surprise; CT21 in the late dark phase is a time of peak activity, while early in the 
light phase one would expect nocturnal animals to be less alert and less active, 
although activity counts did not show any change between these circadian times. After 
receiving a drug injection, rather than saline, these differences due to circadian time
cue u iu itu  (n g u ic  in diuuuaium e u ta i tu  am iuaia u it icvei ui leauiig a i u i / , i
is no different to that at CT1 over the full hour, though it is lower earlier in the 
observation, and at CT1 and CT21 animals showed no differences between observed 
resting levels after receiving d-fenfluramine. Similarly the decreased feeding at CT1 
relative to CT21 seen after saline dosing was not seen after drug dosing. Again, 
although after receiving sibutramine the animals were observed feeding less at CT1 
than at CT21 earlier on in the test period, the differences in the number of feeding 
observations were non-significant over the full hour. This speaks more for the efficacy 
of both drugs in enhancing satiety when given late in the dark phase, when the 
behavioural profiles (see figure 7.5.16-7.5.18) indicate a clearer - though longer- 
developing - shift from feeding to resting behaviour, than in argument against them 
doing so early in the light phase where this pattern is not clearly seen. It is tough to 
argue that an advance of the satiety sequence is taking place when the behavioural 
expression of that sequence is not observed. The question is thus either why the BSS 
is not shown at CT1, or why was it not picked up? Could this be a result of the 
limitations of time sampling as used here? It is always a possibility' that a sampling 
method will produce inaccurate representations of behavioural expression but the 
clear evidence of a satiety sequence shown in the profiles obtained at, for example, 
CT5 or CT13 (figures 7.5.4 and 7.5.13) plus the findings described above [chapter 4j 
indicates that the method is solid enough to observe the BSS, so something else is 
likely to be behind this apparent lack of a sequence. The most obvious answer is 
natural inactivity', sedation or ^tiredness,” a consequence of the time at which the 
experiment was done, affecting the way in which the animals reacted to food (after 
having been deprived during a peak feeding time) with some animals heading straight 
for tne rooc source \vhcr r war or e seme i uns otncr. turnne iomrc* tc rear. e» om r.=.- 
at the records for individual animals, this does appear to be the case.
What of the effect this may have on drug treatment, or the interpretation of the results? 
At CT1 the profiles (figure 7.5.1) and epoch-by-epoch counts (figure 7.5.2) suggest a 
blanket increase in general resting and a decrease in feeding and activity early in the 
test period following drug treatment, a finding backed up by the statistics (table 7.5.1), 
but the impression this leaves is more one of sedation than satiety enhancement. It is
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inactivity masks satiation -  whether natural or drug-induced -  or the mechanisms of 
the drugs change somewhat and elicit some degree of sedative effect. Certainly this is 
a concern with u-fenfluramine, which has previously been characterised as sedative 
(Aulakh et al., 1988; Callaway et a l 1993, Ziance et al., 1972), despite the dose used 
here being lower than that shown to decrease activity. In either case, the present 
results suggest that early in the light phase is not an ideal time at which to cany out 
BSS observations.
It is somewhat surprising then, given the situation described above at CT1, that 
observations carried out at CT5 produced possibly the most classical evidence of a 
shift in the BSS (figures 7.5.4-7.5.6), with a clear progression from initial feeding to a 
resting state observed after saline dosing. Drug treatment significantly modified 
behaviour from 15 minutes in, with feeding reduced and resting increased, and 
although ^-fenfluramine also caused a suppression of activity observations both drugs 
preserved the structure of the BSS. As at CT1, both drugs also attenuated the effect of 
circadian time on behavioural expression as the differences in the levels of feeding 
and resting between mid-light and mid- and late-dark phase observations after saline 
dosing were not seen when drug conditions were examined. As before, this supports 
the efficacy of the drugs at influencing the BSS during the dark phase; the pattern of 
both drugs obscuring the changes caused by time of day when the animals were given 
saline does suggest that their efficacy is tied to when they are administered. If the 
drugs were acting with equal potency and efficacy across the circadian cycle, then one 
might expect that circadian alterations in the behavioural profiles would be the same 
in animals dosed identically — whether with saline or either drug. This is clearly not 
the case in this study and while certain changes in the BSS due to circadian time are 
sec: afie* treatment witr. siDutramint 0 : * -lenfturamim these variation: aft lessens: 
compared to those seen after saline administration. Furthermore, the circadian
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differences in behaviour that are maintained within the drug treatments are largely 
those between the nadir of behavioural expression at CT9 and the times of peak 
behavioural expression in the mid- and late dark phase. This is not to suggest that 
drug action was maintained at CT9 and not at other times; as already stated there was 
little baseline feeding response at this time and there were no drug-induced changes in 
behavioural expression other than a specific increase in grooming induced by d- 
fenfluramine. Instead it suggests the inactivity at CT9 is profound and a very dramatic 
drug effect on behaviours at other times would be required to reach behavioural 
equivalence. It is interesting, then, that such a negation of circadian effect was seen 
with ^-fenfluramine with respect to observations of both activity and resting. Another 
cause for thought with regards to this drug is that it is clear that dosing with d- 
fenfluramine was responsible for a decrease in activity at almost all circadian times, 
an effect not seen with sibutramine (which had little impact on observations of 
activity, and no significance over the whole observation period). This raises a slight 
query about the nature of the drag-induced effects. Both sibutramine and d- 
fenfluramine are described as satiety enhancing drugs in previous work with the BSS 
{e.g. Halford et al., 1995, 1998), and on balance both appear to exhibit satiety 
enhancement in the present experiments, to a roughly equivalent degree — which is 
expected since both doses are close to the respective ED50 values for 2 -hour food 
intake (Halford et al., 1995) and showed equipotent reduction of food intake in 
preliminary experiments [chapter 4]. Yet the effects of d-fenfluramine are strongly 
associated with a decrease in activity scores while those of sibutramine are not. The 
activity category was a catch-all for behaviours not associated with feeding, grooming 
or resting and thus a decrease in activity observations is not directly analogous to an 
inhibitory action on locomotor behaviour or sedation. However, the fact that the 
decrease observed is specific to ^-fenfluramine, which has been previously 
categorised as sedative (Aulakh et al., 1988; Callaway et al., 1993, Ziance et al., 1972) 
and as increasing the energy cost of muscular effort (Even and Nicolaidis, 1986), does 
give pause for thought. It therefore follows that some degree of sedation may play a 
part in mediating the effects of d-fenfluramine on the BSS and on food intake, 
although, if this is the case, the sedation is mild enough not to disrupt the BSS. A 
degree of sedation may be one underlying reason why there have been conflicting 
report 01 tnc effect o. aouu •. c*-irenfiuraminc or tnc Cc.c ir tnc Das*, z mu* select 
effect could cause an increase in activity counts later in an observation as it wears off
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(Halford et a l, 1998) which might explain the disruption of resting seen by Willner 
and colleagues (Montgomery and Willner, 1988; Willner et a l, 1990; McGuirk et al, 
1992u). A nother curiosity about fenfluramine is that here it appeared to cause a 
specific increase in grooming, with the largest increase observed at CT9. There is no 
clearly discemable reason for this change, which saw the active grooming behaviour 
replace passive resting seen in controls rather than active or feeding behaviours 
(though the reduction in resting was non-significant). Table 7.5.1 and figure 7.5.19ft 
demonstrate where this promotion of grooming was noticeable. Given that d- 
fenfluramme was observed to have the effect of promoting grooming at many 
different circadian times, albeit to different degrees, it is likely to be a conserved and 
specific effect of the drug but the mechanism by which the effect is mediated is 
uncertain. Grooming was significantly reduced by sibutramine over the hour of 
observation at CT17 (and when looking at data pooled from all timepoints) but at no 
other point. In this case it is likely the decrease in grooming is symptomatic of the 
general decrease in active behaviour that accompanied the drug-induced facilitation of 
resting behaviour.
Parallel experiments monitoring the effect of both d-fenfluramine and sibutramine on 
locomotor activity across the circadian cycle are described in chapter 5, and a look at 
their effects on exploratory locomotor activity -  a paradigm investigating sedative 
potential — at doses relevant to this study can be found in chapter 6.
Another sign that there is a degree of circadian influence on the drug effect comes 
from the variation in when the behavioural changes induced by the drugs were
 u 4.:____ / -----n e  i  \  nu u  —  +u ..— 0ai cai'ii tiitauian unit utuic /.̂ ».xy, aiuiuugn uitat vanauuus ait auian.
So, given there are variations, what does this mean? When do the drugs exhibit more 
potency? In percentage terms of food intake (figure 7.5.20), sibutramine produced the 
greatest inhibition of consumption at CT1 while d-fenfluramine suppressed intake 
most at CT21. Both drugs decreased food consumption at all times except CT9 (and 
CT5 for sibutramine); af-fenfluramine had a somewhat more potent effect than 
sibutramine but within treatment bounds the degree of inhibition was roughly 
equivalent across all circadian times. The present findings do not therefore support 
thok o:? Davies and Welimar. !00' , maae with Taeemi: fenfiuramint :na : -
jjuicaicy ui uiid vAniipuuiiu iu liimuit iuuu 111 uini/ is liigfltu 111 uic uaiis. jjnaat/ man 111 uit;
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light. This is more likely due to the relatively low levels of consumption seen in the 
present work than anything else. Peak control intake at CT21 was on average just 6.7
   ____n e  A —    i_______________4-u;c a — ~
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light phase. While the drugs were potent enough to reduce food intake reliably at 
individual circadian times with respect to control, the degree of error recorded relative 
to absolute food intake was enough to prevent conclusions as to the variation of this 
efficacy with circadian time.
Of perhaps more relevance than the simple measurements of food intake is the 
attenuation of the effects of circadian rhythm by drug treatment, i.e. that the patterns 
of circadian variation in behavioural expression seen after saline treatment are not 
maintained in animals treated with either drug. Muting these changes is consistent in 
each case with decreasing feeding and increasing rest, and in terms of the circadian 
variations this tends to morph the dark phase behavioural patterns towards those
jjiuuutcu  iii uic iigm  pnasu. m e  aiguinein is u le ie iu ie  mat eniiei me ui ugs anuw mvjie
potency in the BSS during the dark phase when there is a higher level of behavioural 
expression, or that the potency of the drugs is maintained in the light phase but the 
BSS paradigm used here was not sensitive enough to pick up the same alterations in 
behaviour at these times. Given that, CT9 aside, the paradigm was capable of 
demonstrating changes induced by the drugs at times across the circadian cycle, and
— ~ —----------------------------l .v l i : _______________i u — ; — ~ .1— „  — -------— ~
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results obtained from the saline condition, it is unlikely to be simply an artefact of the 
method. Therefore the inference is that both drugs are more effective at modifying 
behaviour in the dark phase despite strong effects at points in the light phase when 
compared to saline. This goes hand in hand with the dark phase being a more 
appropriate choice for observing rat behaviour on the basis that it is their natural 
period of activity and thus more physiologically relevant and provides a strong 
argument for conducting future BSS work in rats under dark phase conditions.
t„   ---------  u ~ * u   :_1 1 c n  „ /1, „  \  ~~.a a r — c\ n  — ~i n  d u i in u a i  y m e n ,  u u m  a i u u u a n n n e  n ig iv g ,  i .p . ) a n u  u - i e i n i u i  a m i n e  ^ i . u  i n g i v g
i.p.) have a profound effect on rat behaviour and food intake measured in the BSS. 
This effect is present at many times over the circadian cycle, but it does require a
DaSCiuU i'SVC: O’ l e e d l n L  a n i  1 0 OC iff iaK . I Q eteC .  . n l  3 L 1  :. aaSi c SUltaDiC meti iO C
for monitoring behavioural changes related to feeding and satiation caused by
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circadian rhythm, and these circadian changes in behavioural expression are 
attenuated by treatment with either drug when compared across the circadian cycle. 
This suggests that both drugs are more effective when given in the mid- or late dark 
phase, when animals are naturally more active. Both sibutramine and d-fenfluramine 
act to enhance satiety, although it is suggested that a mild sedation, whilst not
ji    j.?   i . 1 .A nco  ... _ i A * i . 1 .  _ _ _x* j   n     uiaiupmig tiiC u o j , may jjia}' a ioiC in tnC aodOn 01 u-igiuiuiauullg.
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7.5 Figures for Chapter 7
Figure 7.5.1a Behavioural profiles generated from BSS observations carried out at 

































Figure 7.5.1c Behavioural profiles generated at CT1, early in the light phase.
Sibutramine
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Epoch
Figure 7.5.1(a-c)
Behavioural profiles for animals observed 1 hour into the light phase after dosing with 
each of saline, 1.0 mg/kg i.p. of-fenfluramine and 1.67 mg/kg i.p. sibutramine. 
Observations are aggregates of scores from all animals in each epoch; epochs were of 
5 minutes duration and n = 10 for every condition, with the same animals used in 
each case.
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Figure 7.5.2 Observations of each behaviour during every epoch at CT1
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Figure 7.5.3 Cumulative observations of each behaviour at CT1
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Figure 7.5.4a Behavioural profiles generated from BSS observations carried out at
CT5 -  the middle of the light phase.
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Figure 7.5.4b Behavioural profiles generated from BSS observations carried out at 








Figure 7.5.4c Behavioural profiles generated from BSS observations carried out at
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Figure 7.5.4(a-c)
Behavioural profiles for animals observed 5 hours into the light phase after dosing 
with each of saline, 1.0 mg/kg i.p. d-fenfluramine and 1.67 mg/kg i.p. sibutramine. 
Observations are aggregates of scores from all animals in each epoch; epochs were of 
5 minutes duration and n = 11 for every condition, with the same animals used in 
each case.
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Figure 7.5.5 Observations of each behaviour during every epoch at CT5
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Figure 7.5.6 Cumulative observations of each behaviour at CT5
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Figure 7.5.7a Behavioural profiles generated from BSS observations carried out at


















Figure 7.5.7b Behavioural profiles generated from BSS observations carried out at





Figure 7.5.7c Behavioural profiles generated from BSS observations carried out at





Behavioural profiles for animals observed 9 hours into the light phase after dosing 
with each of saline, 1.0 mg/kg i.p. ^-fenfluramine and 1.67 mg/kg i.p. sibutramine. 
None of feeding, resting or activity were significantly affected by drug treatment at 
this time; grooming was significantly and robustly increased by treatment with d- 
fenfluramine however; this effect was observed 10 minutes into the test period. 
Observations are aggregates of scores from all animals in each epoch; epochs were of 
5 minutes duration and n = 12 for every condition, with the same animals used in 
each case.
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Figure 7.5.8 Observations of each behaviour during every epoch at CT9
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Figure 7.5.9 Cumulative observations of each behaviour at CT9
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Figure 7.5.10a Behavioural profiles generated from BSS observations carried out at

























Figure 7.5.10b Behavioural profiles generated from BSS observations carried out at
CT13 -  early in the dark phase.
d-Fenfluramine




Figure 7.5.10c Behavioural profiles generated from BSS observations carried out at
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Figure 7.5.10(a-c)
Behavioural profiles for animals observed 1 hour into the dark phase after dosing with 
each of saline, 1.0 mg/kg i.p. <i-fenfluramme and 1.67 mg/kg i.p. sibutramine. 
Observations are aggregates of scores from all animals in each epoch; epochs were of 
5 minutes duration and n = 9 for every condition, with the same animals used in each 
case.
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Figure 7.5.11 Observations of each behaviour during every epoch at CT13
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Figure 7.5.12 Cumulative observations of each behaviour at CT13
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Figure 7.5.13a Behavioural profiles generated from BSS observations carried out at







Figure 7.5.13b Behavioural profiles generated from BSS observations carried out at
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Figure 7.5.13c Behavioural profiles generated from BSS observations carried out at















Behavioural profiles for animals observed 5 hours into the dark phase after dosing 
with each of saline, 1.0 mg/kg i.p. ^/-fenfluramine and 1.67 mg/kg i.p. sibutramine. 
Observations are aggregates of scores from all animals in each epoch; epochs were of 
5 minutes duration and n = 12 for every condition, with the same animals used in 
each case.
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Figure 7.5.14 Observations of each behaviour during every epoch at CT17
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Figure 7.5.15 Cumulative observations of each behaviour at CT17
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Figure 7.5.16a Behavioural profiles generated from BSS observations carried out at






Figure 7.5.16b Behavioural profiles generated from BSS observations carried out at







Figure 7.5.16c Behavioural profiles generated from BSS observations carried out at
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Behavioural profiles for animals observed 9 hours into the dark phase after dosing 
with each of saline, 1.0 mg/kg i.p. ^/-fenfluramine and 1.67 mg/kg i.p. sibutramine. 
Observations are aggregates of scores from all animals in each epoch; epochs were of 
5 minutes duration and n = 10 for every condition, with the same animals used in 
each case.
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Figure 7.5.17 Observations of each behaviour during every epoch at CT21
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Figure 7.5.18 Cumulative observations of each behaviour at CT21
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Figure 7.5.19a Representation of the effects of d-fenfluramine and sibutramine on
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Figure 7.5.19b Representation of the effects of d-fenfluramine and sibutramine on
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Figure 7.5.20 Food intake across the circadian cycle, and the degree of reduction 
caused by sibutramine or ^-fenfluramine at each point.
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&p  <0.05 compared with saline treatment at a similar circadian time.
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Table 7.5.1 A summary of how soon into observations the drug-induced changes 
on behaviour were noted with respect to saline, displayed by circadian time.
Footnotes:
• Italicised and bolded entries represent a decrease in observations compared to 
the saline condition. Other entries represent an increase relative to controls
• N/A represents no significant difference at any point.
• Single numbers represent significance at one point only.
• Number: senaratee b; dashes indicate i  period of significan: differer.:.
• Semi-colons are used to separate non-consecutive instances.
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8.0 General Discussion
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isolation but together -  and in the context of the published literature? What remains to 
be done in order to further clarify the nature of the impact of circadian variation on 
treatment with these two drugs, sibutramine and d-fenfluramine?
To tackle the second point first, it would have been interesting to have been able to 
monitor circadian changes not only in the behavioural response to sibutramine and d- 
fenfluramme but also in neurochemical and pharmacokinetic responses to these drugs, 
as well as binding data for relevant regions of the brain. Originally it had been the 
plan to carry out concurrent examinations of changes in neurochemistrv caused by 
both compounds over the circadian cycle, with a view to probing the hypothalamus 
using microdialysis. However it proved impossible to undertake all sets of 
experiments in parallel; since the behavioural experiments were further advanced the 
neurochemistry had to be set aside. It remains an interesting Question. Is circadian 
variation in the efficacy of the drugs simply correlated with basal, or tissue, 
neurotransmitter levels? Maybe it is related to the degree of change in transmitter
i c v c ia  u i u u c t u  uy  uiw u x u g a ; w i  p C iiia jja  w iu i  u i t  m a A .iiiia i iC v c i i t a v u c u :  ijajw  u \j
these parameters vary across the circadian cycle? It would be interesting to investigate 
paradigms of food deprivation and dosing^ comparable to those used with the BSS 
studies and circadian locomotor activity work, whilst measuring extracellular 
neurotransmitter levels in feeding-associated nuclei of the hypothalamus by 
microdialysis. Several dialysis studies have been done with a view to increasing, 
understanding of feeding behaviour and satiation (e.g. Fetissov ei al., 2000; Helm £t 
al., 2003; reviews by Westerink, 1995, and Rueter et a l, 1997) and these generally 
match an increase in extracellular hypothalamic 5-HT to feeding behaviour (Rueter et 
a l , 1997). Similarly dialysis studies have informed understanding of the roles played 
by NA and dopamine in feeding and the 24 hour rhythmicity of NA and 5-HT in 
feeding and other behaviours (Rueter et a l 1997; Westering 1995). Detailed studies 
looking at the rhythmic variation in the efficacy and neurochemical impact of 
sibutramine or <7-fenfluramine have not yet been carried out across the circadian cvcle.
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Perhaps treatment with either drug has a greater or lesser effect on transmitter levels -  
in real or percentage terms -  at different times of day? One can imagine the 
magnitude of effect observed with a releasing agent like d-fenfluramine varying with 
the levels of 5-HT stored within the neurons, a phenomenon which is known to 
exhibit circadian rhythmicitv {e.g. Martin and Redferm 1997); it could be 
hypothesised that the more transmitter is stored the more can be released by the drug. 
On the other hand, the sheer scale of the response to fenfluramine, with around a 
2500% increase in basal levels {e.g. Gundlah et al. 1997; Heal et al.y 1998b) would 
argue against circadian variation in stored 5-HT levels making a sizable impact on 
fenfluramine efficacy. So to would the reasoning of Curzon et al. (1997), who 
describe that 5-HT receptors are required for appetite suppression but high levels of 5- 
I IT itself are not. Yet in the clime fenfluramine does vary in efficacy across the 
circadian cycle (at least in concert with phentermine; Katz et al., 1999), and indeed in 
the work on the BSS described above [chapter 1 * and to a lesser degree chapter 5J; 
raceimc fenfluramine also exhibits rhythmicity when looking strictly at food intake in 
animals (Davies and Wellman, 1991), although this particular finding was not 
supported by the present work. Sibutramine exerts actions over both 5-HT and NA. 
The satiety enhancing function of sibutramine, and its promotion of thermogenesis, 
are both dependent on the inhibition of re-uptake of both neurotransmitters {e.g. Heal 
et al.y 1998a). The synergistic effect of inhibiting re-uptake of the two 
neurotransmitters is such that one might expect the potency to exhibit some level of 
dependence on the circadian rhythmicity of either NA or 5-HT systems, or both. 
Furthermore, since reuptake inhibition requires neuronal firing to raise 
neurotransmitter levels {e.g. Gundlah ei al., 1997) one might expect the efficacy of 
treatment with re-uptake inhibitors to be closely tied to circadian variation in neuronal 
firing rates. These factors suggest that it would be interesting to study the interplay 
between the two transmitters over the circadian cycle. Specifically, it would be 
pertinent to examine any circadian variation in the relative levels of 5-HT and NA, 
and in the degree of change induced after dosing with sibutramine - especially in
i c g i u i i a  u i  m t/ i iy ( jv m ia ia u iu d  n iv c  u i c  i  v in w i i t a c  u \j u i  i i c u i m i a i i a l l i i u t a d  u a v t;  a
prominent role in the control of feeding {e.g. Leibowitz and Alexander, 1998; 
Leibowitz and Hoebel, 1998; Wellman et al.* 1993). Such studies would begin to
mum/nau tn; corrciaiioi r>e?w2S* tru r,~urocnem»oa. anc Dcnavioura rssDOTi.->;\ ;r _
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eliciting further understanding of how multi-substrate drug treatment of obesity may 
be targeted for maximal effect.
Further work may also be appropriate to examine the effect of the drugs on 
macronutrient selection and whether this impact varies over the circadian cycle.
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the ideal dosing schedules are not those which simply aim to satiate soonest, if the 
aim is to maintain a balanced diet. Furthermore. modulations of serotonin are
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Leibowitz and Hoebel, 1998), with a selective suppression of carbohydrate intake 
reported to be associated with hypothalamic increases in 5-FTT (.e.g. Leibowitz and 
Alexander, 1998" Leibowitz and Shor-Posner, 1986). The degree of this selectivity 
and the efficacy of the inhibition are just two factors which may differ with circadian 
time.
Circadian variation in the pharmacokinetics of sibutramine, and to a lesser extent d- 
fenfluramine, would also be worth investigating Both drugs have active metabolites 
and in the case of sibutramine the metabolites are more relevant to the clinical action 
than the parent compound (e.g. Heal et al., 1998a; Rowland and Carlton, 1986; 
Simansky. 1996). The efficiency with which they undergo metabolism -  both from 
parent compound to active metabolites and the clearance of these metabolites -  is 
clearly a relevant issue when looking at drug efficacy. Given that circadian changes in 
metabolism and other pharmacokinetic measures are well characterised with a number
(  t      a  t o —  — .. i  o n  1 \  * u —  ------- -------- — ~  uu i  u i u g d  a n u  J j c i a u g t x ,  i ? y  i ),  u i t a c  i s  c v u i j '  l u a a u n  iu  a u a p t u i  u i a i  s u u n
variation could be mirrored in the case of sibutramine or fenfluramine. Likewise the 
binding profiles of the drugs may change with circadian time, especially if the level of
c  t t t  —  — _~ ------------ j  ~ — m ^ u .  : „ n -------. — „  a ~ . . , ^ ---------------------j - i i i  l t - u p u u v t  u a n i c i  U A jjiu a a iu n  v a n c a ,  a n u  L -u n a tC |u c n u ^  u n i u t i i t c s  u iu g , t x n u a u j .
This is especially true in the case of fenfluramine, with which, in addition to requiring 
the carrier to enter neurons and cause neurotransmitter release, there is a suspicion 
that a  direct action on 5-I IT receptors by the parent compound may contribute to the 
clinical effect (Curzon et al., 1997). Furthermore norfenfluramine, a fenfluramine 
metabolite, is accepted as having direct agonist potency at 5-HT2^ receptors (Gibson 
c u.\. Simansir *-9c arxc sc cireacnar vanatiOr. ir. tnc runeuor or ccirrersir^'. 
of this receptor could potentially affect the efficacy of ^-fenfluramine treatment.
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Similarly it is thought that 5-HT acts through 5-HTib receptors to enhance satiety (e.g. 
Blundell and Halford^ 1999; Simansky. 1996) and this receptor has been shown to
< 1«« 4- /%«<% » » «4-1** /> f  ^44/^  ̂4- a. 7 T  A  A A \  a4- 1 /%/\ 4-U^ X n iD ii iu n v /u u n a i  v a n a u u i i  w it i i  t n t a u i a i i  u n i c  ^ v ja ia u ^ t t t  t i  u i l u w a t  it>aai 111 t i le
SCN which is tangentially associated with feeding (e.g. Leibowitz and Alexander, 
1998).
Sibutramine also enhances thermogenesis (Connoley et al., 1999; Heal et al., 1998a; 
Stock. 1997). It is entirely possible that the metabolic response to sibutramine also 
vanes with circadian time and since the neuronal circuits involved are different 
(though based on the same neurotransmitters) the pattern of circadian variation could 
well be different. When the drug is most effective at stimulating thermogenesis is a
/% />4- « -» rt> />*« AA >»< A4-1 » T 1 /\  / \  1 «* Ar /% A 4-L A A T-f t A A A« » + A A«« I* A -«A Al A A a4-< a 4 i r A •• *• A 1 A A -CA A a!jlihjui p u n u  w n c n  d iii^ t iy  lu u iv iiig  a i u ie  tu  t iu ia n v ^  ^ a u c i )  \ji i c u u t c  iu u u
intake, but it is entirely relevant to the overall efficacy of the drug. Study of circadian 
variation in the thermogenic potential of sibutramine would be essential to selecting a
, j  o ' - - ____ i a ~ .  I* . — , i  a  u ~  f .  i  u .u u s a g t  l c g m i t -  i u i  i i ia X iin a i  i i  w u u iu  u c  u i  l u n u a m t in a i  iiiut-icai iu  s e c  n u w
the rhythmic changes in the efficacy of sibutramine match up on either side of the 
energy balance.
Another key point to consider is that 5-HT and NA are far from the only endogenous 
modulators of food intake and feeding behaviour. Another monoamine -  dopamine -  
has a role and there are extensive implications for a variety of neuronal and homional 
peptides (e.g. Leibowitz and Hoebel, 1998; Wynne et al., 2005). The likelihood is that 
some  ̂ if not most or even alL of these modulators exhibit some level of circadian 
variation. This could be down to a number of factors, including cycles m synthesis, 
release or metabolism. Whilst the circadian variation in 5-HT and NA is likely to be 
of more relevance to the changes in response to anorectics that exert their primary 
effects on these systems, changes in the associated chemical backdrop are possibly a 
factor and should perhaps be investigated -  if not for their relevance to sibutramine or 
^-fenfluramine anorexia then in relation to drugs that work through those systems.
Hand in hand with this is the idea that treatments which act to enhance satiety by their 
very nature require a certain level of feeding to show an effect. It also follows that if
QuC i; iOOiaug VI llmiDH IOGC IiltaK; gSIiSraiij liiCr. trCaTmSri. V luOrc V.
effective when given during periods when feeding is naturally high (e.g. Davies and
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Wellman, 1991). This likelihood grows if the primary mechanism of the drugs used is 
to facilitate and enhance the natural process of meal termination -  satiation. The 
current work was not primarily concerned with food intake per se, although reducing 
food intake is inextricably linked to anti-obesity therapy and the enhancement of 
satiety. The aim of the work presented here was more focused on trying, to determine 
whether two anti-obesity agents, sibutramine and u-fenfluramine, exhibited circadian 
variation specifically in their activity to enhance satiety -  hence the use of the BSS, 
and a time sampling mechanism^ as opposed to a paradigm tailored to specific
/-> f  f/s /I 4 l r»5 /4 A < 1 o. /4 1 /v \  T /\ 4-4 1 1 1* T 4-U ^ Alt f  fiii^asui tanc,in ui iuuu liuaiv  ̂ anu uv̂ tant;u mtai jjauti mug,. iNatuiaxi  ̂ me euiiem
approach would have been more valuable had it proved possible to carry out the 
corresponding dialysis studies alongside the BSS observations. Such a pairing would
U ~, — o llr t  A "r» ___ ----------------------------- 1 „ ~ ~ 1 Ĉ(~,d-------- „+  r ---------------1 1--------- 1 —Have anuweu an cduiuaup ui yuaimavuiugicai cmCav̂ y ai inC ntuiuc-ntmivai icvu, as
well as at the behavioural level.
In hindsight, having been unable to perform both the behavioural and neurochemical 
experiments, the BSS experiments described in chapter 7 would perhaps have been 
better carried out more stringently, using continuous analysis. This would have
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expression of the satiety sequence across the 24 hour day. However, as mentioned in 
the discussion of why the time-sampling method used was chosen [section 4.4L 
continuous analysis would have been a lot more time intensive to set up and run and 
this would have had a negative impact on the attempts then in motion to set up a 
microdialysis program alongside the behavioural work. Ultimately this program failed 
to reach fruition in any case, and looking back it was perhaps a mistake to attempt to 
give full attention to both the behavioural and the neurochemical to such a degree.
This aside, what was leamt from the experiments presented above?
First, in agreement with previous literature (Rowley et al., 2000; Vickers et al., 2000) 
significant locomotor retardation or sedation was not an issue with the doses used for 
circadian work, with neither sibutramine nor u-fenfluramine inducing a significant 
decrease in exploratory locomotor paradigms [chapter 6]. This is not to say that
neither drug afiectec tnt -levs; of be'havioura aciivir however, a.- both we:-, see: t: 
have effects on activity counts m the BSS to different degrees and at different times of
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day (figure 7.5.19, table 7.5.1), It is also worth noting that whilst it was d- 
fenfluramine that proved the more effective modulator of activity counts in the BSS 
(table 7.5.1) it was sibutramine that had the greater impact on locomotor activity 
when that was quantified [chapter 5], The pattern of that locomotor impact was 
consistent with the animals reaching a state of post-ingestive satiety^ and the 
associated resting state, sooner; the initial levels of activity tended to match that seen 
after saline, but the animals reached a plateau in locomotor performance earlier. This 
finding was entirely consistent with the observations that, as in these studies [chapters
a —  a -n  j  ____ ___ _ _ ____ «... 1 o n e  1 n n o .  t t ~ „ i  „ /  1 n n o „ \“t anu / j anu in jjicviuua icpvins ^ n an u iu  c-i un, i ? 7 j ,  i y y o , u c a i ci ui., iyyouj,
sibutramine advanced and preserved the BSS. Similarly J-fenfluramine advanced the 
BSS [chapters 4 and 7L consistent with the accepted effect (Halford et al.y 1995.
1 nOO\ +U,. 1 ,. ct".rli<ac o f f~*TT'G ™.A l-VUf —1 7 7 0 /. n u w c v c i  u ie  p a u e i n  s e e n  in  l u e u n iu iu i  a e u v i iy  s i u u i c s  a i  u u ,  im u  n g i u  jpnasc,
was for d-fenfluramine treatment to inhibit locomotor activity early in the recording 
period but for a plateau phase not to be reached as it was under sibutramine and saline 
conditions at that circadian time. At CT5 animals showed more locomotion in the 
latter half of the recording after receiving d-fenfluramine than after receiving saline. 
This finding is in agreement with earlier reports that fenfluramine disrupted the satiety 
sequence by interfering with resting behaviour (Montgomery and Willner, 1988; 
Willner et al., 1990; McGuirk et al., 1992a), a view that is not generally supported 
(Halford et al.y 1998) and is not in agreement with the BSS results presented above 
[chapters 4 and 7], There are signs from BSS observations at CT5 (figures 7.5.4-7.5.6) 
that ^/-fenfluramine treatment advanced the BSS, although there was a “second meal” 
and a fall in resting counts after the half-way point of the observations. This could 
perhaps be interpreted as a disruption of the satiety' sequence, but one could equally 
argue that the sequence had by then already been expressed. Furthermore, 5-HT is 
considered to be a short-term satiety factor rather than a long term signal {.e.g. 
Leibowitz and Hoebel, 1998) so far from being inconsistent with w-fenfluramine 
causing an advance in the BSS the present findings support the idea that d- 
fenfluramine advances the BSS. Despite this, however, the locomotor activity profile
  a  a  c  n . . .  ____4. r - ' rT G  _______ .e i , .  -------~  o ’t ,c \  ~ — i ap iu u u e e u  w iu i  u - i e m i i u a u m i c  a i  v ^ u  ^aUu s u e u  a  j j i u i n e  w a s  uni_y seen  a i  wuuiu
suggest a reason why other researchers observed a disruption of the BSS with acute 
fenfluramine since the studies suggesting fenfluramine interfered with resting were
camsc git. it tm rmi-iigri. pnasi . iviontgomer 
1990; McGuirk etal., 1992a).
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As to what might be behind this response, the current findings give no insight. It was 
only seen at CT5. so either there was a factor specific to this time that contributed to 
the findings or the results represent an anomaly. The latter seems unlikely given the 
correlation with previous observations with fenfluramine when used at equivalent 
circadian times (Montgomery and Willner, 1988; Willner et al.y 1990; McGuirk et al.y 
1992u). On the other hand there is good evidence that the response to drugs is 
susceptible to circadian variation. Mid light phase is a time of peak tissue 5-HT 
concentration (.e.g. Martin and Redfem. 1997). and so the pool of transmitter released 
may be significantly higher at this time than at others; since 5-1 IT activity is linked to 
general behavioural arousal it is plausible that the drug is having wider reaching 
effects than the specific satiety response seen at other times. This could be because the 
activating effect of the serotonergic response is more than compensating for the non- 
serotonergic sedative effect; Callaway et al. (1993) showed that fenfluramine 
produced its sedative effects -  normally seen only at higher concentrations -  via a 
non-serotonergic mechanism. There is also the possibility that the weak NA releasing 
potential of fenfluramine (Rowland and Carlton, 1986) is playing a role -  with NA 
again implicated in general arousal. One hypothesis consistent with the results shown 
here is that the specific satiating effect is seen initially, but the short-lasting 5-1 IT 
satiety signal wears off and the resting associated with satiety is then reduced by 5- 
HT-driven behavioural activation.
That it is not clear how or why this effect is mediated but that it is none the less there 
goes hand in hand with a basic premise of this thesis: that circadian rhythm is a
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be substantiated and controlled for. Ideally, for complete understanding, the effect of 
individual drugs on the BSS should be assessed across the light-dark cvcler but this is
 1:1,~1.. J T+ U_~ ____ J *1    L U0U---;---1   4: „
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studies are best carried out in the phase of natural activity (e.g. Halford et al., 1998) 
yet the current study is the first to systematically compare the effects of two 
anorectics across the full circadian cycle in a paradigm measuring behavioural 
changes in addition to food intake. The ability of some drugs to affect the extent of
ioon miant nac neer suqiec. ic lSSL acrdo. tn* circadiai cyci* osfort an.
TI 7 a !  1 MA A M 1 OO"! \  4-1*4 A ma a a w -» |» a  4 a  U  AA«T«1« • aJ a m  a m  /4 a *-*4- a m  4-1a a  Ia a  a  a  1 a t t a I a  T  4 m 4 a  1 r a
vv o i l m a n ,  i y y i j  u u i  11112) l i i & a S U i ^  15 n ^ a v n ^  u c j j t n u t i n  u n  m e  l e v e l  \j l  n i i a n e
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under control conditions and potentially not illustrative of the behaviour and/or the 
mechanisms behind the reduction. The BSS experiments described above [chapter 7) 
found that the sequence was preserved across all circadian times at which a significant 
feeding response was seen, and moreover was advanced by the satiety enhancing 
agents, sibutramine and <7-fenfluramine, at each time except late in the light phase 
(CT9) when the sequence was not present under control conditions either.
The degree to which the drugs were effective in advancing the satiety sequence was 
subject to slight variation -  as determined by when the effect on certain behaviours
-m 4-—» / >  ^ « « 4 -  V* »•* « ■TI / \  /x  •» * 1 rs ( 1% 1 /v f f  1  \cuua uiug utaunuin Mglliiiuaini}' uiiiticin nuiii wOiluuib ~~
but the more pertinent finding was that treatment with either drug muted changes seen 
between the groups of animals across the circadian cycle when comparing only 
matching drug treatments from each circadian time. The same differences in the offset 
of feeding and onset of resting that were observed at different times of day in saline 
treated animals were not universally preserved in animals treated with either drug. 
Unsurprisingly the drugs appeared to have been most effective in the dark phase, 
when feeding was at its peak, with the rhythmic differences between dark- and light- 
phase feeding and resting largely obscured by drug treatment. Effectively giving 
either drug in the dark phase caused the animal to behave in manner more like that 
shown in the light phase -  eating less, satiating sooner, and resting more. This is 
unsurprising; both drugs are satiety enhancers and they work to accelerate the natural 
process of meal termination. If the basic meal size is larger then the chances are it will 
naturally last longer, so the potential for reduction in time spent feeding is greater. On 
the other hand, arguably the most classical and clear advancements of the satiety 
sequence — to judge solely on the behavioural profiles — were observed at CT5 (mid 
light phase, when sibutramine advanced the BSS but did not significantly reduce food 
intake relative to saline and when ^-fenfluramine appeared to prevent long periods of 
rest given locomotor results) and at CT21 late in the dark phase.
Ultimately the clarity of shift as shown in the behavioural profile means little; there is 
no question, from these results, that either sibutramine or d-fenfluramine exerted their 
anorectic effect by anything other than satiety enhancement at any time, wiien given
'a. aose.- appropriate tc thei: aeuor tc inhibi:- fooc. intake Higher aoses . 
fenfluramine would likelv demonstrate a degree of sedation in the response which
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may or may not vary with circadian time; the sedative potential o f higher doses of d- 
fenfluramine was illustrated in the exploratory locomotor activity study described 
above [chapter 6] and the pre-existing body o f work describing fenfluramine 
inhibition of motor activity (Aulakh et al., 1988; Callaway et al., 1993, Ziance et al., 
1972). Sibutramine is unlikely to be sedative at any time,, again in agreement with 
previous work (Rowley et al., 2000). The locomotor profiles [chapter 5] by and large 
agree with the BSS findings [chapter 7], and circadian-independent reduction in 
locomotor activity in sibutramine treated animals isr far from being indicative of 
sedation, consistent with an earlier onset of satiety-induced post-prandial resting. 
There is a slight suggestion that the sedative potential o f fenfluramine may have been 
a significant factor at CT17y where locomotor activity significantly differed from the 
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fenfluramine are anorectic drugs that produce their hypophagic effect through the 
enhancement of post-ingestive satiety -  accelerating natural meal termination. This is
1 A «>A  A r t  «■ J 1 A /< ir i  A  ̂  ̂ t *  All«> A A  « A  /V 4  t  .A<4 A«* A a 1 *  A < A  W A  A  » A XaI i U e  x c g a x u x t d d  O x W u e u  i l l  I x x c  i l u u i  u a )  u l c  u i u g  i d  g i v e n .  w i n e i  r Q c w i i a i u d i i i d  d l i v a i
as hyperactivity or sedation, the latter particularly a possibility with ^-fenfluramine, 
do not appear to play any significant role at any time, at the doses used here. There is
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activity at mid-light or mid-dark which could potentially explain some previous 
discrepancies with this drug in the BSS (Montgomery and Willner. 1988; Willner et
a /  1  O O A  • 1  / f  A ^ l l ^ « « * 1 r  A  -4- A  /  1  O  O  A  a \  T  A 4 « %  a 1  V * X a A ^ I a  A < 1 ^ 1  1 ^ « * A « M  1 M  A  A M  / I  «-/u / - ,  X77U ,  i v x e v j u n K  e x  u x . ? i  yy^uj.  u n a i u  p r i d i n g !  y' u u l n  S x u u u a x x i l x i c  a n G  u -
fenfluramine appear more potent at enhancing satiety, i f  not inhibiting food intake per  
sey during the dark phase when natural feeding is more prevalent, and targeting drug 
administration to times o f peak food intake, i.e. before main meals, would appear to 
be a successful strategy to maximise the satiating effect.
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Microsoft Word 2002 -  to write and compile the text and integrate the figures.
Microsoft Excel 2002 — to record and work with raw data and produce and customise 
figures.
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StatView for Windows 5.0.1 (SaS Institute Inc.) and SPSS 12.0 were used for 
statistical analyses.
The locomotor activity data was collected with AM Logger v. 1.216 from CNT 
limited.
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11.2 Sample data sheets used for recording behaviours during BSS observations,
*
shown smaller than actual size.
























































































































11.3 Sample dosing schedule; indicated is the random order of dosing for each 
animal under paradigms where animals were tested with more than one 
treatment. This example was used for the experiments carried out at CT5.
Run
Animal 1 2 3
1 d-fen Sal 1.67 sib
2 d-fen 1.67 sib Sal
3 Sal 1.67 sib d-fen
4 1.67 sib d-fen Sal
5 Sal d-fen 1.67 sib
6 1.67 sib Sal d-fen
7 Sal 1.67 sib d-fen
8 1.67 si I) Sal d-fen
9 Sal d-fen 1.67 sib
10 d-fen 1.67 sib Sal
11 1.67 sib d-fen Sal
12 d-fen Sal 1.67 sib
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